Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
03/2010 | Recent  |  14: Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions March listing by industry category 03/10

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
03/25/2010 > patent applications in patent subcategories. listing by industry category

20100075892 - Inhibition of skp2-cyclin a interaction: Methods of killing a cancer cell are provided. Also provided are methods of treating a subject having a cancer. Additionally, compounds are provided that comprise a peptide from about 18 to about 100 amino acids or peptidomimetics comprising the sequence of SEQ ID NO:1. Additionally provided are methods of screening... Agent: Amster, Rothstein & Ebenstein LLP

20100075891 - Novel polynucleotides encoding polypeptides and methods using same: Novel polypeptides and polynucleotides encoding same are provided. Also provided methods and pharmaceutical compositions which can be used to treat various disorders such as cancer, immunological-related, blood-related and skin-related disorders using the polypeptides and polynucleotides of the present invention. Also provided are methods and kits for diagnosing, determining predisposition and/or... Agent: Fennemore Craig

20100075893 - Preparation of a pharmaceutical composition for increasing bone mineral density: The present invention relates to the use of a cocaine and amphetamine-regulated transcript (CART)-derived peptide for the preparation of a pharmaceutical composition for increasing bone mineral density by continuously providing elevated serum levels of the CART-derived peptide in a subject to be treated. Suitably, the elevated serum levels of the... Agent: Organon Usa, Inc. C/o Schering-plough Corporation

20100075894 - Reducing er stress in the treatment of obesity and diabetes: Endoplasmic reticulum stress has been found to be associated with obesity. Therefore, agents that reduce or prevent ER stress may be used to treat diseases associated with obesity including peripheral insulin resistance, hypergylcemia, and type 2 diabetes. Two compounds which have been shown to reduce ER stress and to reduce... Agent: Edwards Angell Palmer & Dodge LLP

20100075895 - Cyclic natriuretic peptide constructs: where R, R′, Q, Y, W, Z, J, x and n are as defined in the specification, and optionally at least one prosthetic group, pharmaceutical compositions including such cyclic constructs, and methods of treating congestive heart failure or other conditions, syndromes or diseases for which induction of anti-hypertensive, cardiovascular, renal... Agent: Palatin Technologies, Inc.

20100075904 - Carbon nanotube composite scaffolds for bone tissue engineering: The present invention provides biocompatible composite materials that can be fabricated into a scaffold having properties suitable for bone repair and regeneration. These scaffolds have sufficient mechanical strength to be useful for the repair and regeneration of cortical bone.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20100075903 - Lyophilized vegf antagonist formulations for intravitreal administration: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has the amino acid sequence shown in SEQ ID NO:4.... Agent: Regeneron Pharmaceuticals, Inc

20100075897 - Method for sustainedly releasing bioactive peptides and application thereof: The present invention provides a method for sustainedly releasing bioactive peptide, comprising a bioactive peptide conjugated to a serum albumin binding peptide through a molecular linker so as to form a fusion polypeptide, in which the molecular linker is sensitive to plasma environment; and transferring the fusion polypeptide to a... Agent: Law Offices Of Khalilian Sira, LLC

20100075898 - N-terminal vdac variants and uses thereof: The present invention relates generally to variants and peptides of the mitochondrial protein, voltage-dependent anion channel (VDAC) and to polynucleotides encoding same. In particular, the present invention is directed to N-terminal truncated and mutated VDAC and specific amino acid and polynucleotide sequences thereof useful in inhibiting apoptosis, and to pharmaceutical... Agent: Fennemore Craig

20100075907 - Neuromedin u receptor agonists and uses thereof: Neuromedin U receptor agonists for use in the treatment of metabolic disorders such as obesity and diabetes are disclosed.... Agent: Merck And Co., Inc

20100075905 - Novel cellular factor-containing solution compositions: The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.... Agent: Linda O. Palladino

20100075901 - Novel use of hiv nc protein: The present invention relates to a novel use of the HIV NC protein, and more particularly, it is relates to a pharmaceutical composition for preventing and treating AIDS having a polypeptide comprising HIV NC protein as an active component and the method of inhibiting HIV proliferation by using the polypeptide.... Agent: Edwards Angell Palmer & Dodge LLP

20100075902 - Recombinant xrgd-enriched gelatins having high stability: The invention concerns recombinant gelatin monomers and recombinant gelatins comprising or consisting of multimers of the monomers. The recombinant gelatins are of particular use in several applications involving cell attachment such as in cell culture work and applications involving cell cultures of anchor dependent cells and also in a variety... Agent: Morgan Lewis & Bockius LLP

20100075896 - Repair of larynx, trachea, and other fibrocartilaginous tissues: Provided herein are methods and devices for inducing the formation of functional replacement nonarticular cartilage tissues and ligament tissues. These methods and devices involve the use of osteogenic proteins, and are useful in repairing defects in the larynx, trachea, interarticular menisci intervertebral discs, ear, nose, ribs and other fibrocartilaginous tissues... Agent: Ropes & Gray LLP

20100075899 - Targeted photodynamic therapy agent: The present invention relates to the field of conjugates comprising a substrate, a photosensitizer, and a targeting ligand, and methods for their use. More particularly, the invention further relates to methods for treating cancer in a subject using the conjugates of the present invention.... Agent: Pearl Cohen Zedek Latzer, LLP

20100075906 - Targeted therapeutic proteins: Targeted therapeutics that localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor.... Agent: Choate, Hall & Stewart LLP

20100075900 - Use of nutritional compositions for preventing disorders: The present invention relates to a method for preventing and/or treating visceral adiposity by administering a certain nutritional composition to an infant with the age between 0 and 36 months, and preventing the occurrence of diseases later in life.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20100075908 - Mimotope receptors and inhibitors for platelet-platelet and platelet-endothelium interactions: It is provided mimotope receptors and inhibitors that employ peptide mimics that mimic the shape and function of natural receptors and ligands, thus providing synthetic binding sites for ligands and receptors. Receptor mimics can be attached to carriers, such as liposomes, to act as synthetic platelets, for example, by providing... Agent: Ogilvy Renault LLP

20100075909 - Peptide: The present invention relates to a peptide that is derived from a milk protein and has an antioxidative effect, an antioxidant that includes the peptide as an active ingredient, and an antioxidative food, drink, or feed that includes the peptide. The present invention also relates to a peptide that is... Agent: Young & Thompson

20100075910 - Synthetic peptide amides and dimeric forms thereof: e

20100075911 - Dimeric iap inhibitors: Molecular mimics of Smac are capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of... Agent: Banner & Witcoff, Ltd.

20100075912 - Novel morphine derivatives: The present invention relates to new morphine-6-glucuronide derivatives, to pharmaceutical compositions thereof and uses thereof.... Agent: Ladas & Parry LLP

20100075913 - Pharmaceutical anti-infective composition for inhalation: A composition for inhalation which contains at least an effective amount of an antimicrobial aminoglycoside compound or a salt thereof, and an effective amount of a biofilm modifier which is a macrolide compound or a salt thereof.... Agent: The Nath Law Group

20100076055 - Cationic lipids and uses thereof: Cationic lipids, cationic lipid based drug delivery systems, ways to make them and methods of treating diseases using them are disclosed.... Agent: Paul D. Yasger Abbott Laboratories

20100076059 - Method of evaluating compound efficacious in treating obesity by using slc25a10: Evaluation of compounds including screening of therapeutic agents for obesity is performed utilizing expression levels of S1c25a10 gene or protein in a test tissue or a test cell, or utilizing the nature of S1c25a10 gene or protein. Examination of obesity is performed based on expression levels of S1c25a10 gene or... Agent: Merck And Co., Inc

20100076058 - Methods for identifying analgesic agents: The present invention relates to the discovery that mutations in SCN9A are causative of Congenital Indifference to Pain (CIP) in humans. The invention also relates to methods of utilizing the SCN9A gene and expression products thereof for the screening and identification of therapeutic agents, including small organic compounds, which are... Agent: Alan J. Grant, Esq. C/o Carella, Byrne, Bain, Gilfillan,

20100076056 - Modified irna agents: The inclusion of such a monomer can allow for modulation of a property of the iRNA agent into which it is incorporated, e.g., by using the non-ribose moiety as a point to which a ligand or other entity, e.g., a lipophilic moiety. e.g., cholesterol, is directly, or indirectly, tethered. The... Agent: Nixon Peabody LLP

20100076054 - Sensizitation of cancer cells to therapy using sina targeting genes from the 1p and 19q chromosomal regions: The invention relates to the identification of genes involved in resistance of cancer cells to therapy, to short nucleic acid molecules which inhibit the expression of these genes by RNA interference and to their use as adjuvant in cancer therapy, to sensitize cancer cells to conventional anticancer agents; the short... Agent: Young & Thompson

20100076053 - Sequence of dsrna: atn-rna, intervention using irnai, use of a sequence of dsrna: atn-rna, a method of treating and inhibiting a brain tumor, a kit for inhibiting cancer cell which expresses tenascin, a method for a kit preparation in a brain tumor therap: The subject matters of this invention are a sequence of double-stranded RNA: ATN-RNA, intervention using interference RNA (iRNAi), use of a sequence of double-stranded RNA: ATN-RNA, a method of treating a brain tumor and a method of inhibiting a brain tumor cells which express tenascin, a kit for inhibiting cancer... Agent: Walker & Jocke, L.p.a.

20100076057 - Target dna interference with crrna: The present invention provides methods, systems, and compositions for interfering with the function and/or presence of a target DNA sequence in a eukaryotic cell (e.g., located in vitro or in a subject) using crRNA and CRISPR-associated (cas) proteins or cas encoding nucleic acids. The present invention also relates to a... Agent: Casimir Jones, S.c.

20100076060 - Aptamers as agonists: Nucleic acid aptamers are described herein which can transduce a signal into cells by crosslinking a cell surface molecule, thereby inducing of one or more biological activities by the cells; in serving as agonists.... Agent: Nixon & Vanderhye, PC

20100076063 - Genetic modification of targeted regions of the cardiac conduction system: Disclosed are compositions, methods and systems for preventing or treating cardiac dysfunction, particularly cardiac pacing dysfunction by genetic modification of cells of targeted regions of the cardiac conduction system. In particular, a bio-pacemaker composition is delivered to cardiac cells to increase the intrinsic pacemaking rate of the cells, wherein the... Agent: Campbell Nelson Whipps, LLC

20100076061 - Repeated administration of lentiviral vectors to respiratory cells: The invention provides methods for administering lentiviral vectors to the respiratory system of a patient to treat a disease.... Agent: Viksnins Harris & Padys Pllp

20100076062 - Use of a truncated eif-5a1 polynucleotide to induce apoptosis in cancer cells: e

20100075914 - Methods for treating herpes virus infections: The present invention relates to methods for treating, killing, and/or inhibiting the growth of Herpes viruses in human subjects comprising topically administering to a human subject in need thereof a nanoemulsion composition having antiviral properties.... Agent: Foley And Lardner LLP Suite 500

20100075915 - Methods for cancer therapy and stem cell modulation: The present invention relates to a method of inducing apoptosis in a tumour cell as well as modulating pluripotency and/or self-renewing characteristics of a stem/progenitor cell. The method comprises administering to the respective cell a compound of general formula (I). In general formula A is C or N. R1, R4... Agent: Choate, Hall & Stewart LLP

20100075916 - Substituted quinazoline inhibitors of growth factor receptor tyrosine kinases: The present invention relates to new substituted quinazoline inhibitors of vascular endothelial growth factor receptor tyrosine kinase, epidermal growth factor receptor tyrosine kinase, and/or REarranged during Transfection tyrosine kinase, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx

20100075917 - Thionucleosides and pharmaceutical applications: The invention relates to a pharmaceutical composition containing as an active ingredient at least one compound selected from the compounds of the formula (II), in which the S atom is bonded to the nucleoside carbon at T or to the nucleoside carbon at 3′, and from the compounds of the... Agent: Cantor Colburn, LLP

20100075918 - Hyaluronidase inhibitors as anti-cancer agents: Specific inhibitors of hyaluronidase (HYA1-type hyaluronidase) are used to treat cancer, especially carcinoma and solid tumors, and/or precancerous conditions.... Agent: Nixon & Vanderhye, PC

20100075919 - Compositions comprising alkyldimonium hydroxypropyl alkylglucosides: e

20100075921 - Prêparation of hyaluronic acid with desired low molecular weight as a food supplement: A process for preparing hyaluronic acid primarily as a food supplement which is capable of absorption and assimilation by the human body includes desirable control of both the purity and molecular weight range of the resulting product. Chicken comb tissue is subjected to one of two disclosed processes for extracting,... Agent: Law Office Of Terry L. Miller

20100075920 - Small molecule stimulators of neuronal growth: Provided herein are small molecule stimulators of neuronal growth, their preparation, and their use for treatment of neurological disorders. In one embodiment, provided herein are methods of treatment, prevention, or amelioration of a variety of medical conditions associated with neurological disorders using the compounds and compositions provided herein.... Agent: Wilson, Sonsini, Goodrich & Rosati

20100075922 - Heparins including at least one covalent bond with biotin or a biotin derivative, method for preparing same and use thereof: o

20100075923 - Method of enhancing tgf-beta signalling: The present invention is directed to a method of enhancing TGF-β signaling in a subject comprising administering to said subject a clathrin-dependent endocytosis inhibitor in an amount sufficient to enhance TGF-β signaling. In another aspect, the invention is directed to a method of treating a condition associated with decreased TGF-β... Agent: Elmore Patent Law Group, PC

20100075924 - Dutpase inhibitors: e

20100075925 - Hyperthermic technologies and therapeutic uses thereof: The present invention provides nanoscale and microscale compositions useful for a variety of purposes, including the diagnosis and treatment of diseases. In one embodiment, the present invention provides a disease treatment system comprising a thermal induction agent and a radiation source, wherein the thermal induction agent comprises at least one... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20100075926 - Activation of histone deacetylase 1 (hdac1) protects against dna damage and increases neuronal survival: The invention provides methods and compounds for the treatment of neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS (Amyotrophic Lateral Sclerosis), traumatic brain injury, ischemic brain injury or a stroke. In one aspect the compounds are HDAC1 activators. Exemplary HDAC1 activators include metal chelators, iron chelators, deferoxamin, flavonoids,... Agent: Wolf Greenfield & Sacks, P.C.

20100075927 - Chemotherapeutic conjugates and methods of use: Chemotherapeutic conjugates of a peptide substrate to a phosphoramide chemotherapeutic agent in which a peptide substrate is covalently linked to the chemotherapeutic agent by a linker with an aminoarylmethyl or aminoheteroaryl moiety, wherein the linking of the peptide to the chemotherapeutic agent inhibits the cytotoxic activity of the chemotherapeutic agent,... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20100075928 - Cancer treatment method: Invented is a method of treating cancer and pre-cancerous syndromes in a mammal, including a human, in need thereof which comprises the administration of a therapeutically effective amount of a non-peptide TPO receptor agonist to such mammal.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20100075929 - 9-aminoacyl tetracycline compounds and methods of use thereof: A compound of formula (I):... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100075930 - Salicylic salt compositions and related method of treatment of cardiac conditions: A method to deliver salicylic acid to the blood comprised of sublingual administration of a salicylic salt and specifically a method to treat cardiac conditions including myocardial infarctions and angina, comprising sublingual administration of a salicylic salt to a patient suffering from a cardiac condition, wherein said salicylic salt is... Agent: Dara L. Onofrio, Esq., C/o Onofrio Law

20100075931 - Substituted oxazole ketone modulators of fatty acid amide hydrolase: Certain oxazole ketone compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain,... Agent: The Scripps Research Institute

20100075932 - Novel salicylic anilides: Novel salicylic anilides are chemical uncouplers useful e.g. for the treatment of obesity.... Agent: High Point Pharmaceuticals, Inc.

20100075933 - Injectable compositions of vitamin d compounds: Pharmaceutical injectable compositions comprising at least one vitamin D compound as an active agent, processes for preparing such compositions, and methods of using such compositions.... Agent: Dr. Reddy''s Laboratories, Inc.

20100075934 - 5-lipoxygenase activating protein (flap) inhibitor: Described herein are methods for the synthesis of 3-[5-(pyridin-2-ylmethoxy)-3-(2-methyl-2-propylthio)-1-[4-(2-methoxypyridin-5-yl)benzyl]-indol-2-yl]-2,2-dimethyl-propionic acid, pharmaceutically acceptable salts, pharmaceutically acceptable solvates thereof. Also described are pharmaceutical compositions suitable for oral administration to a mammal that include, as well as methods of using such oral pharmaceutical compositions for treating respiratory conditions or diseases, as well as... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20100075935 - Xanthine modulators of adenosine a1 receptor: The present invention relates to new xanthine modulators of adenosine A1 receptors, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx

20100075936 - Use of glucocorticoid receptor antagonists for treatment of infectious conditions: The invention provides the use of a glucocorticoid receptor antagonist for the manufacture of a medicament for immune stimulation, such as prevention or treatment of infections or infectious conditions, in an aging mammalian subject, a mammalian subject with low serum DHEAS values, a mammalian subject with a high serum cortisol/DHEAS... Agent: Organon Usa, Inc. C/o Schering-plough Corporation

20100075937 - Patient populations and treatment methods: The invention provides, inter alia, methods to treat, e.g., hyperglycemia or diabetes patients having two or more of a BMI of at least 28 or 29, a fasting insulin level of at least 4 μU/mL or at least 6 μU/mL and optionally (i) a serum MCP1 level of at least... Agent: Hollis-eden Pharmaceuticals, Inc.

20100075938 - Use of chemical chelators as reversal agents for drug-induced neuromuscular block: e

20100075940 - Dendritic polyamidoamine phthalocyanine derivative: (wherein p is a number from 1 to 4; R9 represents —NH(CH2)NH2 or OR10 (wherein R10 represents an alkyl group); and each of l, m, q, and t is a number from 1 to 8), and each member of the remainder represents a hydrogen atom; M represents a metal atom... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100075939 - Immobilized 1,2-benzisothiazolin-3-one: The present invention provides novel antimicrobial immobilized 1,2-benzisothiazolin-3-one/zinc oxide (BIT/ZnO) complexes useful as antimicrobial agents because of their resistance to being leached from the substrate to which they are attached. The present invention is also directed to methods for preparing the BIT/ZnO complexes, to BIT/ZnO complexes prepared by the novel... Agent: Robert A. Yesukevich C/o Troy Corporation

20100075941 - Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof: or its salt: wherein R1 and R2 represent each a substituent such as hydrogen, halogeno or alkyl; R3 represents alkylamino, amino or hydroxyl; the ring A represents a 5- or 6-membered aromatic heterocycle or a benzene ring; m and n are each an integer of from 1 to 6; and... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100075943 - 1-adamantylazetidin-2-one derivatives and drugs containing same: [wherein A ring represents C6-10 aryl group, 5- to 14-membered heteroaryl group, R1 is a hydrogen atom, halogen atom, C1-6 alkoxycarbonyl group, hydroxyl group, carboxyl group or carbamoyl group; R2 and R3 are the same or different and are a C1-6 alkyl group; R4, R5, and R6 are same or... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20100075945 - Gram-positive carbapenem antibacterials and processes for their preparation: The present invention provides β-methyl carbapenem compounds and pharmaceutical compositions useful in the treatment of bacterial infections and methods for treating such infections using such compounds and/or compositions. The invention includes administering an effective amount of a carbapenem compound or salt and/or prodrug thereof to a host in need of... Agent: King & Spalding

20100075947 - Methods of using pi3k and mek modulators: The invention provides methods of treating cancer with a combination of compounds which inhibit kinases, more specifically MEK and PI3K.... Agent: Patent Dept Exelixis, Inc.

20100075949 - Novel pyrrolidin-2-ones: e

20100075946 - Novel thiophene derivatives: The invention relates to novel thiophene derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunosuppressive agents.... Agent: Hoxie & Associates LLC

20100075948 - Substituted pyrrolidine-2-carboxamides: e

20100075942 - N-phenyl-4-pyridin-2-yl-benzamide derivatives as histone deacylase (hdac) inhibitors for the treatment of cancer: The invention concerns benzamide derivatives of Formula (I) wherein R1a, R1b, R1c, R2, R3, R4, W, m and n have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative... Agent: Astrazeneca R&d Boston

20100075944 - Novel pyridine derivatives and pyrimidine derivatives (3): R1 represents a 3- to 10-membered non-aromatic heterocyclic group or the like; R2 and R3 represent hydrogen; R4, R5, R6, and R7 may be the same or different and each represents hydrogen, halogen, C1-6 alkyl or the like; R8 represents hydrogen or the like; R9 represents a 3- to 10-membered... Agent: Birch Stewart Kolasch & Birch

20100075950 - Phenylpropanone modulators of dopamine receptor: The present invention relates to new phenylpropanone modulators of dopamine receptors, serotonin receptors, and/or nicotinic acetylcholine receptors, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx

20100075951 - Heteroaryls and uses thereof: e

20100075952 - Pyrrolo-nitrogenous heterocyclic derivaties,the preparation and the pharmcetical use theeof: The invention provides new pyrrolo-nitrogenous heterocyclic derivatives represented by formula (I) or their salts, the preparation thereof, pharmaceutical compositions containing such derivatives and the use of such derivatives as therapeutic agents, especially as protein kinase inhibitors, wherein each substituent in formula (I) is same as defined in the description.... Agent: Patent Group Macdonald, Illig, Jones & Britton LLP

20100075953 - Substituted piperazines, (1,4) diazepines, and 2,5-diazabicyclo (2.2.1) heptanes as histamine h1 and/or h3 antagonists or histamine h3 reverse antagonists: The present invention relates to novel piperazine and azepine derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurodegenerative disorders including Alzheimer's disease.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20100075954 - Substituted imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine derivatives: e

20100075955 - Short-acting benzodiazepine salts and their polymorphic forms:

20100075956 - N-(1-arylpyrazol-4l)sulfonamides and their use as parasiticides: The invention relates to a sulfonamide compound of formula (I) or a pharmaceutically, veterinarily or agriculturally acceptable salt or solvate thereof, where the groups R1-R5 are described in the description, to compositions comprising such compounds, processes for their synthesis and their use as parasiticides.... Agent: Pharmacia & Upjohn

20100075957 - Aminodihydrothiazine derivatives substituted with a cyclic group: e

20100075958 - Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis: This invention relates to pyrrozolotriazine compounds, pharmaceutical compositions containing such compounds and the use of those compounds and compositions for the prevention and/or treatment of hyper-proliferative disorders and diseases associated with angiogenesis.... Agent: Edwards Angell Palmer & Dodge LLP

20100075959 - Benzothiazole derivatives with activity as adenosine receptor ligands: The present invention relates to substituted benzothiazole derivatives and to their pharmaceutically acceptable salts useful for the treatment of diseases related to the adenosine receptor.... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100075960 - Benzimidazole thiophene compounds: The present invention provides bezimidazole thiophene compounds pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20100075961 - Modulators of glucocorticoid receptor, ap-1, and/or nf-kb activity and use thereof: Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including inflammatory and immune diseases, obesity and diabetes having the structure of formula (I), its enantiomers, diastereomers, or a pharmaceutically acceptable salt, or hydrate, thereof, wherein X is... Agent: Louis J. Wille Bristol-myers Squibb Company

20100075962 - Indol derivatives, the method for preparing thereof and composition for the prevention and treatment of metabolic disorder containing the same as an active ingredient: Disclosed are indole derivatives a preparation method thereof, and a composition for the prevention and treatment of metabolic diseases, containing the same as an active ingredient. The indole derivatives have inhibitory activity against DGAT (diacylglycerol acyltransferase), which causes metabolic diseases such as obesity and diabetes in the process of lipid... Agent: Greenlee Winner And Sullivan P C

20100075963 - Pharmaceutically active benzensulphonyl-indols: 1-Benzenesulfonyl-1H-indoles, processes for their production and their use as pharmaceuticals, e.g. in the treatment of disorders which are mediated by CCR9, such as e.g. inflammatory bowel disease.... Agent: Novartis Institutes For Biomedical Research, Inc.

20100075964 - Imidazole based lxr modulators: Compounds of the invention, such as compounds of Formulae IIa, IIb, IIc or IId, and pharmaceutically acceptable salts, isomers, and prodrugs thereof, are useful as modulators of the activity of liver X receptors, where R1, R2, R21, R3 and G are defined herein. Pharmaceutical compositions containing the compounds and methods... Agent: Mcdonnell Boehnen Hulbert @ Berghoff LLP

20100075968 - Imidazolidine carboxamide derivatives as p2x7 modulators: The compounds or salts modulate P2X7 receptor function and are capable of antagonizing the effects of ATP at the P2X7 receptor (P2X7 receptor antagonists). The invention also provides the use of such compounds or salts, or pharmaceutical compositions thereof, in the treatment or prevention of disorders/diseases mediated by the P2X7... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20100075965 - Pi3 kinase inhibitors and methods of their use: Phosphatidylinositol (PI) 3 kinase inhibitor compounds, their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one... Agent: Novartis Vaccines And Diagnostics Inc.

20100075967 - Pyrimidine derivatives for treatment of hyperproliferative disorders: in which J and Y represent aromatic or heteroaromatic rings; R2, G, G′, and G″ represent substituent groups and R2a represents H or halogen; L represents a linking group; and M represents CH or N. Pharmaceutical compositions containing these compounds, and methods of using these compounds in treatment of hyperproliferative... Agent: Edwards Angell Palmer & Dodge LLP

20100075966 - Substituted dihydroimidazoles and their use in the treatment of tumors: wherein the radicals and symbols are as defined herein; their use as inhibitors of the interaction of the MDM2 protein with a p53-like peptide, new pharmaceutical formulations comprising said compounds, said compounds for use in the therapeutic treatment of warm-blooded animals, especially humans, their use in the treatment of proliferative... Agent: Novartis Institutes For Biomedical Research, Inc.

20100075969 - Angiogenesis: The invention provides medicaments comprising an agent, which selectively modulates β2-adrenergic receptor conformation, or receptor activity, or activation thereof. The medicaments may be used for treating diseases that are characterised by disorganized and/or abnormal vasculature, such as cancer and metastatic disease. The medicaments may also be used for promoting organized/normal... Agent: Fox Rothschild LLP Blue Bell

20100075970 - Inhibitors of akt activity: The present invention is directed to compounds which contain substituted pyridazines and pyrimidines moieties which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the... Agent: Merck And Co., Inc

20100075971 - Substituted pyridine derivatives useful in the treatment of cancer and other disorders: This invention relates to novel diaryl ureas, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and angiogenesis disorders, as a sole agent or in combination with cytotoxic therapies.... Agent: Millen, White, Zelano & Branigan, P.C.

20100075972 - Agent for treatment of multiple sclerosis: i

20100075974 - Heterocyclic gpr40 modulators:

20100075973 - Polo-like kinase inhibitors:

20100075975 - Medicament for the enhancement of cognitive function and neuroprotection: The medicaments containing 4-chloro-5-{2-[4-(6-fluoro-1,2-benz[d]isoxazol-3-yl)piperidin-1-yl]ethyl-amino}-2-methyl-3-(2H) pyridazinone of the Formula (I) or therapeutically acceptable salt thereof can be used for the treatment or prevention of neuronal death, mental decline, sclerosis multiplex, Creuzfeld-Jacobs disease, Huntington-syndrome, amyotrophic lateral sclerosis, Parkinson-disease, memory disturbance, loss of memory, amnesia, stroke or for the improvement of memory function... Agent: K.f. Ross P.C.

20100075976 - Substituted piperazinyl pyrazines and pyridines as 5-ht7 receptor antagonists: e

20100075977 - Beta-3 receptor ligands and their use in therapy: The present invention relates to new compounds, ligands of the beta-3 adrenergic receptor, their preparation and their use in therapy or as research tools for said receptor; the invention also relates to a process for the preparation of the compounds of the invention and the use of inverse agonists of... Agent: Nixon & Vanderhye, PC

20100075979 - Pyridinylpiperazin derivatives useful as modulators of dopamine d3 receptors: The present invention provides compounds of provides formula I, having affinity and selectivity for the dopamine D3 receptors, their manufacture, pharmaceutical compositions containing them and their use for the therapeutic and/or prophylactic treatment of cognitive disorders.... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100075978 - Sulfonamide derivatives as bradykinin antagonists: R1-R5 and Z are as defined in the claims, and optical antipodes or racemates and/or salts and/or hydrates and/or solvates thereof, which are selective antagonists of bradykinin B1, to processes for producing these compounds, pharmacological compositions containing them and to their use in therapy or prevention of painful and inflammatory... Agent: Fish & Richardson P.C.

20100075981 - Isoxazolo[4,5]pyridin-3-yl-piperazin derivatives useful as modulators of dopamine d3 receptors: The present invention provides compounds of formula I, having affinity and selectivity for the dopamine D3 receptors, their manufacture, pharmaceutical compositions containing them and their use for the therapeutic and/or prophylactic treatment of cognitive disorders.... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100075980 - Phenylacetamides being flt3 inhibitors: wherein the residues R1, R2, R3, R9, R10 and Q and X, Y and Z are as defined in the specification, salts thereof; their use, methods of their use, processes for their production, pharmaceutical compositions comprising them, their combinations with second drug substances and the use thereof and the like.... Agent: Novartis Institutes For Biomedical Research, Inc.

20100075982 - Pyridinone derivative for the treatment of premature ejaculation: e

20100075983 - D3 and 5-ht2a receptor modulators: wherein X, n and R1 are as described herein, as well as pharmaceutically acceptable salts and esters thereof, methods for their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are dual modulators of the serotonin 5-HT2a and dopamine D3 receptors, useful... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100075985 - Benzo[d]isoxazol-3-yl-piperazin derivatives useful as modulators of dopamine d3 receptors: The present invention provides compounds of the general formula (I), having affinity and selectivity for the dopamine D3 receptors, their manufacture, pharmaceutical compositions containing them and their use for the therapeutic and/or prophylactic treatment of cognitive disorders.... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100075984 - Dicarbonylic compounds with antibacterial activity: Compounds of formula (I), and their pharmaceutically acceptable salts and solvates, wherein X represents —O—, —NH—, —S—, —NHC(═O)— or —NHC(═S)—; R1 represents —H or a hydrocarbon chain; R2 represents —H, alkoxy, amino, a hydrocarbon chain or a radical of a cycle; R3 represents —H, a hydrocarbon chain or a radical... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100075986 - Oxophenyl-cyclohexyl-propanolamine derivatives, production and use thereof in therapeutics: where n is equal to 0, 1 or 2, R4 and R5 represent H, a (C1-C4)alkyl, hydroxyl, cyano, phenyl, benzyl, piperidyl, —CONH2, —CO-phenyl, —COOR3, —CH(phenyl) (OH) and —C(phenyl)2(OH) group, or R4 and R5 form together an optionally substituted 6-membered aromatic ring, R6 represents H, a (C1-C4)alkyl, phenyl or benzyl group,... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100075987 - Acyl bipiperidinyl compounds, compositions containing such compounds and methods of treatment: Bipiperidyl compounds of the formula: (I) are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. Pharmaceutically acceptable salts and solvates are included as well. The compounds are useful as agonists of the g-protein coupled receptor GPR-119.... Agent: Merck And Co., Inc

20100075989 - Novel compounds having selective inhibiting effect at gsk3: wherein Z, X, Y, ring P, ring Q, R, R3, R4, n and m are as defined in the specification, as a free base or a pharmaceutically acceptable salt, solvate or solvate of a salt; processes for their preparation and new intermediates used therein, pharmaceutical formulations containing said compounds, and... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20100075988 - Tetrahydroquinazoline compounds and their use in preparing medicaments for treating and preventing virosis: The present invention relates to a compound of formula (I) or isomers thereof, or pharmaceutically acceptable salts or hydrates thereof. The present invention further relates to processes for the preparation of the compounds of formula (I) and optical isomers, and to the use of the compounds of formula (I), or... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100075990 - Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases: Multiheteroaryl compounds, their preparation, pharmaceutical compositions comprising these compounds, and their pharmaceutical use in the prevention and treatment of prostaglandin D2 mediated diseases and conditions that may be modulated by the inhibition of hematopoietic prostaglandin D synthase (H-PGDS).... Agent: Macmillan Sobanski & Todd, LLC

20100075991 - Post-translational regulation of catalytic activities of cytochrome p450 46a1 and uses thereof: Provided herein are methods and compounds for post-translational regulation of cytochrome P450 46A1 (CYP46A1) enzyme activity in the brain and retina. Also, a method for identifying a potential regulator of a CYP46A1 enzyme using crystal structures of the enzyme and a subsequent method for screening for a regulatory activity in... Agent: Benjamin Aaron Adler Adler & Associates

20100075992 - Tetrodotoxin and its derivatives for the treament of peripheral-nervously derived neuropathi pain: The present invention refers to the use of a sodium channel blocker such as tetrodotoxin or saxitoxin, their analogues and derivatives as well as their physiologically acceptable salts, in medicinal products for human therapeutics for the treatment of peripheral-nervously derived neuropathic pain.... Agent: Fish & Richardson PC

20100075993 - Small molecule inhibitors against west nile virus replication: The invention provides flavivirus replication inhibitors of WNV and other flaviviruses, such as, for example, JEV, SLEV, AV, KV, JV, CV, YV, TBEV, DENV-1, DENV-2, DENV-3, DENV-4, YFV and MVEV. The invention further provides pharmaceutical compositions including one or more such flavivirus replication inhibitors. The invention further provides methods of... Agent: Woodcock Washburn LLP

20100075994 - Substituted dihydro and tetrahydro oxazolopyrimidinones, preparation and use thereof: Wherein p, n, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein. This invention also relates to methods of making these compounds including novel intermediates. The compounds of this invention are modulators of metabotropic glutamate receptors (mGluR), particularly, mGluR2 receptor. Therefore, the compounds of... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100075995 - Compounds: wherein R1 is C1-6alkylamino, C1-6alkoxy, or C3-7cycloalkyloxy; m is an integer having a value of 3 to 6; n is an integer having a value of 0 to 4; and salts thereof are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20100075996 - Pyrrolo[2,3-d]pyrimidine compounds: Described herein is pyrrolo{2,3-d}pyrimidine compounds, their use as Janus Kinase (JAK) inhibitors, pharmaceutical compositions containing this compounds, and methods for the preparation of these compounds.... Agent: Pharmacia & Upjohn

20100075997 - Use of pkc inhibitors in transplantation: The present invention pertains to the use of a PKC inhibitor in the treatment of insulin-producing cell and tissue rejection, such as islet transplantation rejection or rejection of transdifferentiated insulin-producing hepatocytes.... Agent: Novartis Corporate Intellectual Property

20100075999 - Process for the preparation of ethyl-n-(2,3-dichloro-6-nitrobenzyl)glycine hydrochloride: e

20100075998 - Tricyclic indoles and (4,5-dihydro) indoles: The present invention provides tricyclic indoles and (4,5-dihydro) indoles of the formula (I) or a pharmaceutically acceptable salt thereof: wherein the ring A represents a fused pyrazole, pyridine or pyrimidine, means either simple or double carbon-carbon bond and R1, R2 and R3 are as defined in the specification. Further... Agent: Scully Scott Murphy & Presser, PC

20100076000 - Sulfoximine-substituted pyrimidines as cdk- and/or vegf inhibitors, their production and use as pharmaceutical agents: e

20100076001 - Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer: The present invention provides novel imidazolidinonyl aminopyrimidine compounds believed to have clinical use for treatment of cancer through inhibiting Plk1. wherein: R1 hydrogen, hydroxy, halo, methyl, C1-C2 alkoxy, amino, or methylamino; R2 is hydrogen, halo, or cyano; R3 is hydrogen or halo; R4 is hydrogen, halo, or methyl; provided that... Agent: Eli Lilly & Company

20100076002 - Method of treating atherosclerosis, dyslipidemias and related conditions and pharmaceutical compositions: A method of treating atherosclerosis is disclosed wherein nicotinic acid or another nicotinic acid receptor agonist is administered to the patient in combination with a DP receptor antagonist. The DP receptor antagonist is administered to reduce, prevent or eliminate flushing that may otherwise occur.... Agent: Merck And Co., Inc

20100076003 - 5-oxazolidin-2-one substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful as orl-1 receptor modulators: The present invention is directed to novel 5-oxazolidin-2-one substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful in the treatment of disorders and conditions mediated by the ORL-1 receptor. The present invention is further directed to processes for the preparation of said derivatives, pharmaceutical compositions comprising said derivatives and methods for the treatment of ORL-1... Agent: Philip S. Johnson Johnson & Johnson

20100076004 - Bicyclic spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease: which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of... Agent: Merck And Co., Inc

20100076005 - Isocarbostyril alkaloid derivatives having anti-proliferative and anti-migratory activities: Isocarbostyril alkaloid derivatives having an anti-proliferative and anti-migratory activities are disclosed. In particular, compounds of formula (I) or (II), as well as stereoisomers, tautomers, racemates, prodrugs, metabolites thereof, pharmaceutically acceptable salt and/or solvate are encompassed which are useful in the treatment and prophylaxis of cancer. Methods of preparation are also... Agent: Knobbe Martens Olson & Bear LLP

20100076007 - Polymorphs of 6-beta-naltrexol: The present invention provides polymorphs of 6-beta-naltrexol and process for their preparation. In particular, the present invention provides crystalline forms of the free base of 6-beta-naltrexol and processes for their preparation. The present invention also provides crystalline and amorphous forms of the hydrochloride salt of 6-beta-naltrexol and processes for their... Agent: Mallinckrodt Inc.

20100076006 - Topiramate plus naltrexone for the treatment of addictive disorders: The present invention provides for the use of combinations of drugs to treat addictive disorders.... Agent: University Of Virginia Patent Foundation

20100076009 - Adjuvant chemotherapy for anaplastic gliomas: The present invention involves the use of 2,4-disulfonyl phenyl tert-butyl nitrone (2,4-ds-PBN) in the treatment and prevention of gliomas. The 2,4-ds-PBN may be used alone or combined with other traditional chemo- and radiotherapies and surgery, to treat or prevent glioma occurrence, recurrence, spread, growth, metastasis, or vascularization.... Agent: Fulbright & Jaworski L.L.P.

20100076008 - Pharmaceutical compositions containing plasma protein: The invention is related to water-soluble products and pharmaceutical formulations in solid or liquid form mainly for parenteral use. They consist of or comprise a therapeutically active substance (having low aqueous solubility and a substantial binding affinity to plasma proteins) and a plasma protein fraction in controlled aggregation state, whereby... Agent: Birch, Stewart, Kolasch & Birch, LLP

20100076010 - Alpha 1a-adrenoceptor antagonists: This invention relates to novel compounds that are dihydroindoles derivatives and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel dihydroindoles derivatives that are derivatives of silodosin. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the... Agent: Foley & Lardner LLP

20100076011 - Enantiomer-pure hexahydro-pyrrolocyclopenta-pyridine derivatives: The invention relates to the novel therapeutically valuable enantiomer-pure [3aα,8bα]-1,2,3a,4,8b-hexahydropyrrolocyclopentapyridine derivatives of the general formula (I), wherein Z is a single bond or CH2, R1 represents hydrogen or a straight-chain or branched, optionally unsaturated lower alkyl group which may be perfluorated, R2 and R3 independently represent hydrogen, a straight-chain or... Agent: Fulbright & Jaworski L.L.P.

20100076012 - Tetrahydroquinoline derivatives and the use thereof for the treatment of cancer: Compounds of the formula (I), in which E, R3, R4, R5, X, Y, W, Q1, Q2, Z, s and m have the meanings indicated in claim 1, can be employed, inter alia, for the treatment of tumours.... Agent: Millen, White, Zelano & Branigan, P.C.

20100076013 - Methods of treatment: The present invention relates to methods of treating hematological malignancies, including acute myeloid leukemia (AML), comprising the use of compounds that inhibit the binding of the Smac protein to IAPs (“IAP inhibitor”). The present invention also relates to the use of IAP inhibitors for the preparation of a medicament to... Agent: Novartis Institutes For Biomedical Research, Inc.

20100076014 - Modulators of glucocorticoid receptor, ap-1, and/or nf-kb activity and use thereof: Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, and/or AP-1, and/or NF-κB activity including inflammatory and immune diseases, obesity and diabetes having the structure of formula (I), its enantiomers, diastereomers, or a pharmaceutically-acceptable salt, or hydrate, thereof, wherein (Ia) is... Agent: Louis J. Wille Bristol-myers Squibb Company

20100076015 - Aminopyridine derivatives: v

20100076016 - Isoquinolinone derivatives as nk3 antagonists: The invention relates to compounds useful in therapy, in particular in the treatment of psychosis, to compositions comprising said compounds, and to methods of treating diseases comprising the administration of said compounds.... Agent: Darby & Darby P.C.

20100076018 - Compounds and methods for treatment of alpha-1 antitrypsin deficiency: The invention features compositions and methods that are useful for treating or preventing AAT deficiency and associated conditions. In addition, the invention provides methods for identifying compounds useful for treatment of AAT deficiency and associated conditions.... Agent: Edwards Angell Palmer & Dodge LLP

20100076017 - Sitamaquine tosylate for the treatment of leishmaniasis: Disclosed in a novel compound of formula (IA) and its use in the treatment of leishmaniasis infections.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20100076019 - Alcohol free formulation of argatroban: An aqueous formulation of argatroban and of related compounds is disclosed along with a reconstitutable formulation, each of which is substantially, if not totally alcohol free. The formulations are also substantially free, if not totally free, of mono-, di-, and oligo-saccharides. An especially preferred embodiment is a ready-to-use 1 mg/ml... Agent: Lucas & Mercanti, LLP

20100076020 - Quinolynylmethylimidizoles as therapeutic agents: Disclosed herein is a compound of the formula (I): (I). Therapeutic methods, compositions and medicaments related thereto are also disclosed.... Agent: Allergan, Inc.

20100076021 - Organic compounds: s

20100076023 - Amorphous solid composition containing a pyrazole-3-carboxamide in amorphous form and stabilising carriers: The invention relates to a pyrazole-3-carboxamide in amorphous form, to an amorphous solid solution containing the same, and more generally to pharmaceutical composition containing the same... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100076022 - Novel polymorphs of rimonabant: The present invention discloses novel and stable polymorphs of rimonabant, its hydrates and solvates, to the processes for their preparation and to pharmaceutical compositions comprising them. The present invention further discloses a novel and stable amorphous form of rimonabant, process for its preparation and a pharmaceutical composition comprising it. The... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20100076024 - Novel compounds as serine protease inhibitors: The invention relates to compounds of formula (I) wherein the substituents are as defined in claim 1; to compositions comprising said compounds and to their use as pharmaceutical agents, in particular as inhibitors of serine proteases.... Agent: Novartis Institutes For Biomedical Research, Inc.

20100076026 - 3-amino-indazole or 3-amino-4,5,6,7-tetrahydro-indazole derivatives: e

20100076027 - Indazole or 4,5,6,7-tetrahydro-indazole derivatives:

20100076025 - Process for solvent removal from omeprazole salts: The present invention relates to a process for removing an organic solvent from a salt of omeprazole, in particular a magnesium salt of omeprazole, a composition comprising a salt of omeprazole, in particular a magnesium salt of omeprazole obtainable by such a process, and pharmaceutical compositions comprising said composition or... Agent: Arent Fox LLP

20100076029 - Compounds which selectively modulate the cb2 receptor: e

20100076028 - Design and synthesis of novel antimicrobials: The synthesis and activity of novel LpxA inhibitors is described, these inhibitors present antibacterial activity. The compounds were designed based on a receptor model developed using the crystal structure of LpxA and are arranged to have a favorable binding interaction at the active site of the enzyme. In particular, the... Agent: Ade & Company Inc.

20100076030 - Methods of treating rheumatoid arthritis: Imidazole-based compounds, compositions comprising them, and methods of their use for the treatment, prevention and management of inflammatory and autoimmune diseases and disorders are disclosed. Particular compounds are of formula I:... Agent: Lexicon Pharmaceuticals, Inc.

20100076031 - Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis: Compounds of the formula (I) are disclosed and are suitable for the treatment of seborrheic dermatitis.... Agent: Reed Smith LLP

20100076032 - Insecticidal n-substituted sulfoximines: N-Substituted sulfoximines are effective at controlling insects.... Agent: Dow Agrosciences LLC

20100076033 - Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics: Methods for treating hyperlipidemia with intermediate release nicotinic acid formulations having unique biopharmaceutical characteristics, without causing drug-induced hepatotoxicity to a level which would require discontinuation of the therapy, whereby a majority of the nicotinic acid is release and metabolized in the individual within about 5 to about 9 hours. The... Agent: Polsinelli Shughart PC

20100076034 - 2-aryl-2-fluoropropanoic acids and derivatives and pharmaceutical compositions containing them: The present invention relates to (R,S) 2-aryl-2-fluoropropanoic acids, their single enantiomers (R) and (S), their derivatives amides and acylsulfonamides and to pharmaceutical compositions containing them, which are used in the prevention and treatment of tissue damage due to the exacerbated recruitment of polymorphonucleated neutrophils (PMN leukocytes) at inflammation sites. The... Agent: King & Spalding

20100076035 - Transdermal drug delivery using an osmolyte and vasoactive agent: A formulation and method for delivery of bioactive substances when applied to, or within, the skin or other exterior region of a mammal. for example, a patient, includes a vasoactive agent; an osmolyte; and an active ingredient. The formulation is sufficiently hygroscopic so as to create a condition of hypertonicity... Agent: Sunstein Kann Murphy & Timbers LLP

20100076036 - Heterocyclyl-substituted sulfonamides for the treatment of cognitive or food ingestion related disorders: The present invention relates to heterocyclyl-substituted sulfonamides with 5-HT6 receptor affinity, and compositions thereof, and the use of said compounds for the treatment or prophylaxis of various disorders.... Agent: Heslin Rothenberg Farley & Mesiti PC

20100076037 - Methods of treating neuropathic pain with agonists of ppar-gamma: Embodiments of the invention relate to the treatment of neuropathic pain in mammals. Embodiments of the invention include methods for treating neuropathic pain as well as methods for preparing medicaments used in the treatment of mammalian pain. Preferably, methods of the invention comprise the use of PPARgamma agonists for the... Agent: Aestus Therapeutics Inc.

20100076038 - Therapeutic agent for urinary excretion disorder: a salt thereof, a solvate thereof or a prodrug thereof. The compound, a salt thereof, a solvate thereof or a prodrug thereof is effective for prevention, treatment and/or symptom improvement of a dysuria (e.g., slow stream, splitting or spraying of the urine stream, intermittent stream, hesitancy, straining to void or... Agent: Sughrue-265550

20100076039 - Composition for the prevention and treatment of metabolic disorder containing benzazole derivatives as an active ingredient: Disclosed is a composition for the prevention and treatment of metabolic diseases, which comprises a benzazole derivative as an active ingredient. The benzazole derivative has inhibitory activity against DGAT (diacylglycerol acyltransferase), which causes metabolic diseases such as obesity and diabetes in the process of lipid metabolism. With the ability to... Agent: Greenlee Winner And Sullivan P C

20100076040 - Method for producing bisbenzoxazoles: The invention relates to a method for producing bisbenzoxazoles that are interconnected by means of a system of conjugated double bonds, according to which o-aminophenols are reacted with dicarboxylic acids, the carboxyl groups of which are interconnected via a double bond or a system of conjugated double bonds, to form... Agent: Clariant Corporation Intellectual Property Department

20100076041 - Indole- and benzimidazole amides as hydroxysteroid dehydrogenase inhibitors: The use of substituted amides of structure (I) for modulating the activity of 11 β-hydroxysteroid dehydrogenase type 1 (11 βHSD1) and the use of these compounds as pharmaceutical compositions, are described. Also a novel class of substituted amides, their use in therapy, pharmaceutical compositions comprising the compounds, as well as... Agent: High Point Pharmaceuticals, Inc.

20100076042 - Pharmaceutical composition: e

20100076043 - Nitric oxide amino acid ester compound, compositions for increasing nitric oxide levels and method of use: There is provided novel amino acid ester compounds comprising at least one nitric oxide releasing group and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one amino acid ester compound comprising at least one nitric oxide releasing group, and, optionally, at least one nitric oxide donor and/or at... Agent: Benoit & Cote, S.e.n.c.

20100076044 - Therapeutic agent for inflammatory bowel disease and tnf-alpha production inhibitor: Disclosed is an agent for use in the treatment or prevention of inflammatory bowel disease. Also disclosed is an agent for inhibiting the production of TNF-α. A therapeutic or prophylactic agent for inflammatory bowel disease comprising at least one amino acid selected from the group consisting of lysine, histidine, phenylalanine,... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100076045 - Stabilized pharmaceutical sub-micron suspensions and methods of forming same: The present invention is directed to a pharmaceutical submicron suspension and a method of forming the submicron suspension. The submicron suspension is useful for delivery of relatively hydrophobic and/or low solubility therapeutic agent. The submicron suspension and method of forming the submicron suspension typically employ a polymeric material that aids... Agent: Alcon

20100076046 - Antiviral indoles: Compounds of the formula (I) wherein A, B, D, M, Ar, W, X, Y, Z and R1 are as defined herein, are useful in the prevention and treatment of hepatitis C infections. The compounds, their preparation, pharmaceutical compositions containing them and their use in medicine are disclosed.... Agent: Merck And Co., Inc

20100076047 - Amorphous 1-(9h-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol phosphate salt: The present invention relates to a novel amorphous form of 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol phosphate (Carvedilol dihydrogen phosphate) of Formula (I), and a process for the preparation thereof.... Agent: Jay R Akhave

20100076048 - Isoindol derivatives as ep4 receptor agonists: The present invention relates to indole derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their use in medicine.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20100076049 - Novel oxindole derivative: [wherein, R1 to R8 may have a hydrogen atom, a halogen atom, a hydroxy group, a C1-C6 alkyl group, a C2-C8 alkenyl group, a C1-C6 alkylcarbonyl group or —COOR9 (wherein R9 represents a hydrogen atom, a C1-C6 alkyl group or a C2-C8 alkenyl group) as a substituent; and X represents... Agent: Arent Fox LLP

20100076050 - Solid betalain compositions and methods: Solid, free-flowing, and substantially completely dissolvable preparations with high betalain content are presented. Most typically, the betalain profile of the preparations is near natural and includes betalains in an amount of between 10-40 wt %. As the preparations of the inventive subject matter maintain chemical stability and flowability over extended... Agent: Fish & Associates, PC Robert D. Fish

20100076051 - Isoindolinone kinase inhibitors: l

20100076052 - Perindopril formulations: Pharmaceutical formulations comprising perindopril or its salts, isomers, enantiomers, polymorphs, metabolites, solvates, hydrates, and mixtures thereof, and at least one surface stabilizer. Also disclosed are methods of stabilizing perindopril in the formulations, and polyoxyethylene-polyoxypropylene block copolymers as surface stabilizers.... Agent: Dr. Reddy''s Laboratories, Inc.

20100076064 - Methods for improving liver clearance of xenobiotic substances in an animal: A method for improving liver clearance of xenobiotic substances in an animal by feeding the animal lipoic acid in amounts of from about 10 mg to about 1000 mg per day.... Agent: Colgate-palmolive Company

20100076065 - Vitamin d receptor modulators: The present invention relates to novel, non-secosteroidal, phenyl-benzothiophene compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1α,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.... Agent: Eli Lilly & Company

20100076066 - Novel ido inhibitors and methods of use thereof: Novel indoleamine 2,3-dioxygenase (IDO) inhibitors, compositions comprising the same, and methods of use thereof are disclosed.... Agent: Dann, Dorfman, Herrell & Skillman

20100076067 - Biodegradable block copolymeric compositions for drug delivery: An improved drug delivery composition and method of use is disclosed. The composition comprises one or more biodegradable block copolymer drug carriers; and a reconstitution enhancing and enabling agent comprising polyethylene glycol (PEG), a PEG derivative or a mixture of PEG and a PEG derivative. The composition can be administered... Agent: Novartis Corporate Intellectual Property

20100076068 - Aminoalcohol derivatives and their therapeutic use: A compound of formula (1) Including pharmaceutically acceptable salts thereof, wherein: R1 is aryl or heteroaryl optionally substituted with R8; R2 is H or alkyl or CH2 (when forming part of a ring with R3, R4 or R5); R3 is H, alkyl, CH2OH or CH2OR6 and can be part of... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100076070 - Forskolin compositions and methods for administration: An administration method is provided, in which a composition comprising a forskolin 1α,9α-carbonate compound is administered to a human subject. According to an embodiment, the forskolin 1α,9α-carbonate compound has a skeletal structure of 8,13-epoxy-1α,6β,7β,9α-tetrahydroxylabd-14-en-11-one. A carbonyl group links the 1-position hydroxy oxygen and the 9-position hydroxy oxygen to one another... Agent: Don D. Cha

20100076069 - Forskolin dosing regimen in open angle glaucoma and patient compliance methods thereof: Disclosed is an optimal dosing regimen for forskolin to ensure the most optimal pharmacokinetic/pharmacodynamic responses desired in the therapeutic management of open angle glaucoma. The optimal dosing regimen involves the ocular application of 2% forskolin solubilized using randomly-methylated beta-cyclodextrins one drop once a day to patients requiring therapy for open... Agent: Sabinsa Corporation

20100076071 - Use of equol for treating skin diseases: Equol (7-hydroxy-3(4′hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5α-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These... Agent: Brinks Hofer Gilson & Lione

20100076072 - Compositions and methods of vitamin e administration: The present invention relates to compositions and methods of vitamin E administration. In particular, the present invention provides opposing effects, relative to inflammation, from the administration of two major forms of vitamin E (α-tocopherol and γ-tocopherol).... Agent: Casimir Jones, S.c.

20100076073 - Combination of an nmda receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders: The present invention provides a method for the treatment of depression, including treatment-resistant depression, and other mood disorders using a combination of an NMDA receptor antagonist and a SSRI that is citalopram or escitalopram. It has unexpectedly been shown that the combination has a synergistic and potentiated effect of either... Agent: The Firm Of Hueschen And Sage

20100076074 - Carbamate reducers of skeletal muscle tension: The present invention relates to new carbamate skeletal muscle relaxants, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx

20100076075 - Methods of treating neurological disease using antagonists of the nmda receptor complex: Provided is a method for treating depression with an open-channel antagonists of the NMDA (N-methyl-D-aspartate) receptor complex. The open-channel antagonists include memantine (a 1-amino-3,5-dimethyl-adamantane hydrochloride), felbamate, acamprosate, and MRZ 2/579 (1-amino-1,3,3,5,5-pentamethyl-cyclohexane hydrochloride). The method includes oral, controlled or sustained release, intravenous, rectal, transcutaneous or other preparations such as lipid emulsion... Agent: Rosenberg, Klein & Lee

20100076076 - Methods of treating neurological disease using antagonists of the nmda receptor complex: Melanoma is a solid tumor that is notoriously resistant to chemotherapy, and its incidence is rapidly increasing. Recently, several signaling pathways have been demonstrated to contribute to melanoma tumorigenesis, including constitutive activation of MAP kinase, Akt and stat-3. The activation of multiple pathways may account in part for the difficulty... Agent: Nutter Mcclennen & Fish LLP

20100076077 - Esters of 4,5-disubstituted-oxy-2-methyl-3,6-dioxo-cyclohexa-1,4-dienyl alkyl acids and preparation thereof: Esters of 4,5-disubstituted-oxy-2-methyl-3,6-dioxo-cyclohexa-1,4-dienyl alkyl acids were prepared chemically and/or enzymatically. Depending upon the ester, improved melanocyte cytotoxicity was achieved. Improved cytotoxicity characteristics are consistent with ester analogs being more physiologically compatible and less irritating to skin than their corresponding acids.... Agent: Brett L. Nelson Eastman Chemical Company

20100076078 - Insecticidal compounds: Novel compounds of formula (I): wherein A1, A2, A3, A4, R1, R2, G1, G2, Q1 and Q2 are as defined in claim 1; or salts or N-oxides thereof. Furthermore, the present invention relates to processes for preparing compounds of formula (I), to insecticidal, acaricidal, molluscicidal and nematicidal compositions comprising them... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20100076079 - Pharmaceutical compositions of short-acting sedative hypnotic agent: The invention provides pharmaceutical compositions comprising a phenylacetic acid ester compound useful for inducing or maintaining general anesthesia or sedation in mammals, methods for preparing such compositions, and methods for inducing or maintaining anesthesia or sedation using such compositions.... Agent: Pepper Hamilton LLP

20100076080 - Synthesis of cyclohexane derivatives useful as sensates in consumer products: The present invention provides synthetic routes for preparing various isomers of cyclohexane-based coolants, such as menthyl esters and menthanecarboxamide derivatives, in particular those substituted at the amide nitrogen, for example with an aromatic ring or aryl moiety. Such structures have high cooling potency and long lasting sensory effect, which make... Agent: The Procter & Gamble Company Global Legal Department - Ip

20100076081 - Method for producing salt of 4-sulfinylamino-1-cyclohexanecarboxylic acid: Disclosed is a salt of trans-4-sulfinylamino-1-cyclohexanecarboxylic acid. Also disclosed is a method for producing a salt of trans-4-sulfinylamino-1-cyclohexanecarboxylic acid.... Agent: Birch Stewart Kolasch & Birch

20100076082 - New cleaning, descaling and disinfecting composition for dialysis generators: Composition comprising, per 100% of its mass, essentially: from 0.50% by mass to 1.50% by mass of peracetic acid, from 3.00% by mass to 15.00% by mass of hydrogen peroxide, from 3.00% by mass to 15.00% by mass of acetic acid, from 0.10% by mass to 1.00% by mass of... Agent: Air Liquide Intellectual Property

20100076083 - Treprostinil administration using a metered dose inhaler: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.... Agent: Foley And Lardner LLP Suite 500

20100076084 - Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes: or repaglinide and at least one other antidiabetic compound selected from the group consisting of thiazolidinedione derivatives (glitazones), sulfonyl urea derivatives and metformin for simultaneous, separate or sequential use in the prevention, delay of progression or treatment of diseases, especially metabolic disorders and in particular type 2 diabetes and diseases... Agent: Novartis Corporate Intellectual Property

20100076085 - Hcl polymorphs of 3-((2-(dimethylamino)methyl-(cyclohex-1-yl))phenol: A crystalline salt of 3-[2-(dimethylamino)methyl(cyclohex-1-yl)]phenol and hydrogen chloride, preferably in a 1:1 composition, including various crystalline forms of this salt, processes for preparing the various crystalline forms of this salt, pharmaceutical compositions containing the various crystalline forms of this salt, and the use of this salt as a pharmacologically active... Agent: Crowell & Moring LLP Intellectual Property Group

20100076086 - Process for the preparation of o-desmethyl venlafaxine: The present invention relates to a novel process for the preparation of O-desmethyl venlafaxine (ODV).... Agent: Fulbright & Jaworski L.L.P. Attn: MnIPDocket

20100076088 - Crystalline form iv of agomelatine, a process for its preparation and pharmaceutical compositions containing it: e

20100076087 - Methods of reduction of interpatient variability: Disclosed herein are methods for the reduction of inter-patient variability of a drug, such as in one or more parameters including half-life (t1/2), maximum plasma concentration (Cmax), time at maximal plasma concentration (Tmax), area under the time-versus-concentration curve (AUC). Also provided are methods of reducing side effects associated with drugs.... Agent: Global Patent Group, LLC

20100076089 - Antimicrobial gel formulations: Disclosed herein are formulations comprising an N-halogenated or N,N-dihalogenated amine compound dispersed in a water-swellable polymer, wherein the compound is 90% stable for at least 30 days at about 25° C. Also disclosed are methods of treating or preventing infections caused by a bacterial, a microbial, a sporal, a fungal... Agent: Hamilton Desanctis & Cha, LLP

20100076090 - Topical skin care formulations: A topical anti-aging skin care formulation comprising an effective amount of a benzoquinone, such as CoQ10, plus a synergistic pair of stabilizers and a synergistic pair of whiteners. The stabilizers are octyl salicylate and octyl methoxycinnamate. The whiteners are titanium dioxide and zinc oxide. When proper amounts of these ingredients... Agent: Gary C. Honeycutt

20100076091 - Composition and method for suppressing lipooxidation of erythrocyte: The present invention relates to a composition for suppressing lipoperoxidation of erythrocytes, which comprises xanthophyll or an ester thereof as an active ingredient, a composition for preventing or treating dementia, and a method for diagnosing dementia, which comprises measuring the concentration of xanthophyll or an ester thereof in mammalian erythrocytes.... Agent: Sughrue Mion, PLLC

20100076094 - Formulation containing phosphate derivatives of electron transfer agents: There is provided an emulsion composition for therapeutic administration comprising: (a) at least one mono-(electron transfer agent) phosphate derivative; (b) at least one di-electron transfer agent phosphate derivative; wherein the amount of transfer agent phosphate derivatives is no less than equimolar to the amount of di-electron transfer agent phosphate; and... Agent: Michael Best & Friedrich LLP

20100076092 - Lipid-derived nanoparticles for brain-targeted drug delivery: Disclosed herein are compositions and methods useful for the delivery of compounds across the blood brain barrier. Nanoparticles comprising lipids, such as brain lipids, are used to encapsulate drugs and to facilitate drug delivery to the brain.... Agent: C. Rachal Winger C/o Ocip Group

20100076093 - Use of ergothioneine as a preservative in foods and beverages: The invention relates to the novel use of ergothioneine and preferably, L ergothioneine, as a nutritional additive and preservative in foods, medicines, and/or beverages. According to the invention, the powerful antioxidant ergothioneine was found to be very stable over time in and to have no deleterious effects on taste or... Agent: Mckee, Voorhees & Sease, P.L.C

20100076095 - Method and apparatus for mitigating acute reoxygenation injury during percutaneous coronary intervention: A system and methods are described for improving the management of ischemic cardiac tissue during acute coronary syndromes. The system combines a catheter-based sub-system which allows for simultaneous balloon dilation of a coronary artery and infusion of a carefully controlled perfusate during percutaneous coronary intervention. The system allows for modulation... Agent: King & Spalding

  
03/18/2010 > patent applications in patent subcategories. listing by industry category

20100069289 - Animal feeds and veterinary compositions: The present invention relates to an animal feed composition comprising protein from the family Fabaceae and protein from the family Asteraceae and to such formulations which also comprise glucan and/or mannan; such feeds finding utility in stabilising or increasing weight in a target animal, particularly fish, as well as in... Agent: Crowell & Moring LLP Intellectual Property Group

20100069291 - Combination comprising cndac (2'-cyano-2'-deoxy-n4-palmitoyl-1-beta-d-arabinofuranosyl-cytosine) and a cytotoxic agent: A first aspect of the invention relates to a combination comprising 2′-cyano-2′-deoxy-N4-palmitoyl-1-β-D-arabinofuranosyl-cytosine, or a metabolite thereof, or a pharmaceutically acceptable salt thereof, and a cytotoxic agent selected from: (a) a HDAC inhibitor; and (b) a topoisomerase inhibitor selected from etoposide, topotecan and SN-38, or a prodrug thereof. A second aspect... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20100069290 - Ejection liquid and ejection method: The ejection liquid of the present invention includes a compound having a guanidine group, and a carboxyl group or a sulfonic acid group in one molecule, and being represented by the general formula (1), or a salt of the compound, for the purpose of stably ejecting a solution including at... Agent: Fitzpatrick Cella Harper & Scinto

20100069288 - Use of cysteine-rich whey derived protein in patients receiving chemotherapy or radiotherapy to improve patient survival: A cysteine-rich undenatured whey-derived protein formulation did not interfere with the tumor-cytotoxic effects of chemotherapy and radiation therapy and did not have a negative effect on the clinical outcome, that is, negatively affect survival and increase mortality. Indeed, use of a high-cysteine undenatured whey derived protein in the treatment of... Agent: Roylance, Abrams, Berdo & Goodman, L.L.P.

20100069292 - Insulin with a basal release profile: A clear basal insulin formulation composed of insulin (preferably human recombinant insulin), buffering agents, precipitating agents, and/or stabilizing agents for subcutaneous, intradermal or intramuscular administration. The formulation is designed to form a precipitate of insulin following injection, creating a slow releasing “basal insulin” over a period of 12 to 24... Agent: Pabst Patent Group LLP

20100069293 - Polymeric carrier compositions for delivery of active agents, methods of making and using the same: In part, the present invention is directed to compositions and methods of making compositions comprising a polymeric backbone, a chelating group, a metal ion, and an active agent with a metal binding domain. The compositions can optionally further comprise protective groups. In part, the present invention is directed to prolonging... Agent: Wilson Sonsini Goodrich And Rosati / Pharmain Ltd

20100069294 - Hcv protease inhibitors and uses thereof: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.... Agent: Choate, Hall & Stewart LLP

20100069295 - Novel poly(ethylene oxide)-block-poly(ester) block copolymers: The present invention relates to micelle-forming poly(ethylene oxide)-block-poly(ester) block copolymers having reactive groups on the polyester block therein. The biodegradability of these copolymers and their biocompatibilities with a large number of bioactive agents make them suitable as carriers for various bioactive agents. The bioactive agents, such as DNA, RNA, oligonucleotide,... Agent: Bennett Jones LLP C/o Ms Roseann Caldwell

20100069296 - Use of somatostatin analogs in cluster headache: The present invention relates to the use of a Somatostatin (SRIF) analog which has a high binding affinity to human SSTR1,2,3,5, or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition for the treatment of cluster headache.... Agent: Novartis Corporate Intellectual Property

20100069300 - C-type lectin fold as a scaffold for massive sequence variation: This invention provides a class of binding proteins with a range of binding specificities and affinities based upon variation at select amino acid positions within a scaffold. The variable positions may be readily modified to produce a library of binding proteins with different binding specificities and affinities. The library may... Agent: Sughrue Mion, PLLC

20100069305 - Composition for maintaining gastrointestinal homeostasis: The invention relates to a suspension of albumin and tannic acid for maintaining gastrointestinal homeostasis.... Agent: Collen A. Beard

20100069301 - Compositions and methods for treating pathologic angiogenesis and vascular permeability: Compounds, compositions and methods for inhibiting vascular permeability and pathologic angiogenesis are described herein. Methods for producing and screening compounds and compositions capable of inhibiting vascular permeability and pathologic angiogenesis are also described herein. Pharmaceutical compositions are included in the compositions described herein. The compositions described herein are useful in,... Agent: Stoel Rives LLP - Slc

20100069299 - Ghrelin analogs: The invention comprises peptidyl analogs that possess agonist or antagonist ghrelin activity, along with therapeutic and non-therapeutic uses thereof.... Agent: Alan F. Feeny, Esq.

20100069298 - Methods for detecting overexpression of sparc and therapeutic and diagnostic methods relating to same: Methods for detecting elevated levels of SPARC in biological samples using immunohistochemical staining and therapeutic and diagnostic methods relating to those detection methods.... Agent: Caris Mpi

20100069303 - Methods of treating bone disease using vascular endothelial growth factor fusion constructs: The 121-amino acid isoform of vascular endothelial growth factor (VEGF121) is linked by a flexible G4S tether to a cytotoxic molecule such as toxin gelonin or granzyme B and expressed as a soluble fusion protein. The VEGF121 fusion protein exhibits significant anti-tumor vascular-ablative effects that inhibit the growth of primary... Agent: Fulbright & Jaworski, L.L.P.

20100069304 - Protective effects of inhibiting the interaction of calmodulin and mutant huntingtin protein: An artificial polypeptide can be used in a treatment for Huntington's disease. The inventive polypeptide sequence is capable of interacting with mutant huntingtin so as to inhibit interactions between mutant huntingtin or a fragment of mutant huntingtin and calmodulin. The inventive polypeptide sequence can be a portion of calmodulin described... Agent: Workman Nydegger 1000 Eagle Gate Tower

20100069297 - Selective inhibition of tlr4 signaling: Blocking peptides comprised of the 14 amino acids that correspond to the sequences of the BB-loops of the four known TIR domain-containing adapter proteins (i.e. MyD88, TRAM, TIRAP, and TRIF) and homologous sequences of four TLRs (TLR2, TLR4, TLR1, and TLR6) are described. Adapter BB loop peptides disrupted TLR4, but... Agent: Elizabeth Hart-wells University Of Maryland Baltimore

20100069302 - Specific therapy and medicament using integrin ligands for treating cancer: The invention relates to a combination therapy for the treatment of tumors and tumor metastases comprising administration of integrin ligands, preferably integrin antagonists, together with co-therapeutic agents or therapy forms that have synergistic efficacy when administered consecutively with said ligands, such as chemotherapeutic agents and or radiation therapy. The therapy... Agent: Arent Fox LLP

20100069306 - Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders: The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100069307 - Neuropeptide-2 receptor (y-2r) agonists: e

20100069308 - Surfaces containing antibacterial polymers: This invention provides a surface that has been coated with anti-bacterial polymers. Such surfaces would be suitable for use in, for example, medical devices and public surfaces. Additionally, the invention provides a method for coating surfaces with the anti-bacterial polymer.... Agent: Ilya Chorny Ceo, Simprota Corporation

20100069309 - Method for medical treatment utilizing glutathione: A method of treating a condition or conditions caused by damage to cells by a process of oxidative stress and glutathione depletion. In some exemplary embodiments, the condition or conditions may be treated by administering reduced L-glutathione to a patient through injection or intravenous infusion. In other exemplary embodiments, the... Agent: Maier & Maier, PLLC

20100069310 - Glucopyranosyl-substituted benzyl-benzonitrile derivates, medicaments containing such compounds, their use and process for their manufacture: Glucopyranosyl-substituted benzyl-benzonitrile derivatives of general formula (I) as defined according to claim 1, including the tautomers, the stereoisomers thereof, the mixtures thereof and the salts thereof. The compounds according to the invention are suitable for the treatment of metabolic disorders.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100069311 - Medicament comprising a reducing alkyl-sugar monomer for the treatment of inflammatory disorders: The invention relates to a medicament comprising at least one reducing alkyl-sugar monomer having a hydroxyl function which is substituted by an alkoxy radical at C2-C40, said medicament being preferably intended to regulate inflammatory mechanisms. The reducing sugar is preferably selected from the group containing rhamnose, fucose and glucose. The... Agent: Birch Stewart Kolasch & Birch

20100069312 - Aminoalkyl glucosamine phosphate compounds for treating autoimmune diseases: The invention provides prophylactic and therapeutic applications of select aminoalkyl glucosamine phosphate (AGP) compounds in autoimmune diseases.... Agent: Knobbe Martens Olson & Bear LLP

20100069313 - Novel powders based on vegetation water from olive oil production: The present invention is directed a process for the manufacture of a powder comprising vegetation water rich in water-soluble polyphenols, especially rich in hydroxytyrosol, as well as to the powders themselves and dietary supplements, especially in form of tablets, food, feed and cosmetic preparations containing such powders. The process comprises... Agent: Nixon & Vanderhye, PC

20100069314 - Pesticidal compositions: Stabilized mixtures of pesticides are disclosed.... Agent: Dow Agrosciences LLC

20100069315 - Method and medicament for treating ocular infections: The invention relates to a method for treating ocular infections, by topical application twice a day in each eye to be treated, for less than four days, of a medicament essentially consisting of azithromycin in solution in a pharmaceutically acceptable vehicle of linear medium-chain fatty acid triglycerides, at the concentration... Agent: Millen, White, Zelano & Branigan, P.C.

20100069317 - Crystalline nemorubicin hydrochloride: This invention relates to a novel crystalline polymorphic form of nemorubicin hydrochloride dihydrate, useful for the preparation of pharmaceutical composition for the treatment of tumors. A process for preparing this novel polymorphic form, named form A, is within the scope of the present invention.... Agent: Scully Scott Murphy & Presser, PC

20100069316 - Treatment for multiple myeloma: The present invention provides methods of treating a subject suffering from multiple myeloma comprising administering to the subject an effect amount of a compound according to Formula I:... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20100069318 - Combination of an hdac inhibitor and an antimetabolite: for simultaneous, concurrent, separate or sequential use, especially for use in the treatment of proliferative diseases, more specifically MDS or AML. The invention also relates to pharmaceutical compositions comprising such a combination and to a method of treating MDS or AML, in a mammal, particularly a human, with such a... Agent: Novartis Corporate Intellectual Property

20100069461 - Compositions and methods for inhibiting expression of factor v leiden mutant gene: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Factor V Leiden mutant gene (Factor V Leiden mutant gene), comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a... Agent: Alnylam/fenwick

20100069464 - Compositions and methods for modulating activity of capped small rnas: Compositions and methods for modulating transcription by RNA polymerases are described.... Agent: King & Spalding LLP

20100069466 - Compositions and methods for the systemic treatment of arthritis: The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1β.... Agent: Chalker Flores, LLP

20100069465 - Methods and compositions for the specific inhibition of gene expression by double-stranded rna: The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100069463 - Methods for the diagnosis and treatment of affective disorders and cushing's syndromes: The present invention relates to a method for identifying a TMEFF2 modulator, comprising (a) contacting a cell which expresses TMEFF2 with a candidate compound to be tested; (b) measuring whether said compound to be tested decreases or increases the level of a constituent of the cAMP signalling pathway, preferably the... Agent: Foley And Lardner LLP Suite 500

20100069462 - Mitochondrial function of prohibitin 2 (phb2): The present invention relates to a PHB2 gene regulator and a therapeutic drug for mitochondrial-function-related disease containing the same, for example.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100069471 - Chemically modified oligonucleotides: This invention relates composition and methods for making and using chemically modified oligonucleotides agents for inhibiting gene expression.... Agent: Nixon Peabody LLP

20100069472 - Compositions and their uses directed to huntingtin: Disclosed herein are compounds, compositions and methods for modulating the expression of huntingtin in a cell, tissue or animal. Further provided are methods of slowing or preventing Huntington's disease progression using an antisense compound targeted to huntingtin. Additionally provided are methods of delaying or preventing the onset of Huntingtin's disease... Agent: Jones Day For Isis Pharmaceuticals, Inc.

20100069467 - Double-stranded/self-complementary vectors with a truncated cba promoter and methods of gene delivery: The present inventors concerns vectors carrying a truncated chimeric CMV-chicken β-actin (smCBA) promoter in which the hybrid chicken β-actin/rabbit β-globin intron is greatly shortened, and their use to deliver to an operatively linked polynucleotide to host cells in vitro or in vivo, resulting in expression of the polynucleotide in the... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100069469 - Formulations and composites with reactive fillers: The invention provides composite materials prepared by i) providing a fluid formulation comprising (1) at least one compound capable of polymerisation and/or cross-linking and (2) a water-consuming reactive filler; ii) optionally injecting said formulation into a site of use; iii) polymerising and/or cross-linking said compound, to form a solid polymer... Agent: Michael Best & Friedrich LLP

20100069470 - Identification of protein biomarkers associated with lymph node metastasis in colorectal cancer: Disclosed herein are compositions and methods relating to the diagnosis, prognosis, and treatment of colorectal cancer. The compositions and methods generally relate to the differential expression of transgelin in colorectal cancer cells with metastatic potential.... Agent: Gardner Groff Greenwald & Villanueva. PC

20100069468 - Inhibition of beta-amyloid peptide aggregation: The present invention relates to methods of using cocaine-binding-site ligands and cocaine-binding-site RNA aptamers to treat or prevent Alzheimer's Disease and to reduce or prevent aggregation of beta-amyloid peptides in a subject.... Agent: Nixon Peabody LLP - Patent Group

20100069319 - Mercaptopurine derivatives and uses thereof: The invention provides novel mercaptopurine derivatives, e.g., S-allylthio-6-mercaptopurine and S-allylthio-6-mercaptopurine 9-riboside, as well as pharmaceutical compositions thereof. These compounds are highly efficient anti-proliferative agents, thus can be useful for treatment of various diseases or disorders, in particular, proliferative, inflammatory, skin and immune diseases or disorders.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20100069321 - Biological materials and uses thereof: The invention relates to the modification of proteins to improve their, biochemical, immunological or biophysical properties, in turn leading to such proteins having increased diagnostic, biotechnological or therapeutic benefit. In particular the invention relates to polysialylation of proteins or conjugates of proteins. There is also provided, nucleotide sequences and expression... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100069323 - Composition for application to skin or mucosa: Disclosed is a composition for application to skin or mucosa comprising alginic acid and/or salts thereof, which has reduced cytotoxicity against a skin cell or mucosa cell and higher safety, the composition for application to skin or mucosa comprises an alginic acid and/or salts thereof that contains substantially no low-molecular-weight... Agent: Roylance, Abrams, Berdo & Goodman, L.L.P.

20100069322 - Inhibition of cholera toxins by galatooligosaccharides (gos): The invention relates to nutritional and pharmaceutical compositions comprising non-digestible galactooligosaccharides (GOS) and uses thereof. In particular, it relates to the use of GOS species in preventing or treating disease caused by bacterial toxins. Provided is the use of GOS having a polymerization degree of 5 or higher, preferably 6... Agent: Hoffmann & Baron, LLP

20100069324 - Nanoparticle of glucidamin for treating tumor and preparation method thereof: A nanoparticle of glucidamin derived from organism for treating tumor and preparation method thereof, wherein the viscosity-average molecular weight of glucidamin is in the range of 1×103-9×105, and the amount of free amino groups in the glucidamin is in the range of 50%-100% based on the total amino groups. The... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20100069325 - Pharmaceutical composition for treatment of chronic liver diseases and use thereof: A pharmaceutical composition for treatment of chronic liver diseases, the composition including at least cordyceps sinensis polysaccharide, amygdaloside, and gypenoside. The pharmaceutical composition slows down liver fibrosis, stops the development thereof, or reverses the same. A method of using the pharmaceutical composition for treatment of chronic liver diseases.... Agent: Matthias Scholl

20100069320 - Synergism of gos and polyfructose: The present invention relates to the filed of prebiotics. Provided are uses for compositions comprising synergistically effective amounts of polyfructose and galactooligosaccharides (GOS).... Agent: Foley And Lardner LLP Suite 500

20100069326 - Combination therapies to treat cardio- and cerebro-vascular disorders: The invention is compositions and methods for treating vascular disorders and/or conditions that involve administering a first agent comprising triflusal (or a triflusal analog or derivative) in combination with at least one other active agent.... Agent: William J Bundren The Law Office Of William J Bundren

20100069327 - Nutritional products comprising saccharide oligomers: Indigestible oligosaccharides having a molecular weight of 450 Da to 3700 Da are used for the improvement of insulin resistance, the prevention of post-prandial glycaemic dip, and/or the decrease of the post-prandial glucose response of a meal, which is consumed within 72 hours after the consumption of the first product.... Agent: Foley And Lardner LLP Suite 500

20100069329 - Cosmetic compositions comprising hydrolysis resistant organomodified disiloxane surfactants: d

20100069328 - Novel ortho-aminoanilides for the treatment of cancer:

20100069330 - Pharmaceutical compositions and methods for preparing and using lipophilic organosulfur cell proliferation inhibitors: Novel compositions of lipophilic organosulfur compounds, their preparation and use in methods for treating disease are described. Silicon confers lipophilicity that can enhance the penetration of the silicon derivative compounds across the gut wall, cell membranes and blood brain barrier, thus improving therapeutic properties including bioavailability, metabolism, and/or pharmacokinetics. The... Agent: Duane Morris LLP - ChicagoIPDepartment

20100069331 - Treatment or prevention of cancer and precancerous disorders: The NSAID, sulindac and/or its metabolites and derivatives, in combination with an agent that generates or induces reactive oxygen species (ROS), significantly enhances the killing of abnormal cells but does not affect normal cells. This effect occurs at concentrations of each compound that individually have little or no activity directed... Agent: Darby & Darby P.C.

20100069332 - Lipids containing omega-3 and omega-6 fatty acids: A lipid preparation including a glycerophospholipid or salt, conjugate and derivatives thereof, particularly phosphatidylserine (PS), phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidyl-inositol (PI), phosphatidylglycerol (PG) and phosphatidic acid (PA), and poly-unsaturated fatty acid (PUFA) acyl groups, particularly long-chain poly-unsaturated fatty acid (LC-PUFA) acyl groups such as omega-3 and/or omega-6 acyl groups, wherein... Agent: Cooper & Dunham, LLP

20100069333 - Alpha-helix mimetics and method relating to the treatment of cancer stem cells: The invention provides α-mimetic structures and a chemical library relating thereto. Additionally, the invention provides methods wherein α-mimetic compounds are used to treat cancer stem cells.... Agent: Seed Intellectual Property Law Group PLLC

20100069334 - Diagnostic method: A method for prognosing osteoporosis phenotypes or estimating osteoporosis quantitative traits comprising determining outcomes for selected SNP variables and clinical variables. Products and methods for genotyping multiple osteoporosis associated genetic variations.... Agent: Wolf Greenfield & Sacks, P.C.

20100069335 - Prevention and treatment of ophthalmic complications of diabetes: An method and formulation are provided for the prevention and treatment of adverse ocular conditions which are complications of diabetes. In one embodiment, the invention comprises administering to a person having diabetes, insulin resistance, or a risk factor for diabetes a formulation comprising a metal chelator and a transport enhancer.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100069336 - High penetration prodrug compositions of mustards and mustard-related compounds: The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of mustards and mustard-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier... Agent: Perkins Coie LLP

20100069337 - Butyrylcholinesterase inhibitors: Butyrylcholinesterase inhibitors, their formulation, and their use primarily in the treatment of neurodegenerative diseases. These inhibitors generally are phosphates, phosphonates, phosphinates, and phosphoramidates. These inhibitors can be incorporated in pharmaceutical compositions and administered to a patient in therapeutically effective amounts to treat neurodegenerative diseases.... Agent: K&l Gates LLP

20100069338 - Pharmaceutical compositions: The present invention provides a composition for topical administration to the skin for treating and/or preventing a dermatological condition involving an abnormal decrease in the cell-to-cell adhesion between epithelial cells comprising a zinc salt which is at least partially soluble in water and an acid, wherein the composition has a... Agent: Davis Wright Tremaine LLP/los Angeles

20100069339 - Novel method of treatment of male sub-fertility: There is provided a method of treatment of male sub-fertility by using a vitamin D compound. Compositions and uses are also provided.... Agent: Edwards Angell Palmer & Dodge LLP

20100069342 - Formoterol/steroid bronchodilating compositions and methods of use thereof: Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof, and a steroidal anti-inflammatory agent. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided... Agent: Lucas & Mercanti, LLP

20100069340 - Pharmaceutical compositions of an src kinase inhibitor and an aromatase inhibitor: This invention is directed to a pharmaceutical composition comprising an Src kinase inhibitor and an aromatase inhibitor, and to the use of a combination of an Src kinase inhibitor and an aromatase inhibitor in treating abnormal cell proliferation and abnormal angiogenesis associated with cancer, including breast cancer.... Agent: Wyeth LLC Patent Law Group

20100069341 - Tetrahydro-pyranopyrazole cannabinoid modulators: i

20100069343 - Methods of predicting steroid responsiveness with il-1rii: Methods are provided for determining in vitro whether or not a patient will respond to steroid treatment based on the levels of interleukin-1 receptor type II (IL-1RII) in a sample of mononuclear immune cells obtained from the patient before steroid treatment and/or on the change in IL-1RII in the patient's... Agent: Amster, Rothstein & Ebenstein LLP

20100069344 - Small molecule antagonists of bcl2 family proteins: The present invention relates to naturally occurring and chemically synthesized small molecule antagonists of Bcl-2 family proteins. In particular, the present invention provides gossypol compounds (e.g., isomers, enantiomers, racemic compounds, metabolites, derivatives, pharmaceutically acceptable salts, in combination with acids or bases, and the like) and methods of using these compounds... Agent: Casimir Jones, S.c.

20100069345 - Lanthanide-porphyrin complexes as anti-tumor agents: The present invention relates to lanthanide porphyrin complexes and their uses as anti-tumor agents. The described complexes show promising cytotoxic properties toward cancer cells in both in vitro and in vivo studies.... Agent: Cooper & Dunham, LLP

20100069347 - Heterocyclyl-substituted anti-hypercholesterolemic compounds: This invention provides cholesterol absorption inhibitors of Formula I: and the pharmaceutically acceptable salts thereof, wherein R12 is a hydroxylated alkyl group and R9 contains a heterocyclic ring. The compounds are useful for lowering plasma cholesterol levels, particularly LDL cholesterol, and for treating atherosclerosis and preventing atherosclerotic disease events.... Agent: Merck And Co., Inc

20100069350 - New pyridine analogues iii: The present invention relates to certain new pyridin analogues of Formula (I), to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-trombotic agents etc, their use as medicaments in cardiovascular diseases as well as pharmaceutical compositions containing them.... Agent: Pepper Hamilton LLP

20100069346 - New azetidine derivatives as neurokinin receptor antagonists for the treatment of gastrointestinal diseases: The application relates to new piperazine- or morpholine-substituted azetidine derivatives of formula I. These compounds are antagonists at the neurokinin receptor and can be used for the treatment of gastrointestinal diseases. The application also relates to processes for the preparation of the compounds and to intermediates in said preparation.... Agent: Fish & Richardson P.C.

20100069348 - Novel compounds as cannabinoid receptor ligands: e

20100069349 - Novel compounds as cannabinoid receptor ligands:

20100069352 - 5- [4-(azetidin-3-yloxy)-phenyl]-2-phenyl-5h-thiazolo[5,4-c] pyridin-4-one derivatives and their use as mch receptor antagonists: The present invention relates to a melanin concentrating hormone antagonist compound of formula I: wherein “ - - - ” is absent or is optionally a bond; q is 1 or 2; R1 is independently selected from hydrogen, —C1-C2 alkyl, halo, hydroxy, —C1-C2 haloalkyl, —C1-C3 alkoxy, cyano, —O—C3-C4 cycloalkyl, and... Agent: Eli Lilly & Company

20100069354 - 7-azaindole derivatives and their use in the inhibition of c-jun n-terminal kinase: The present invention provides a compound of formula (I); or a pharmaceutically acceptable salt thereof, the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the inhibition of c-Jun N-terminal kinase (JNK) activity and the use in medicine and particularly in the treatment of neurodegenerative... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20100069355 - Analogs of indole-3-carbinol and their use as agents against infection: Compounds useful as antibacterial agents are provided. The compounds are analogs of indole-3-carbinol and have a backbone selected from dihydroindolo[2,3-b]carbazole, 2,2′-diindolylmethane, 2′,3-diindolylmethane, and 3,3′-diindolylmethane. The compounds are useful therapeutic and prophylactic treatment of bacterial infections in mammals. Methods of synthesis of the compounds are provided, as are pharmaceutical compositions containing... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100069353 - Inhibitors of hiv replication: The present invention relates to compounds of formula (I) wherein R1, R2, R3 and R4 are as defined herein, compositions and uses thereof for treating human immunodeficiency virus (HIV) infection. In particular, the present invention provides novel inhibitors of HIV replication, pharmaceutical compositions containing such compounds and methods for using... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100069351 - Spiro compound and use thereof: e

20100069356 - Dibenzothiazepine modulators of dopamine, alpha adrenergic, and serotonin receptors: The present invention relates to new dibenzothiazepine modulators of D1 receptors, D2 receptors, alpha-1 adrenergic receptors, alpha-2 adrenergic receptors, H1 receptors, 5-HT1A receptors, and/or 5-HT2 receptors, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx

20100069357 - Pyrimidine compounds, compositions and methods of use: Disclosed are compounds of Formula I, including steroisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, that are useful in modulating PIKK related kinase signaling, e.g., mTOR, and for the treatment of diseases (e.g., cancer) that are mediated at least in part by the dysregulation of the PIKK... Agent: Genentech, Inc.

20100069358 - Use of 7-azaindoles in the inhibition of c-jun n-terminal kinase: The present invention provides a compound of formula (I); or a pharmaceutically acceptable salt thereof in the inhibition of c-Jun N-terminal kinase (JNK) activity and particularly in the treatment of neurodegenerative disorders, inflammatory diseases and/or and autoimmune diseases. The invention also provides processes for the manufacture of said compounds of... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20100069359 - Constrained spirocyclic compounds as cgrp receptor antagonists: (wherein variables A1, A2, A3, G1, G2, G3, J, m, n, p, R1, R2, R3, R4 and Y are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention... Agent: Merck And Co., Inc

20100069360 - Organic compounds: h

20100069361 - Fused thiazole derivatives as kinase inhibitors: A series of 5,5-dimethyl-5,6-dihydro-1,3-benzothiazol-7(4H)-one and 7,7-dimethyl-5,6,7,8-tetrahydro-4H-[1,3]thiazolo[5,4-c]azepin-4-one derivatives, and analogues thereof, which are substituted in the 2-position by an optionally substituted benzofused morpholin-4-yl moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100069362 - Thienopyrimidone compound: s

20100069363 - Substituted 4-amino-3,5-dicyano-2-thiopyridines and use thereof: The present application relates to novel substituted 4-amino-3,5-dicyano-2-thiopyridine derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of hypertension and other cardiovascular disorders.... Agent: Barbara A. Shimei Director, Patents & Licensing

20100069364 - Substituted pyrazoline compounds with acat inhibition activity, their preparation and use as medicaments: The present invention relates to substituted pyrazoline compounds, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals, especially in dyslipidaemia.... Agent: Heslin Rothenberg Farley & Mesiti PC

20100069366 - Antibacterial quinoline derivatives: The claimed compounds are useful for the treatment of a bacterial infection. Also claimed is a composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of the claimed compounds, the use of the claimed compounds or compositions for the manufacture of a medicament for the... Agent: Philip S. Johnson Johnson & Johnson

20100069370 - Compounds, compositions and methods: Certain substituted sulfonamide derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100069365 - Diazepane-acetamide derivatives as selective 11b-hsd1 inhibitors: The present invention relates to diazepane-acetamide derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD-1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension... Agent: Millen, White, Zelano & Branigan, P.C.

20100069369 - Kinase inhibitors and their uses: e

20100069367 - Lxr and fxr modulators: Compounds of the invention are disclosed, such as compounds of formulae LX-LXIV, and pharmaceutically acceptable salts, isomers, or prodrugs thereof, which are useful as modulators of the activity of liver X receptors (LXR) and Farnesoid X receptors (FXR), where R00, R200, R400, R500, J11, J21, G1, G21, and Q are... Agent: Mcdonnell Boehnen Hulbert @ Berghoff LLP

20100069368 - Organic compounds and their uses: The present disclosure relates to compounds relating to the diagnosis and treatment of pathologies relating to the Hedgehog pathway, including but not limited to tumor formation, cancer, neoplasia, and non-malignant hyperproliferative disorders; specifically relating to compounds of formula I:... Agent: Novartis Institutes For Biomedical Research, Inc.

20100069371 - Thienopyridine and furopyridine kinase inhibitors: e

20100069372 - Compositions and methods for modulating poly(adp-ribose) polymerase activity: The present invention is based, in part, on assays we conducted that revealed compounds that modulate (e.g., inhibit) PARP-1 and are therefore useful in treating or preventing diseases characterized by abnormal PARP-1 activity (e.g., undesirable PARP-1 activity).... Agent: Fish & Richardson PC

20100069373 - Substituted lactams as inhibitors of a beta protein production: having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the... Agent: Kelley Drye & Warren LLP

20100069374 - Tricyclic benzopyrane compound: wherein R1 and R2 are independently of each other hydrogen atom, C1-6alkyl group or C6-14aryl group, R3 is hydrogen atom or C1-6alkylcarbonyloxy group, or together with R4 forms a bond, R4 is hydrogen atom, or together with R3 forms a bond, m is an integer of 0 to 4, n... Agent: Oliff & Berridge, PLC

20100069375 - Indolone-acetamide derivatives, processes for preparing them and their uses: The present invention relates to indolone-acetamide derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as for the treatment of epilepsy, epileptogenesis, seizure disorders and convulsion.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100069376 - 5-hydroxymethyl-oxazolidin-2-one antibacterials: e

20100069377 - Treatment of female sexual dysfunction by compounds that positively modulate ampa-type glutamate receptors: The present invention provides methods of increasing sexual arousal and performance behaviors in female mammals by administration of a therapeutically acceptable amount of a positive modulator of an AMPA-type glutamate receptor.... Agent: Townsend And Townsend And Crew, LLP

20100069379 - Bicyclic androgen and progesterone receptor modulator compounds and methods: The present invention is directed to compounds, pharmaceutical compositions, and methods for modulating processes mediated by AR and PR. More particularly, the invention relates to nonsteroidal compounds and compositions that are high affinity, high specificity agonists, partial agonists (i.e., partial activators and/or tissue-specific activators) and antagonists for AR and PR.... Agent: K&l Gates LLP

20100069378 - Substituted indanyl sulfonamide compounds, their preparation and use as medicaments: The present invention refers to new indanyl sulphonamide compounds with general formula (I), as well as to their preparation procedure, their application as medicine and the pharmaceuticals composition which they are made up of. The new compounds of formula (I) show affinity for 5-HT6 receptors and are, therefore, effective for... Agent: Knobbe Martens Olson & Bear LLP

20100069380 - Heterocyclic inhibitors of bacterial peptidyl trna hydrolase and uses thereof: Provided herein are compounds that modulate the activity of a bacterial peptidyl tRNA hydrolase, including compositions and dosage forms comprising the compounds. Further provided herein are methods for screening and identifying compounds that modulate the activity of a bacterial peptidyl tRNA hydrolase. In particular, provided herein are assays for the... Agent: Jones Day

20100069381 - Gsk-3betainhibitor: o

20100069382 - Agent for prophylaxis or treatment of alcohol dependence or drug dependence: The present invention provides an agent for the prophylaxis or treatment of substance abuse and dependence, which contains a compound of the formula (I) represented by (R)-2-{3-[1-(acenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide, or a pharmaceutically acceptable salt thereof as an active ingredient.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100069383 - Compounds and therapeutical use thereof: Disclosed are 4-arylamino-quinazolines and analogs thereof that are effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.... Agent: Myriad Pharmaceuticals, Inc. C/o Cpa Global

20100069384 - 5-alkyloxy-indolin-2-one derivatives, preparation thereof and application thereof in therapy: The present invention relates to derivatives of 5-alkyloxy-indolin-2-one, their method of production and their therapeutic applications. These novel derivatives have affinity and selectivity for the V2 receptors of vasopressin (“V2 receptors”) and can therefore constitute active principles of pharmaceutical compositions.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100069385 - Liquid formulations of phospholipase enzyme inhibitors: The present invention is directed to liquid formulations of inhibitors of phospholipase enzymes, such as cytosolic PLA2, compositions containing the same and processes for manufacture thereof.... Agent: Wyeth LLC Patent Law Group

20100069386 - Modulators of hedgehog signaling pathways, compositions and uses related thereto: The present invention makes available methods and reagents for inhibiting aberrant growth states resulting form hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting the cell with a hedgehog antagonist, such as a small molecule, in a sufficient amount to aberrant growth state, e.g., to agonize a normal ptc pathway... Agent: Dla Piper LLP (us)

20100069387 - Ikk inhibitors for the treatment of endometriosis: This invention relates to a method of treating and/or preventing endometriosis comprising administering an IKK inhibitor. The IKK inhibitor can also be administered combined with a hormonal suppressor. The invention further relates to the treatment of endometriosis-related infertility.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20100069388 - N-hydroxyacrylamide compounds: A compound having the following formula (I): wherein —R1 is hydrogen, optionally substituted lower alkyl, cyclo(lower)alkyl, cyclo(higher)alkyl, optionally substituted aryl, optionally substituted heterocyclyl, or aryl-fused cyclo(lower)alkyl, R2 is hydrogen or halogen, Z is CH or N, X is formula (II) R3 is lower alkyl which may be substituted with —OH... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100069390 - Method of treatment of attention deficit/hyperactivity disorder (adhd): The invention comprises a method for treatment of ADHD or ADHD-related disorders by a pharmaceutical agent exhibiting combined serotonergic or noradrenergic reuptake transporters and monoamine receptor activity.... Agent: Foley And Lardner LLP Suite 500

20100069389 - Novel forms of reboxetine: The invention relates to novel crystalline forms of (2R)-2-[(R)-(2-ethoxyphenoxy)-phenylmethyl]morpholine hydrochloride. In various embodiments, the novel crystalline forms may be substantially enantiopure. The preparation and characterization of the novel crystalline forms of (2R)-2-[(R)-(2-ethoxyphenoxy)-phenylmethyl]morpholine hydrochloride is also described. The invention also relates to pharmaceutical compositions containing novel crystalline forms of (2R)-2-[(R)-(2-ethoxyphenoxy)-phenylmethyl]morpholine hydrochloride,... Agent: O'brien Jones, PLLC

20100069391 - Novel seh inhibitors and their use: The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20100069392 - Combination of hmg-coa reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary disease: The invention relates to the combined use of a PDE4 inhibitor with a HMG-CoA reductase inhibitor for the preventive and curative treatment of an inflammatory pulmonary disease.... Agent: Nath & Associates PLLC

20100069393 - Method of treatment and agents useful for same: The present invention relates generally to therapeutic agents, formulations comprising them and their use in the treatment, amelioration and/or prophylaxis of glioma brain tumours and related conditions. The therapeutic agent comprises two fused 6-membered rings with at least a nitrogen at position 1 and a hydroxyl at position 8.... Agent: Scully Scott Murphy & Presser, PC

20100069394 - Fast-dissociating dopamine 2 receptor antagonists: The present invention relates to 4-aryl-6-piperazin-1-yl-3-substituted-pyridazines that are fast dissociating dopamine 2 receptor antagonists, processes for preparing these compounds, pharmaceutical compositions comprising these compounds as an active ingredient. The compounds find utility as medicines for treating or preventing central nervous system disorders, for example schizophrenia, by exerting an antipsychotic effect... Agent: Philip S. Johnson Johnson & Johnson

20100069396 - 4-amino-3-(imidazolyl)-pyrazolo[3,4-d]pyrimidines: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are 4-amino-3-imidazoyl-pyrazolo[3,4-d]pyrimidine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.... Agent: Townsend And Townsend And Crew, LLP

20100069395 - Pyrazolo[1,5-a]pyrimidine-3-carboxylic acid compounds as protein kinase inhibitors: m

20100069397 - Sexual dysfunction compounds: The present invention provides for a sexual dysfunction compound comprising a rapid-onset pharmaceutical composition that further comprises cocoa powder. The invention also provides for a process for manufacturing the composition, and use of the composition in sexual dysfunction therapy.... Agent: Fulbright & Jaworski, LLP

20100069398 - Combination therapy: The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumour... Agent: Morgan Lewis & Bockius LLP

20100069399 - Arylpiperazine modulators of d2 receptors, 5-ht1a receptors, and/or 5-ht2a receptors: The present invention relates to new arylpiperazine modulators of D2 receptors, 5-HT1A receptors, and/or 5-HT2A receptors, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx

20100069400 - Methods for treating inflammation and related conditions: A method for treating an inflammatory condition or immune disorder comprises administering to a subject having such a condition or disorder a therapeutically effective amount of at least one compound selected from irindalone, physiologically active enantiomers thereof, and pharmaceutically acceptable salts thereof. The invention further provides a method for elevating... Agent: Harness, Dickey, & Pierce, P.l.c

20100069401 - Use of catecholamines and related compounds as anti-angiogenic agents: A catecholamine or related compound of formula (I) having (S)-configuration at β-carbon and having a lipophilicity greater than (S)-noradrenalme, a physiologically tolerated salt thereof, a prodrug thereof, a physiologically functional derivative thereof or any mixture thereof is useful as an anti-angiogemc agent A catecholamine or related compound of formula (II)... Agent: National Research Council Of Canada 1200 Montreal Road

20100069403 - Methods for preventing or treating cardiac arrhythmia: Disclosed are methods of preventing or treating cardiac arrhythmia comprising administering to a mammal in need thereof, such as a human, an effective amount of vanoxerine (GBR 12909) or a pharmaceutically acceptable salt, derivative or metabolite thereof.... Agent: Duane Morris LLP - Dc

20100069402 - Treatment of behavioral disorders: The present invention relates to a method for treating a behavior disorder comprising the administration of a therapeutically effective amount of antihistamine, such as cetirizine, fexofenadine; loratadine, and desloratadine. The behavioral disorders may include ADHD, anxiety, depression, and autism. The method may include the administration of the antihistamine in combination... Agent: Sheridan Ross PC

20100069404 - Tetrahydrocyclopenta[b] indole compounds as androgen receptor modulators: The present invention provides a compound of the formula: Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly reduced bones mass, osteoporosis, osteopenia, or reduced muscle mass... Agent: Eli Lilly & Company

20100069405 - Derivatives of heteroaryl-alkylcarbamates, methods for their preparation and use thereof as fatty acid amido hydrolase enzyme inhibitors: e

20100069406 - Aspartyl protease inhibitors: Disclosed are compounds of formula I (Chemical formula should be inserted here as it appears on abstract in paper form) Formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein R1, R2, R3, R4, R14, V, W, X, Y, Z, p, and ring A are as... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20100069407 - Cxcr2 inhibitors: The present invention relates to compounds of formula (I) and the use of these compounds as pharmaceuticals, e.g. in preventing or treating a CXCR2 receptor mediated condition or disease.... Agent: Novartis Institutes For Biomedical Research, Inc.

20100069408 - Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition: The invention provides new triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation.... Agent: Nixon & Vanderhye, PC

20100069409 - \"novel compounds\": Novel substituted 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds, and 1,5,7-trisubstituted-3,4-dihydro-pyrimido[4,5-d]pyrimidin-2-(M)-one compounds and compositions, and their use in therapy as CSBP/RK/p38 kinase inhibitors.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20100069410 - acyclovir formulations: The present invention relates to acyclovir formulations having improved bioavailability resulting in better efficacy and/or requiring less frequent administration.... Agent: Emisphere Technologies, Inc

20100069411 - Cancer treatment method: The present invention relates to a method of treating cancer in a mammal by administration of 4-quinazolinamines and at least one additional anti-neoplastic compound. In particular, the method relates to a methods of treating cancers by administration of N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine and salts and solvates thereof in combination with at least one... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20100069414 - Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them: Ra to Rc, A to E and X are defined as in claim 1, the tautomers, stereoisomers and salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, in particular an inhibitory effect on signal transduction mediated by tyrosine kinases,... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100069412 - Phosphonoxy quinazoline derivatives and their pharmaceutical use:

20100069413 - Pyrimidine and quinazoline derivatives: wherein A, R1 to R5 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100069415 - 2,6-diphenyl-4,8-diazoadamantan-1-one and derivatives thereof, process of manufacture and use for the formulation of solutions with sterilizing and disinfectant effect: A chemical compound having the following structural formula wherein optionally at least one of the phenyl —C6H5 groups bound to the Carbon atoms in position 2 and 6 is independently substituted with a methyl —CH3 or ethyl —C2H5 group, and wherein optionally the ═CH2 group in position 10 is substituted... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20100069416 - Azabicyclo [3.1.0] hexyl derivatives as modulators of dopamine d3 receptors: c

20100069418 - 3-heteroaryl (amino or amido)-1-(biphenyl or phenylthiazolyl) carbonylpiperidine derivatives as orexin receptor inhibitors: The invention relates to piperidine compounds of formula (I) wherein X-R1 represents —N(H)-pyrimidinyl, wherein said pyrimidinyl is unsubstituted or mono-substituted wherein the substituent is selected from (C1-4)alkyl or halogen, or X-R1 represents —NH—C(O)-heterocyclyl, wherein the heterocyclyl is selected from benzofuranyl and imidazo[2,1-b]-thiazolyl, wherein said heterocyclyl is unsubstituted or independently mono-,... Agent: Hoxie & Associates LLC

20100069417 - Novel phenyl(4-phenylpyrimidin-2-yl)amine derivatives, their preparation, as medicaments, pharmaceutical compositions and in particular as ikk inhibitors: e

20100069420 - Spiro-piperidine inhibitors: Provided are compounds that are capable of modulating the activity of the influenza A virus via interaction with the M2 transmembrane protein. Also provided are methods for treating an influenza A-affected disease state or infection comprising administering a composition comprising one or more compounds that have been identified as being... Agent: Woodcock Washburn LLP

20100069419 - Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease: which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of... Agent: Merck And Co., Inc

20100069421 - Compositions and methods for the treatment of radiation proctosigmoitis: The present invention provides a new method of preventing, ameliorating and/or treating enteritis induced by abdominopelvic therapies. The present invention also relates to the prophylactic treatment of traveler's diarrhea.... Agent: Edwards Angell Palmer & Dodge LLP

20100069422 - Methods and compositions for promoting bone and joint health: Methods and compositions that can be used to promote bone and joint health through amelioration, stabilization and repair of damage associated with various pathophysiological conditions are disclosed.... Agent: Mcdermott Will & Emery LLP

20100069424 - 3-cyano-quinoline derivatives with antiproliferative activity: t

20100069423 - Use of chk2 kinase inhibitors for cancer treatment: Described herein are Chk2-inhibitor compounds and derivatives thereof, and methods of treating or preventing disease and disease symptoms using the compounds and compositions thereof.... Agent: Edwards Angell Palmer & Dodge LLP

20100069425 - Glucocorticoid receptor modulator and methods of use: The present invention provides Compound (I): Compound (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising Compound (I) in combination with one or more pharmaceutically acceptable carriers, excipients, or diluents; and methods for the treatment of inflammatory and immune disorders comprising administering to a patient in need thereof an... Agent: Eli Lilly & Company

20100069426 - Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same: The present disclosure generally relates to therapeutic nanoparticles. Exemplary nanoparticles disclosed herein may include about 1 to about 20 weight percent of a mTOR inhibitor; and about 70 to about 99 weight percent biocompatible polymer.... Agent: Goodwin Procter LLP Patent Administrator

20100069427 - Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods: Imidazo[4,5-c] ring compounds, (e.g. imidazo[4,5-c]pyridines, imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydro imidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridine, and 6,7,8,9-tetrahydro imidazo[4,5-c]naphthyridine compounds) having an oxime or hydroxylamine substituent at the 2-position, pharmaceutical compositions containing the compounds, intermediates, and methods of making and methods of use of these compounds as immunomodulators, for modulating cytokine biosynthesis in animals and in the... Agent: Wolf Greenfield & Sacks, P.C.

20100069428 - Acridone compounds: A class of acridone compounds has been discovered that exhibits chemosensitizing and antiparasitic activity. Described herein are pharmaceutical compositions and methods for their use to treat parasitic infections, such as malaria and toxoplasmosis, and to sensitize resistant cells, such as multidrug resistant cells to other therapeutic agents. The pharmaceutical compositions... Agent: Klarquist Sparkman, LLP

20100069429 - Tea polyphenol composition and method for producing the same: The objective of the present invention is to provide a tea polyphenol composition that has reduced bitterness and astringency while containing catechins with high purity. The present invention provides a tea polyphenol composition, (A) comprising 85% by weight to 95% by weight of catechins, (B) wherein the catechins contains epigallocatechin... Agent: Fish & Associates, PC Robert D. Fish

20100069430 - Pyrrolo[2,3-c]pyridine derivatives and processes for the preparation thereof: The present invention provides novel pyrrolo[2,3-c]pyridine derivatives or pharmaceutically acceptable salts thereof, processes for the preparation thereof, and compositions comprising the same. The pyrrolo[2,3-c]pyridine derivatives or pharmaceutically acceptable salts thereof of the present invention have excellent proton pump inhibition effects and possess the ability to attain a reversible proton pump... Agent: Sughrue Mion, PLLC

20100069431 - Imidazopyridine compounds: Compounds, pharmaceutical compositions, kits and methods are provided for use with glucokinase that comprise a compound selected from the group consisting of formula (I) wherein the variables are as defined herein.... Agent: Takeda San Diego, Inc.

20100069432 - Bis-quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors: Provided are bis-quaternary ammonium compounds which are modulators of nicotinic acetylcholine receptors. Also provided are methods of using the compounds for modulating the function of a nicotinic acetylcholine receptor, and for the prevention and/or treatment of central nervous system disorders, substance use and/or abuse, and or gastrointestinal tract disorders.... Agent: Crowell & Moring LLP Intellectual Property Group

20100069433 - Prophylactic and/or therapeutic agent for hyperlipidemia: o

20100069434 - Compositions of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide: Pharmaceutical compositions including N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1) and methods of using such compositions are described herein.... Agent: Jonathan P. O''brien, Ph.d. Honigman Miller Schwartz & Cohn LLP

20100069435 - Method of selectively introducing amino substituent: a

20100069436 - Imidazole compounds having an antiinflammatory effect: The invention relates to imidazole derivatives of the Formula (I) in which the radicals R1, R2, R3, R4 and R5 have the meanings indicated in the description. The compounds of the invention have an immunomodulating and/or cytokine release-inhibiting effect and are therefore suitable for the treatment of disorders associated with... Agent: Edwards Angell Palmer & Dodge LLP

20100069437 - Therapeutic agents useful for treating pain: 4-Tetrazolyl-4-phenylpiperidine Compounds, compositions comprising an effective amount of a 4-Tetrazolyl-4-phenylpiperidine Compound, methods for treating or preventing pain or diarrhea in an animal comprising administering to an animal in need thereof an effective amount of a 4-Tetrazolyl-4-phenylpiperidine Compound and methods for stimulating opioid-receptor function in a cell comprising contacting a cell... Agent: Dechert LLP

20100069438 - Anesthesia induction and maintenance drug: Disclosed herein is a combination drug designed for use by anesthesiologists for the purposes of inducing and/or maintaining general anesthesia and minimizing the stress response to pain that results from the noxious stimuli associated with surgical procedures. The present invention is suitable for use in general anesthesia to decrease the... Agent: Hogan & Hartson LLPIPGroup, Columbia Square

20100069439 - Microorganism control agent and stabilizing method: Disclosed is a microorganism control agent containing not less than 1% by weight but less than 10% by weight of N,N′-hexamethylenebis(4-carbamoyl-1-decylpyridinium bromide), not less than 35% by weight but less than 60% by weight of at least one alcohol having 2 or 3 carbon atoms, water and an acid.... Agent: Buchanan, Ingersoll & Rooney PC

20100069440 - Pyridine non-classical cannabinoid compounds and related methods of use: s

20100069441 - Antimicrobial indoline compounds for treatment of bacterial infections:

20100069442 - Pyrazole compounds that modulate hsp90 activity: Variable R5 is an optionally substituted heteroaryl; an optionally substituted 6 to 14-membered aryl; a bicyclic 9-member heterocycle optionally substituted at any substitutable nitrogen or carbon atoms; or a substituent R18, defined herein. Ring A is an aryl or a heteroaryl optionally further substituted with one or more substituents in... Agent: Foley & Lardner LLP

20100069443 - Compound with benzamide skeleton having cyclooxygenase-1 (cox-1)-selective inhibitory activity: This invention provides a novel COX-1-selective inhibitor. This invention relates to a novel compound represented by the formula below or a salt thereof. This invention also relates to an analgesic agent, an antiinflammatory agent, an antitumor agent, an antiplatelet aggregation agent, and a cyclooxygenase-1-selective inhibitor comprising, as an active ingredient,... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100069444 - Phenathrenone compounds, compositons and methods: i

20100069446 - L-threonine derivatives of high therapeutic index: The present invention is directed to a derivative comprised of an L-Threonine bonded to a medicament or drug having a hydroxy, amino, carboxy or acylating derivative thereon. The derivative has the same utility as the drug from which it is made, but it has enhanced therapeutic properties. In fact, the... Agent: Scully Scott Murphy & Presser, PC

20100069445 - Method for the separation of s-(-)-amlodipine from racemic amlodipine: Disclosed is a method for the separation of S-(−)-amlodipine from a racemic amlodipine. Featuring the use of inexpensive L-tartaric acid as an optical resolution agent and DMAC as a solvent, the separation method allows the resolution of S-(−)-amlodipine from racemic amlodipine at high yield and to a satisfactory enantiomeric excess... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20100069447 - Benzamide derivatives and uses related thereto: s

20100069448 - Human protein tyrosine phosphatase inhibitors and methods of use: The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-β) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising said human protein tyrosine phosphatase beta (HPTP-β) inhibitors, and to methods for regulating angiogenesis.... Agent: Ballard Spahr LLP

20100069449 - Novel oxazolidinone derivative with difluorophenyl moiety, pharmaceutically acceptable salt thereof, preparation method thereof and antibiotic composition containing the same as an active ingredient: e

20100069450 - Salt of 3-benzyl-2-methyl-2,3,3a,4,5,6,7, 7a- octahydrobenzo[d]isoxazol-4-one: The present invention relates to fumarate salt of the compound of formula (I) in all its stereochemical configurations, a process for its preparation and its use in treating mood disorders, disorders of anxiety, depression and convulsive conditions, in the improvement of learning ability, in the reversal of amnesia, in resolving... Agent: Knobbe Martens Olson & Bear LLP

20100069451 - Salt of 3-benzyl-2-methyl-2,3,3a,4,5,6,7, 7a- octahydrobenzo[d]isoxazol-4-one: The present invention relates to oxalate salt of the compound of formula (I) in all its stereochemical configurations, a process for its preparation and its use in treating mood disorders, disorders of anxiety, depression and convulsive conditions, in the improvement of learning ability, in the reversal of amnesia, in resolving... Agent: Knobbe Martens Olson & Bear LLP

20100069452 - Mineralocorticoid receptor modulators: e

20100069453 - Certain chemical entities, compositions, and methods: Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100069454 - Novel compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection: The present invention provides compounds, pharmaceutical compositions and methods for treating, immuno-allergical diseases, autoimmune diseases, and organ or tissue rejection following transplantation.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100069455 - Bone model, bone filler and process for producing bone filler: A method for producing a bone filler basically comprising: a bone model producing step (step 1) for producing a bone model; a figure forming material filling step (step 2) for filling a figure forming material into a bone defect site of the bone model obtained in the bone model producing... Agent: Osha Liang L.L.P.

20100069456 - Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels: Use of a compound of formula (I) in which R, R′ and R″ have the meanings given in the description, optionally in the form of a salt thereof with a pharmaceutically acceptable organic or mineral base, to prepare a pharmaceutical composition for reducing the blood triglyceride, cholesterol and glucose levels.... Agent: Darby & Darby P.C.

20100069457 - Naphthalene derivatives used as ep4 receptor agonists: e

20100069458 - Combination of lbh589 with other therapeutic agents for treating cancer: The invention relates to a combination comprising the N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide; and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; methods of treatment comprising said combination; processes for making said combination; and a commercial package comprising said combination.... Agent: Novartis Corporate Intellectual Property

20100069459 - Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid magnesium: Novel forms of atorvastatin magnesium salt designated Form A, Form B, Form C, Form D, Form E, and Form F, pharmaceutical compositions containing such compounds, methods for their preparation and methods utilizing the compounds for treatment of hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia (BPH) and Alzheimer's disease are described.... Agent: Pfizer Inc. Patent Department

20100069460 - 1-phenyl 1-thio-d-glucitol derivative: or a pharmaceutically acceptable salt thereof or a hydrate thereof, or a pharmaceutical preparation comprising the same as an active ingredient is useful as a novel type of prophylactic or therapeutic agent for diabetes, diabetes-related diseases or diabetic complications, which inhibits both SGLT1 and SGLT2 activities to achieve not only... Agent: Sughrue Mion, PLLC

20100069473 - Inhibitors of ikk-beta serine-threonine protein kinase: R1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular esterase enzymes to a carboxylic acid group; R6 is hydrogen, or optionally substituted C1-C6 alkyl, C3-C7 cycloalkyl, aryl or heteroaryl or —(C═O)R3, —(C═O)OR3, or —(C═O)NR3 wherein R3 is hydrogen or optionally... Agent: Banner & Witcoff, Ltd.

20100069474 - Novel coumarin derivatives as ion channel openers: The present invention is directed to novel coumarin derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders related to ion channels such as potassium channels... Agent: Philip S. Johnson Johnson & Johnson

20100069475 - Method of activating nk cells: The present invention provides a method of mediating hypo-activation of NK cells. Methods of the present invention comprise administering to a subject an effective amount of broad acting phosphotase inhibitor, such as sodium orthovanadate, SHP specific inhibitor. In one embodiment, the SHP specific inhibitor is NSC119910.... Agent: Smith Hopen, Pa

20100069476 - Compositions and methods for reduction of cutaneous photoageing: Compositions and methods are provided in which a topical hydrophilic formulation includes a catechin and a hydrophilic antioxidant in a hydrophilic composition at a ratio of between 2.3 to 1.7 (by weight), ad wherein the catechin and the antioxidant are present in an amount such that application of the composition... Agent: Fish & Associates, PC Robert D. Fish

20100069478 - Isoflavone derivatives and uses thereof: Isoflavone derivatives are provided comprising a carboxyalkylene moiety linked via its alkylene chain to the aromatic ring and via its carboxy group to an aminoalkyleneamino residue, which, in turn, is covalently linked to a functional group B. The isoflavone derivatives are preferably derived from biochanin A, genistein, and daidzein, and... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20100069477 - Methioninase inhibitor and composition and food or drink containing the same: The invention provides a methioninase inhibitor to suppress the production of methyl mercaptan that is a causative substance of a bad smell by inhibiting methioninase originated from bacteria, as well as a composition and a food or drink containing the same, wherein the methioninase inhibitor contains an extract obtained from... Agent: Rader Fishman & Grauer PLLC

20100069480 - Methods and compositions for the treatment of cancer: Isolated compounds and combinations of isolated compounds isolated from Scutellaria barbata D. Don are effective in the generation of reactive oxygen species, induction of DNA damage and induction of apoptosis in cancer cells. The compounds and combinations may be prepared as pharmaceutical compositions for administration to mammals, such as humans,... Agent: Wilson, Sonsini, Goodrich & Rosati

20100069481 - Methods and compositions for the treatment of cancer: Isolated compounds and combinations of isolated compounds isolated from Scutellaria barbata D. Don are effective in the generation of reactive oxygen species, induction of DNA damage and induction of apoptosis in cancer cells. The compounds and combinations may be prepared as pharmaceutical compositions for administration to mammals, such as humans,... Agent: Wilson, Sonsini, Goodrich & Rosati

20100069479 - Neurodegenerative disease treatment using jak/stat inhibition: The invention relates to treatment of neurodegenerative diseases with JAK/STAT pathway inhibitors to eliminate extracellular cell signaling events leading to cell cycle abrogation and/or apoptosis. Primary neurons were administered neurotoxic proteins, such as gp120, Tat, or gp120 and Tat, with or without IFN-γ added, resulting in neuronal death, and simulated... Agent: Smith Hopen, Pa

20100069482 - Gel useful for the delivery of ophthalmic drugs: It is described a gel composed of a mixture of a polymer which forms a gel, a buffer; a saccharide and one or more active ingredients useful for treating diseases of the eyes.... Agent: Lucas & Mercanti, LLP

20100069483 - Dual inhibition of cyclooxygenase-2 and carbonic anhydrase: Compounds of Formula I potently inhibit both cyclooxygenase-2 and carbonic anhydrases. Inhibition of carbonic anhydrases by a cyclooxygenase-2 inhibitor may affect significantly the safety and efficacy profiles of such a dual inhibitor in the treatment of cyclooxygenase-2 mediated disorders, compared to a cyclooxygenase-2 inhibitor without carbonic anhydrase inhibitory activity.... Agent: Sughrue Mion, PLLC

20100069484 - Sigma(s)-receptor ligands with anti-apoptotic and/or pro-apoptotic properties over cellular biochemical mechanisms, with neuroprotective, anti-cancer, anti-metastatic and anti-(chronic) inflammatory action: The present invention involves new and original sigma receptors ligands : (Mono- or di-alkylaminoalkyl)-γ-butyrolactones, their analogues aminotetrahydrofuranes, the (1-adamantyl)phenyl(s) alkylamines, the N,N Dialkyl α-[(adamantyl-1)benzyloxy-2] alkylamines and the 3-cyclopentyl adamantyl-amines or alkylamines or -alkyl phenylamines, their enantiomers or diastereoisomers and their pharmaceutically acceptable salts, with pro-apoptotic and/or anti-apoptotic properties over cellular... Agent: David A. Guerra International Patent Group, LLC

20100069485 - Method for maintaining freshness of fruits and vegetables: A process and a composition to extend the freshness of fruits and vegetables are disclosed. The method comprises treating fresh fruit or vegetable structures with a solution comprising organic acids including N-acetyl cysteine.... Agent: Dodds & Associates

20100069486 - Anti-tumor composition: The present invention provides composition having as active ingredients a stilbene derivative and a platinum coordination compound which is highly efficacious and highly safe for treating tumors, particularly for the treatment of solid or malignant tumors and thus methods of cancer and tumor treatment using the composition are also provided.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100069487 - Method for the treatment of psoriasis: A method for the therapeutic treatment of psoriasis by the administration of an anti-psoriasis effective amount of Doxivir (CTC-96) is discloses.... Agent: Buckley, Maschoff & Talwalkar LLC

20100069488 - Fire retardant composition: A composition can embrace a fire retardant can be combined with a fluoropolymer, which can be a coating, for example, a paint, especially a latex paint, or which can be an organic solvent based coating, for example, a paint. The fire retardant can be an ammonium phosphate containing fire retardant,... Agent: Christopher John Rudy

20100069489 - L-threonine derivatives of high therapeutic index: The present invention is directed to a derivative comprised of an L-Threonine bonded to a medicament or drug having a hydroxy, amino, carboxy or acylating derivative thereon. The derivative has the same utility as the drug from which it is made, but it has enhanced therapeutic properties. In fact, the... Agent: Scully Scott Murphy & Presser, PC

20100069490 - Composition for a pharmaceutical treatment based on triethyl citrate and adapalene: The invention proposes a composition for pharmaceutical use containing as active principles triethyl citrate and adapalene in quantities efficacious for use in the treatment of cutaneous pathologies of inflammatory origin, caused by bacterial infections or altered lipid metabolism, both in the treatment of chronologic and photo induced cutaneous ageing,... Agent: Mcglew & Tuttle, PC

20100069491 - Lipid-amino acid conjugates and methods of use: N-fatty acid-amino acid conjugates and J2 prostanoid-amino acid conjugates are disclosed along with methods for making such conjugates and methods of using these conjugates in the treatment of conditions that involve dysfunctional lipid metabolism, insulin sensitivity, glucose homeostasis, and/or inflammation.... Agent: Fish & Richardson PC

20100069492 - Production of ultrapure epa and polar lipids from largely heterotrophic culture: Eicosapentaenoic acid (EPA) compositions and EPA-rich polar lipids for prophylactic or therapeutic applications are described. Production from certain cultured micro-organisms (like Nitzschia laevis) promotes synthesis of EPA, including polar lipids including EPA. The EPA-rich polar lipids themselves may be used as polar compounds. EPA can be selectively hydrolysed from particular... Agent: Pearl Cohen Zedek Latzer, LLP

20100069493 - Aqueous pharmaceutical formulation of 4-[((4-carboxybutyl)-amino)methyl]benzoic acid: The present invention relates to an aqueous pharmaceutical formulation which comprises 4-[((4-carboxybutyl)-{2-[(4-phenethylbenzyl)oxy]phenethyl}amino)methyl]benzoic acid or a salt thereof. The present invention relates in particular to an aqueous pharmaceutical formulation which comprises 4-[((4-carboxybutyl)-{2-[(4-phenethylbenzyl)oxy]phenethyl}amino)methyl]benzoic acid and 2-amino-2-(hydroxymethyl)-1,3-propanediol (trometamol).... Agent: Barbara A. Shimei Director, Patents & Licensing

20100069494 - Lowering of proteins associated with alzheimer's disease by interrupting gene transcription with a small molecule: A method of treating Alzheimer's disease in a patient. The method includes administrating tolfenamic acid to the patient to modulate precursors of pothgene intermediates. The treatment also lowers SP1, APP and Aβ1 levels.... Agent: Gauthier & Connors, LLP

20100069495 - Topical application of adapalene for the long-term treatment of acne vulgaris: Administration of adapalene in a topical medicament to a patient so as to sustain its biological response in the treatment of acne vulgaris, wherein the administration pattern of the topical medicament comprises topically applying onto the afflicted skin area a therapeutically effective amount of adapalene at least once every two... Agent: Buchanan, Ingersoll & Rooney PC

20100069496 - 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs: The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR delta modulators to treat or inhibit the progression of, for example, dyslipidemia.... Agent: Philip S. Johnson Johnson & Johnson

20100069497 - Compositions comprising jasmonic acid derivatives and use of these derivatives: e

20100069498 - Use of alpha-ketoglutaric acid for the treatment of high plasma glucose condition: A method for improving adsorption of amino acids in a vertebrate, including mammal and bird, is included. The method comprises administering to a vertebrate, including mammal and bird, in a sufficient amount and/or at a sufficient rate to enable a desired effect, AKG, AKG derivates or metabolites, AKG analogues or... Agent: Morrison & Foerster LLP

20100069499 - Amide compound and use thereof: In the formula, X1 represents a fluorine atom or a methoxy group; X2 represents a chlorine atom, a bromine atom, an iodine atom, a C1-C4 alkyl group or the like; Z represents an oxygen atom or a sulfur atom; and A represents an A1-CR11R12R13 group or A2-Cy group, wherein A1... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100069500 - Amide dendrimer compositions: Amide compounds, amide polymers, compositions including amide compounds and amide polymers may be used to bind target ions, such as phosphorous-containing compounds in the gastrointestinal tract of animals. In some cases, amide compounds and amide polymers may include a core derived from an amide polyol and an organic polyacid or... Agent: Jones Day

20100069501 - Pharmaceutical composition comprising 6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol and paracetamol: A combination comprising (a) at least one 6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol component, and (b) Paracetamol or a derivative thereof; a pharmaceutical composition and/or dosage form comprising such a combination as well as a method of treating one or more of pain and ostheoarthritis in a mammal characterized in that components (a) and (b)... Agent: Crowell & Moring LLP Intellectual Property Group

20100069502 - Assay: The invention relates to a method for identifying a candidate agent for use in a medicament for diabetes or obesity said method comprising (i) providing a candidate inhibitor of PPM phosphatase, (ii) providing a first and a second sample comprising PPM phosphatase, (iii) contacting said candidate inhibitor with said first... Agent: Bradley Arant Boult Cummings LLP Intellectual Property Department

20100069503 - Inhibition of mitogen-activated protein kinases in cardiovascular disease: The present invention relates to methods for inhibiting subacute thrombosis and/or intimal hyperplasia following an interventional vascular procedure by contacting a blood vessel or a synthetic material with a mitogen-activated protein kinase (MAPK) pathway inhibitor. The present invention further relates to vascular devices comprising a MAPK pathway inhibitor.... Agent: Darby & Darby P.C.

20100069504 - Aminobenzocycloheptene derivatives, methods for preparing the same and uses thereof in therapy: A compound of the general formula (I) as an active principle for treating cancer, specifically tumors, in particular diseases involving inhibition of metalloproteases, such as Aminopeptidase-N. Pharmaceutical compositions comprising the compound of general formula (I). Methods of treatment using the compound of general formula (I).... Agent: Young & Thompson

20100069505 - Alcoholic pump foam: An alcoholic foam composition, which can be dispensed as a foam via a pump-foam system contains a) at least 52 to ≦99 wt % of an alcohol or mixture of alcohols, b) a surfactant or a surfactant mixture, c) at least one polyalkylene glycol, d) optionally, at least one foam... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100069506 - Composition for pest control: Methods for killing amphibians include contacting the amphibian with said compositions. Kits are described wherein said xylenol compounds and ethanol and optionally methanol and/or at least one C3-6 alcohol may be administered simultaneously or sequentially.... Agent: Klauber & Jackson

20100069507 - Porous carbon materials and production process thereof, and adsorbents, masks, adsorbing sheets and carriers: By a process for producing a porous carbon material from a plant-derived material as a raw material, said process including carbonizing the plant-derived material at 800° C. to 1,400° C. and then applying a treatment with an acid or alkali, a porous carbon material having a value of specific surface... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20100069509 - Nonionic emulsifiers for emulsion concentrates for spontaneous emulsification: The present invention relates to a nonionic emulsifier for spontaneous emulsification, containing a chemical compound having the general structure tallow alcohol -n PO-m EO, the average number of hydrocarbon atoms of the tallow alcohol amounting to between 16 and 18, and the iodine count being lower than or equal to... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100069508 - Organic compounds: e

20100069510 - Process for the manufacture of a powder containing carotenoids: The present invention relates to a process for the manufacture of an emulsion or dispersion containing one or more carotenoids, in a preferred embodiment it relates to the manufacture of a powder containing one or more carotenoids, furthermore to the powder obtainable by said process and a food composition, especially... Agent: Nixon & Vanderhye, PC

20100069511 - Stable mixed emulsions: Stable mixed emulsion systems containing at least two discrete and distinctly different dispersed particle size ranges, i.e., both nanoemulsion and macroemulsion semisolid dispersions, as well as a method of making the same, are disclosed. The stable mixed emulsions may be used for cosmetic and dermatological applications and provide unique benefits.... Agent: Fitzpatrick Cella Harper & Scinto

20100069512 - Process for preparing an oil-in-water emulsion stabilised with recombinant collagen-like material and products prepared: The invention provides oil-in-water emulsions comprising recombinant collagen-like polymer in an amount sufficient to act as stabiliser of the emulsion. The polymer is especially a polypeptide which is free of helix structure, has an isoelectric point at least 0.5 pH units removed from the pH of the oil-in-water emulsion. Furthermore,... Agent: Ip Patent Docketing K&l Gates LLP

  
03/11/2010 > patent applications in patent subcategories. listing by industry category

20100062967 - Coated lipid complexes and their use: The present invention is related to a lipid composition comprising at least a first lipid component, at least a first helper lipid, and a shielding compound which is removable from the lipid composition under in vivo conditions.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100062969 - Hydrophilic polymer-conjugated lipids for peptide and protein folding disorders: The present invention provides a method of correcting peptide or protein misfolding, which can be used to treat peptide and protein disorder in a mammalian subject. The method comprises administering to the mammalian subject, preferably a human subject, an effective amount of a composition comprising sterically stabilized simple micelles (SSM)... Agent: Polsinelli Shughart PC

20100062968 - Novel strategies for delivery of active agents using micelles and particles: The present invention provides biodegradable particles (e.g., three-dimensional particles) and micelles which can be used to encapsulate active agents for delivering to a subject. The present invention further provides methods for producing and delivering such particles and micelles. Additionally, the invention provides vaccination strategies that encompass the use of the... Agent: Mandel & Adriano

20100062970 - Synthesis of propyl phenoxy ethers and use as delivery agents: The present invention provides propyl phenoxy ether compounds and pharmaceutically acceptable salts thereof, compositions containing the same and one or more active agents, and methods of administering active agents with the same. The delivery agents of the present invention are well suited for forming non-covalent mixtures with active agents for... Agent: Emisphere Technologies, Inc

20100062971 - Substituted indazole-o-glucosides: Substituted indazole-O-glucosides, compositions containing them, and methods of using them, for example for the treatment of diabetes and Syndrome X are disclosed.... Agent: Philip S. Johnson Johnson & Johnson

20100062972 - Triazole compounds and uses related thereto: b

20100062974 - Combination therapy for the treatment of bacterial infections: The invention features a method for treating a subject diagnosed with, or at risk of developing, a bacterial infection by administering to the subject a combination of biologically active agents.... Agent: Clark & Elbing LLP

20100062973 - Production of bioactive glycoproteins from inactive starting material: A method for preparing a conjugate comprising a glycoprotein and a polymer or a derivative of said polymer, wherein the polymer is a hydroxyalkylstarch (HAS), the method comprising the steps a) reacting said glycoprotein with a modified polyol carrying attached thereto, by a covalent linkage, a functional group Z, in... Agent: Fish & Richardson P.C.

20100062975 - Method for the treatment and prevention of ocular disorders: Provided herein are methods for treatment of ocular diseases. The methods comprise administering a compound of general Formula (I): wherein R1, R2, R3, R4 and Ak are as defined in the specification.... Agent: Jones Day

20100062976 - Synthesis of cyclosporin analogs: The invention is directed to isomeric mixtures of cyclosporine analogues that are structurally similar to cyclosporine A. The mixtures possess enhanced efficacy and reduced toxicity over the individual isomers and over naturally occurring and other presently known cyclosporines and cyclosporine derivatives. Embodiments of the present invention are directed toward cis... Agent: Fish & Richardson P.C.

20100062982 - Avian derived fusion proteins: The invention encompasses among other things fusion proteins including Fc fusion proteins such as CTLA4-Fc having avian N-linked glycosylation patterns obtained from egg white of eggs laid by transgenic avians.... Agent: Synageva Biopharma Corp.

20100062978 - Method for inhibiting signal transduction, signal transduction inhibitor to be used therein and use thereof: An object of the present invention is to provide a method for inhibiting activation of signaling pathway mediated by erbB1 or erbB2 in human cell and a signaling inhibitor to be used therefor. The above-described activation of signaling pathway can be inhibited by a polypeptide comprising at least one of... Agent: Cantor Colburn, LLP

20100062977 - Tcr-independent activation of t cells: A method for TCR-independent T cell activation which comprises the co-ligation of CD28 and CD81.... Agent: Novartis Vaccines And Diagnostics Inc.

20100062980 - Therapeutic uses of beta-antagonists: Polypeptides derived from Ophiophagus hannah (king cobra) are disclosed together with their use in the treatment of disease, disorder or pathological condition in a patient in need of treatment. The polypeptides disclosed are functionally characterised by their ability to reduce the mammalian heart rate and/or their β-antagonist activity.... Agent: Speckman Law Group PLLC

20100062979 - Treatment of ectoparasitic infestation: The present invention relates to Asteraceae protein for use in treating an ectoparasitic infection or infestation in an animal as well as to a method of treating an ectoparasitic infection or infestation in an animal which comprises administering to an animal in need thereof an effective amount of Asteraceae protein;... Agent: Crowell & Moring LLP Intellectual Property Group

20100062983 - Use of factor viia or factor viia equivalents for treating late complications of trauma: The invention relates to the use of Factor VIIa or a Factor VIIa equivalent for the manufacture of a medicament for preventing late complications in trauma patients.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100062981 - Use of fibrinogen as a prophylactic treatment to prevent bleeding during and after surgery and as a biomarker to identify patient with an increased risk for excessive bleeding and blood transfusion: The present invention provides a method for preventing peri- and postoperative bleeding in subjects undergoing surgery, in particular subjects with a preoperative fibrinogen plasma level equal to or above the normal range. The method comprises administration of a substance with fibrinogen-like activity to the subject in an amount that result... Agent: Stoel Rives LLP - Slc

20100062985 - Agents and methods for treating pain: The invention provides agents useful for treating pain. An exemplary agent comprises or consists of the a portion of a retroviral Tat protein. One such agent is the peptide Tat-NR2B9c. This peptide has previously been described as an agent for inhibiting damaging effects of stroke and similar conditions via inhibition... Agent: Townsend And Townsend And Crew, LLP

20100062984 - Fgf-23 polypeptides: This document relates to FGF-23 polypeptides, FGF-23 polypeptide fragments, and methods for making and using such polypeptides and polypeptide fragments. For example, FGF-23 polypeptide fragments that can be used to treat disorders associated with hyperphosphatemia such as chronic renal failure and hypoparathyroidism are provided.... Agent: Fish & Richardson P.C.

20100062986 - Method to treat blood cell depletion: Neuropeptides are used to treat mammals which have depletion of count of one or more blood cell types. Intramuscular administration or administration via inhalation causes the blood cell count to increase.... Agent: Jones Day

20100062987 - Anticonvulsive pharmaceutical compositions: The present invention pertains to pharmaceutical compositions including, as the active ingredients, a combination of vigabatrin and of at least one glutamate receptor activating substance.... Agent: Young & Thompson

20100062988 - Chewable sustained release formulations: Sustained release compositions in tablet or multiparticulate forms comprising (a) an active ingredient, (b) a primary sustain release agent, (c) a wax-like agent, and (d) a bulking or spheronizing agent are provided. The compositions are chewable and/or taste masked. Oral dosage forms comprising such compositions and methods for preparing and... Agent: Seed Intellectual Property Law Group PLLC

20100062990 - Novel pseudoglycolipid and use thereof: s

20100062989 - Optimal biological marker for the biological potency of emblica officinalis gaertn. (amla) fruit-methods and products thereof: Disclosed is the most optimal biomarker for the BIOLOGICAL POTENCY of Emblica Officinalis Gaertn. (Amla) fruit and products standardized for 5% and above w/w of the said biomarker. Further, the products described herein contain from about 0.00010% to about 4% of free ascorbic acid depending on the raw material used.... Agent: Sabinsa Corporation

20100062991 - Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with fluorine, method for producing the same, drugs containing said compounds and use thereof: This invention relates to Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with fluorine, method for producing the same, drugs containing said compounds and use thereof.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100062992 - Salts of 5-azacytidine: The present invention relates to salts of 5-azacytidine as well as methods for synthesizing the salts described herein. Pharmaceutical compositions and methods of using the 5-azacytidine salts are also provided, including methods of administering the salts or pharmaceutical compositions thereof to treat conditions, such as cancer and hematological disorders.... Agent: Wilson, Sonsini, Goodrich & Rosati

20100063133 - Antisense antiviral compound and method for treating arenavirus infection: The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Arenaviridae family and in the treatment of a viral infection. The compounds are particularly useful in the treatment of Arenavirus infection in a mammal. The antisense antiviral compounds are... Agent: Seed Intellectual Property Law Group PLLC

20100063130 - Method for promoting immune response comprising inhibiting cd22 function in b cells: The purpose of the present invention is to elucidate a relationship between deregulation of signaling by CD22 and a rapid response of B cells by IgG-BCR and the like, and to provide a method capable of inducing a rapid immune response and defending against infection instead of vaccine. The present... Agent: Morris Manning Martin LLP

20100063131 - Prompt nucleic acid delivery carrier composition: A carrier for nucleic acid delivery is prepared by using (A) a diacylphosphatidylcholine, (B) at least one member selected from the group consisting of cholesterol and derivatives thereof, and (C) an aliphatic primary amine. Also, a composition for nucleic acid delivery is prepared by mixing the carrier for nucleic acid... Agent: Sughrue Mion, PLLC

20100063132 - Small interfering rna and pharmaceutical composition for treatment of hepatitis b comprising the same: The present invention relates to RNA interference mediated inhibition of Hepatitis B virus (HBV) by short interfering RNA (siRNA) molecules. Specially, siRNAs of the present invention which are double-stranded RNAs concern directing the sequence-specific degradation of viral RNA in mammalian cells. Disclosed is a DNA vector encoding the RNA molecules... Agent: Sughrue Mion, PLLC

20100063134 - Treatment of neurodegenerative disease through intracranial delivery of sirna: The present invention provides devices, small interfering RNA, and methods for treating a neurodegenerative disorder comprising the steps of surgically implanting a catheter so that a discharge portion of the catheter lies adjacent to a predetermined infusion site in a brain, and discharging through the discharge portion of the catheter... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20100063135 - Polyethylene glycol lipid conjugates and uses thereof: Polyethylene glycol (PEG)-lipid conjugates, polyethylene glycol (PEG)-lipid conjugate based drug delivery systems, ways to make them and methods of treating diseases using them are disclosed.... Agent: Paul D. Yasger Abbott Laboratories

20100062993 - Adenosine nucleotides as dietary supplements and as agents in the prevention of cancer and the metastasis thereof: It is the embodiment of this invention that Methylthioadenosine and its pharmaceutically acceptable salts as dietary supplements are more efficient, more economical and better tolerated than conventional existing dietary supplements such as S-Adenosylmethionine in the promotion of normal cell growth. It is a further embodiment of this invention that Methylthioadenosine... Agent: Life Science Laboratories, Inc.

20100062994 - Adenosine receptor antagonists: The present application discloses locked nucleoside compounds of the Formula I which act as antagonists of adenosine receptors, in particular the adenosine A3 receptor, and the use of such adenosine A3 receptor compounds in medicine, e.g. for the treatment or alleviation or prophylaxis of selected from the group consisting of... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100062995 - Transition state structure of human 5'methylthioadenosine phosphorylase: Provided are methods of designing a putative inhibitor of a human 5′-methylthioadenosine phosphorylase (MTAP). Also provided are methods of inhibiting a human MTAP.... Agent: Amster, Rothstein & Ebenstein LLP

20100062996 - Dioxolane derivates for the treatment of cancer: This invention relates to certain unsaturated fatty acid derivatives of therapeutically active 1,3-dioxolane nucleoside analogues and to pharmaceutical formulations containing them. The said derivatives are referred to as “Compounds of formula (I)” herein. Compounds of formula (I) can be used in the treatment of a cancerous disease. Treatment of both... Agent: Fitzpatrick Cella Harper & Scinto

20100062999 - Composition extracted from shark cartilage marrow: The present invention relates to a composition extracted from shark cartilage marrow. This composition possesses effects of anti-melanoma effect, neutralization of gastric acid, and improvement of blood circulation and comprises Chondroitin Sulfate that is the active component thereof and is 50-60 wt % of the total weight of the composition.... Agent: Bacon & Thomas, PLLC

20100063000 - Food containing glycogen and use thereof: The object is to improve a blood glucose level, a visceral fat level, a blood cholesterol level, a neutral fat level and the like. Disclosed is a food containing glycogen as a carbohydrate. The food can be ingested to improve a blood glucose level, a visceral fat level, a blood... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100063002 - Method of improving skills with a composition comprising non-digestible saccharide: The present invention concerns a therapy aimed at language and/or social skills in infants through administration of components stimulating the development of a healthy intestinal flora.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20100063001 - Microbial-derived chondroitin sulfate: Described is chondroitin sulfate obtained from microbial sources, and related compositions and methods.... Agent: Foley And Lardner LLP Suite 500

20100063003 - Pet food composition: Pet food comprising trisodium L-ascorbic acid-2-monophosphate (STAY-050) or sodium-calcium L-ascorbic acid-2-monophosphate (STAY-C35), or mixtures thereof and, optionally, a polymer (for fixation of the ascorbate on the dental surface) and use 5 thereof as additive to pet food for preventing or treating calculus, plaque, gingivitis and periodontal disease and for enhancing... Agent: Nixon & Vanderhye, PC

20100062998 - Prevention and/or treatment of neurodegenerative disorders: A pharmaceutical composition for use in the prevention and/or treatment of a neurodegenerative disorder comprising a compound comprised of one or more disaccharide units, the or each disaccharide unit comprising a uronate moiety linked to a glucosamine moiety, wherein the 2-O atom of the uronate moiety is substituted with a... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20100062997 - Use of idraparinux for extended prophylaxis of thromboembolism: The invention relates to the use of idraparinux for the extended prophylaxis of thromboembolism, in particular for the prevention of the recurrence of thromboembolism during 6 months after permanent discontinuation of the treatment with this drug.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100063004 - Topical pharmaceutical composition: This invention relates to a novel topical pharmaceutical composition. In particular, this invention is an overnight topical composition for treating cold sores.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20100063005 - Methods for treating cystic fibrosis or pneumonia with bacterial infection via pulmonary administration of fosfomycin: The present invention provides methods for treating a bacterial infection and/or bacterial airway colonization in a subject by administering via pulmonary administration an effective amount of fosfomycin as the only active pharmaceutical ingredient. Methods of the present invention are useful in treating bacterial pneumonia infection of any type and/or airway... Agent: Licata & Tyrrell P.C.

20100063006 - Compositions and methods to reduce fat and retract skin: Compositions, methods, and apparatuses for treatment of subcutaneous fat tissue for the purpose of fat tissue reduction or other alterations of the subcutaneous fat tissue which affect the appearance of the overlying skin layer.... Agent: Cr Miles, P.C. Craig R. Miles

20100063007 - Pesticide composition comprising fosetyl-aluminum and an insecticide active substance: The present invention relates to a pesticide composition intended for protecting plants, crops or seeds against phyto-pathogenic fungi or damaging insects, and the corresponding methods of treatment using the said composition. More precisely, the subject of the present invention is a pesticide composition based on fosetyl-Al, an insecticide active substance... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20100063008 - Gelatinous elastomer compositions: The present invention is directed to gelatinous elastomer compositions that are useful for topical application of biologically active agents. In certain embodiments, the invention is directed to a gelatinous elastomer composition comprising about 1.0% to 50.0% block copolymer, about 0% to 98% mineral and/or synthetic oil, and about 0.0% to... Agent: Darby & Darby P.C.

20100063009 - Pharmaceutical combination comprising 6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1.3-diol and an nsaid: A combination comprising (a) at least one 6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol component, and (b) at least one non-steroidal anti-inflammatory drug (NSAID) component; a pharmaceutical composition and a dosage form comprising such as combination, and a method of treating pain and/or ostheoarthritis in a mammal characterized in that components (a) and (b) are administered... Agent: Crowell & Moring LLP Intellectual Property Group

20100063010 - Method for administering a spill resistant pharmaceutical system: A method for administering a spill-resistant pharmaceutical formulation comprises delivery from a squeezable container of a pharmaceutical agent in a suitable vehicle comprising a liquid base and a thickening agent.... Agent: Taro Pharmaceuticals U.s.a., Inc. C/o Venable LLP

20100063012 - Compositions and methods for the treatment of inflammatory diseases: Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or... Agent: Techlaw LLP

20100063011 - Organic compounds: f

20100063013 - Cathepsin cysteine protease inhibitors: The present invention relates to novel compounds of the formula (I), wherein R′-R7, X, Y, D and n are as defined in the specification. These compounds are cysteine protease inhibitors which include but are not limited to inhibitors of cathepsms K, L, S and B and are useful for treating... Agent: Merck And Co., Inc

20100063014 - Drug comprising at least one gestagen: The present invention relates to the use of at least one gestagen selected from the group consisting of chlormadinone acetate, 3α-hydroxy-6-chloro-17α-acetoxy-4,6-pregnadien-20-one (3α-hydroxy-chlormadinone acetate) and 3β-hydroxy-6-chloro-17α-acetoxy-4,6-pregnadien-20-one (3β-hydroxy-chlormadinone acetate) as gestagen component and optionally at least one oestrogen selected from the group consisting of ethinyl oestradiol, oestrone, oestriol as oestrogen component and... Agent: Briscoe, Kurt G. Norris Mclaughlin & Marcus, Pa

20100063017 - Ophthalmic suspension for ocular use: A gatifloxacin and prednisolone topical ophthalmic pharmaceutical compositions for prevention and treatment of ophthalmic bacterial infections and inflammatory conditions associated with pre-surgical and/or post surgical ocular surgeries.... Agent: Allergan, Inc.

20100063016 - Pharmaceutical combinations: A pharmaceutical combination comprising (a) a combination of two or more bronchodilators; or (b) a combination of at least one bronchodilator in combination with at least one corticosteroid.... Agent: Conley Rose, P.C.

20100063015 - Skin-care preparations containing mupirocin and betamethasone dipropionate: The present invention relates to a topical skin-care preparation in the form of an ointment containing mupirocin and betamethasone dipropionate as active principles and a carrier formulated with all or some of the following components: hydrogenated castor oil, polyethylene glycols and preservatives. The inventive preparation is advantageous over prior art... Agent: Banner & Witcoff, Ltd.

20100063018 - Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated diseases or conditions: e

20100063019 - Low dose estrogen interrupted hormone replacement therapy: A hormone replacement therapy, comprising a plurality of daily doses of a pharmaceutical preparation, the doses being administered continuously and consecutively in alternating phases of three daily doses, a relatively dominant estrogenic activity phase comprising three daily doses of a substance exhibiting estrogenic activity equivalent to about 1 mg per... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100063020 - Oral pharmaceutical formulations and methods for producing and using same: Oral pharmaceutical formulations and methods of producing and using the same are described and claimed. The formulations are dispersions of phospholipids and one or more pharmacologically active compounds, In preferred embodiments, the pharmaceutically active compounds are ansamycins, pharmaceutically acceptable salts, or prodrugs thereof.... Agent: Biogen Idec / Finnegan Henderson, LLP

20100063021 - Modulators of muscarinic receptors: The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.... Agent: Johnathan P. O'brien, Ph. D Honigman Miller Schwartz & Cohn LLP

20100063023 - Bicyclic and tricyclic substituted 6-methylidene carbapenems as broad spectrum beta-lactamase inhibitors: Provided is a β-lactamase antibiotic and a compound of formula I, a process of producing the compound, pharmaceutical compositions and the use thereof for the treatment of bacterial infection or disease in a patient in need thereof.... Agent: Wyeth LLC Patent Law Group

20100063024 - Dihydropyrazolopyrimidinone derivatives: o

20100063022 - Novel compounds as cannabinoid receptor ligands:

20100063026 - Antibacterial quinoline derivatives: a pharmaceutically acceptable salt thereof, a N-oxide form thereof or a solvate thereof. The claimed compounds are useful for the treatment of a bacterial infection. Also claimed is a composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of the claimed compounds, the use of... Agent: Philip S. Johnson Johnson & Johnson

20100063025 - Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase: p

20100063027 - Amine derivative having npy y5 receptor antagonistic activity:

20100063028 - Triazabenzo[e]azulene derivatives for the treatment of tumors: Novel triazabenzo[e]azulene derivatives of the formula, (I) in which R1, R2 and R3 have the meanings indicated in Claim 1, are inhibitors of TGF-beta receptor kinase and can be employed, inter alia, for the treatment of tumours.... Agent: Millen, White, Zelano & Branigan, P.C.

20100063029 - Use of s-10-hydroxy-10,11-dihydro-carbamazepine for the treatment of anxiety and bipolar disorders: The present invention relates to the use of a racemate of the compound of formula (I) consisting of at least 85% S-enantiomer and not more than 15% R-enantiomer or of pharmaceutically acceptable salts of said racemate or of the S-enantiomer of formula I or of pharmaceutically acceptable salts of said... Agent: Novartis Corporate Intellectual Property

20100063030 - Benzenesulfonyl compounds and the use thereof: The invention relates to pyrrolidinyl, piperidinyl, and hexahydroazepinyl compounds of Formula I: and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein R1, R2, Z and m are defined as set forth in the specification. The invention is also directed to the use compounds of Formula I to treat a disorder... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100063031 - Kinase inhibitor compounds: Pyridine and pyridazine derivatives have unexpected drug properties as inhibitors of protein kinases and are useful in treating disorders related to abnormal protein kinase activities such as cancer.... Agent: Edwards Angell Palmer & Dodge LLP

20100063032 - Substituted pyrido[2,3-d]pyrimidine derivatives as cannabinoid-1 receptor modulators: Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis,... Agent: Merck And Co., Inc

20100063033 - Methods of using substituted morpholine derivatives: The present invention relates to morpholine and thiomorpholine derivatives of the general formula I or pharmaceutically acceptable salts thereof and their use.... Agent: Lundbeck Research Usa, Inc. Attention: Stephen G. Kalinchak, Legal

20100063034 - Conjugated psychotropic drugs and uses thereof: Novel chemical conjugates of psychotropic drugs and organic acids, uses thereof in the treatment of psychotic and/or proliferative disorders and diseases and as chemosensitizing agents, and their syntheses are disclosed. The organic acids are selected to reduce side effects induced by the psychotropic drugs and/or to exert an anti-proliferative activity.... Agent: Martin D. Moynihan Prtsi, Inc.

20100063035 - Carbonic anhydrase inhibitors derivatives: Nitroderivatives of dorzolamide and brinzolamide having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma, ocular hypertension, age-related macular degeneration, diabetic macular edema, diabetic retinopathy, hypertensive retinopathy and retinal vasculopathies.... Agent: Arent Fox LLP

20100063036 - Substituted morpholine and thiomorpholine derivatives: The present invention relates to morpholine and thiomorpholine derivatives of the general formula I or pharmaceutically acceptable salts thereof and their use.... Agent: Lundbeck Research Usa, Inc. Attention: Stephen G. Kalinchak, Legal

20100063037 - 6-substituted benzoxazines: wherein X, Y, R1 and R2 are as described herein, their manufacture, and pharmaceutical compositions containing them. The active compounds of the present invention are 5-HT5A receptor antagonists, useful in the prevention and/or treatment of depression, anxiety disorders, schizophrenia, panic disorders, agoraphobia, social phobia, obsessive compulsive disorders, post-traumatic stress disorders,... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100063038 - Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis: This invention relates to novel pyrrozolotriazine compounds, pharmaceutical compositions containing such compounds and and the use of those compounds or compositions for treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients.... Agent: Barbara A. Shimei Director, Patents & Licensing

20100063039 - Use of fungicides for the treatment of fish mycoses: The composition, comprising at least one fungicide selected from the abovementioned group for use in fish farming and keeping is suitable for the prophylaxis and therapy of diseases of fish in aquaculture, in breeding ponds, breeding tanks, aquariums, natural stretches of game fish waters, ponds, and marine fish farms. Addition... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100063042 - 5-substituted benzoxazines: wherein X, R1 and R2 are as described herein, as well as their manufacture, pharmaceutical compositions containing them. Compounds of the present invention are 5-HT5A receptor antagonists, and are useful in the prevention and/or treatment of depression, anxiety disorders, schizophrenia, panic disorders, agoraphobia, social phobia, obsessive compulsive disorders, post-traumatic stress... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100063041 - Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators, method of the same, and pharmaceutical composition comprising the same: The present invention provides a novel phenylpropionic acid derivative and a PPAR-γ modulator comprising the same as an active ingredient. The phenylpropionic acid derivative of the present invention has modulatory action on function of PPAR-γ and then exhibits hypoglycemic, hypolipidemic and insulin resistance-reducing effects on PPAR-mediated diseases or disorders. Therefore,... Agent: The Nath Law Group

20100063040 - Sulfonamide derivative having pgd2 receptor antagonistic activity: e

20100063043 - Substituted 2-oxo-3-phenyl-5-carbonylaminomethyl-1, 3-oxazolines and their use as anticoagulant and antithrombotics:

20100063044 - Substituted aniline derivatives:

20100063045 - Novel pyridinecarboxylic acid (2-aminophenyl) amide derivative having urea structure: Objects of the present invention are to study the synthesis of a novel pyridinecarboxylic acid (2-aminophenyl)amide derivative having a novel urea structure and to find a pharmacological effect of the derivative. The invention provides a compound represented by the formula (1) or a salt thereof. In the formula, R1 and... Agent: Frishauf, Holtz, Goodman & Chick, PC

20100063046 - Tetracyclic imidazole analogs: The present invention provides tetracyclic imidazole analogs which may inhibit cell proliferation and/or induce cell apoptosis. The present invention also provides methods of preparing these compounds, and methods of using the same.... Agent: Morrison & Foerster LLP

20100063047 - Aminopyrimidine inhibitors of histamine receptors for the treatment of disease: The present invention relates to compounds and methods which may be useful as inhibitors of H1R and/or H4R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.... Agent: Global Patent Group - Kal

20100063048 - Remedy for angiospasm accompanying subarachnoid hemorrhage containing thrombin receptor antagonist as the active ingredient: A therapeutic agent for subarachnoid hemorrhage or a drug for improving prognosis of subarachnoid hemorrhage, comprising a compound having a PAR1 inhibitory effect, its pharmaceutically acceptable salt or a hydrate thereof... Agent: Dickstein Shapiro LLP

20100063049 - 2-carbocycloamino-4-imidazolylpyrimidines as agents for the inhbition of cell proliferation: t

20100063051 - Modulators of glucocorticoid receptor, ap-1, and/or nf-kb activity and use thereof: Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including inflammatory and immune diseases, obesity and diabetes having the structure of formula (I) an enantiomer, diastereomer, tautomer, solvate (e.g. a hydrate), or a pharmaceutically-acceptable salt, thereof, wherein:... Agent: Louis J. Wille Bristol-myers Squibb Company

20100063050 - Novel heteropyrrole analogs acting on cannabinoid receptors: Disclosed are biologically active hetero pyrrole analogs such as imidazoles, thiazoles, oxazoles and pyrazoles capable of interacting with the CB1 and/or the CB2 cannabinoid receptors. One aspect discloses hetero pyrrole analogs acting as antagonists for the CB1 and/or the CB2 receptors. Another aspect discloses hetero pyrrole analogs having selectivity for... Agent: Alix Yale & Ristas LLP

20100063052 - Use of serum amyloid a gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents: The present invention provides compositions and methods for treating glaucoma, methods for diagnosing glaucoma, and methods for identifying agents which may be useful in the treatment of glaucoma. More specifically, the present invention describes the use of agents that modulate the expression of serum amyloid A.... Agent: Alcon

20100063053 - Heterocyclic inhibitors of mek and methods of use thereof: and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8 and R9, W, X and Y are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are... Agent: Hogan & Hartson LLP

20100063054 - Cmet inhibitors: d

20100063056 - Bipyridine carboxamide orexin receptor antagonists: The present invention is directed to bipyridyl carboxamide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the... Agent: Merck And Co., Inc

20100063057 - Compositions and methods for delivery of anti-cancer agents: The present invention relates to compositions comprising 5-fluorouracil, or a pharmaceutically acceptable salt or analogue thereof, folinic acid, or a pharmaceutically acceptable salt thereof and a cyclodextrin, or a pharmaceutically acceptable salt or derivative thereof. The invention also relates to methods for the treatment of cancer using such compositions.... Agent: Knobbe Martens Olson & Bear LLP

20100063055 - Condensed tetrahydroquinoline derivative and use thereof for medical purposes: e

20100063058 - 4-alkoxypyridazine derivatives as fast dissociating dopamine 2 receptor antagonists: The present invention relates to (1-benzyl-piperidin-4-yl)-(4-alkoxy-pyridazin-3-y1)-amines that are fast dissociating dopamine 2 receptor antagonists, processes for preparing these compounds, pharmaceutical compositions comprising these compounds as an active ingredient. The compounds find utility as medicines for treating or preventing central nervous system disorders, for example schizophrenia, by exerting an antipsychotic effect... Agent: Philip S. Johnson Johnson & Johnson

20100063059 - Novel pyridazine compound and use thereof: A compound of formula (1) and its salts and solvates are provided for the treatment or prophylaxis of hepatitis C virus infections. Methods of making and formulating compound (1) are provided.... Agent: Gilead Sciences Inc

20100063060 - Therapeutic agent for glaucoma comprising rho kinhase inhibitor and prostaglandin: A combination of a Rho kinase inhibitor and a prostaglandin as a therapeutic agent for treating glaucoma. The actions of reducing intraocular pressure are complemented and/or enhanced by combining a Rho kinase inhibitor with a prostaglandin. Each of the Rho kinase inhibitor and the prostaglandin can be administered in combination... Agent: Frishauf, Holtz, Goodman & Chick, PC

20100063061 - Antibacterial quinoline derivatives: a pharmaceutically acceptable salt thereof, a N-oxide form thereof or a solvate thereof. The claimed compounds are useful for the treatment of a bacterial infection. Also claimed is a composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of the claimed compounds, the use of... Agent: Philip S. Johnson Johnson & Johnson

20100063062 - Novel use of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and its physiologically acceptable salts: 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof is used for the manufacture of a medicament for the treatment of sub-type anxiety disorders chosen from the sub-types panic disorder with or without agoraphobia, agoraphobia. obsessive-compulsive spectrum disorders, social phobia, posttraumatic stress disorder, acute stress indication or generalized-anxiety disorder, bipolar disorders, mania,... Agent: Millen, White, Zelano & Branigan, P.C.

20100063063 - Substituted heteroaryls: [

20100063064 - Substituted triazole derivatives as oxytocin antagonists: The present invention relates to a class of substituted 1,2,4-triazoles of formula (I) with activity as oxytocin antagonists, uses thereof, processes for the preparation thereof and compositions containing said inhibitors. These inhibitors have utility in a variety of therapeutic areas including sexual dysfunction, particularly premature ejaculation (P.E.).... Agent: Pfizer Inc. Patent Department

20100063068 - Compounds for the treatment of hepatitis c: The disclosure provides compounds of formula I, II, III, IV, and V, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.... Agent: Louis J. Wille Bristol-myers Squibb Company

20100063067 - Cyclic derivatives as modulators of chemokine receptor activity: The present application describes modulators of MIP-1α of formula (I), or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein n, A, T, R1, R2 and R8, are as defined herein. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune... Agent: Louis J. Wille Bristol-myers Squibb Company

20100063069 - Gyrase inhibitors and uses thereof: The present invention relates to compounds that inhibit bacterial gyrase and/or Topo IV and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions thereof, are useful in treating bacterial infection. Accordingly, the present invention also relates to methods for treating bacterial infections in mammals.... Agent: Vertex Pharmaceuticals Inc.

20100063066 - Raf inhibitor compounds and methods of use thereof: Compounds of Formulas (I), (IIA) and (IIIA) are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using compounds of Formulas (I), (IIA) and (IIIA) and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such... Agent: Viksnins Harris & Padys Pllp

20100063065 - Thiophene derivatives as ppar agonists i: The invention discloses compounds of formula (I); wherein: R is a carboxylic acid or a derivative thereof; R1 is alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, alkylthio, halo or trihalomethyl; R2 is aryl, heteroaryl, arylalkyl or heteroarylalkyl; R3 is H or F; and L is a linking group comprising a chain of... Agent: Woodcock Washburn LLP

20100063070 - Combination for use in the treatment of inflammatory disorders: There is provided combination products comprising (a) pemirolast, or a pharmaceutically-acceptable salt or solvate thereof; and (b) a statin, or a pharmaceutically-acceptable salt or solvate thereof. Such combination products find particular utility in the treatment of atheresclerosis and related conditions.... Agent: Ryan Kromholz & Manion, S.c.

20100063071 - Therapeutic compositions and related methods of use: Compositions and dosage forms including adenosine receptor antagonists such as 3-[4-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo[2.2.2]oct-1-yl]-propionic acid and methods of using the same are described herein.... Agent: Lando & Anastasi, LLP B2047

20100063072 - Solid forms of pemetrexed: Duplex coating schemes and associated methods of formation, including a siloxane-based soft coating and a plasma-based SiOxCy hard coating used in combination to improve the durability of polymeric substrates.... Agent: Dr. Reddy''s Laboratories, Inc.

20100063074 - Cancer treatment method: The present invention relates to a method of treating cancer in a mammal by administration of 4-quinazolinamines and pharmaceutical compositions containing the same. In particular, the method relates to a methods of treating cancers which are mediated by the tyrosine kinases EGFR and/or erbB2 by administration of N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine and salts... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20100063073 - Methods and compositions utilizing quinazolinones: Quinazolinones of formulae 1a, 1b, 1c and 1d are disclosed. They are useful for treating cellular proliferative diseases and disorders associated with KSP kinesin activity.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100063075 - Aryl-quinazoline/aryl-2amino-phenyl methanone derivatives: A compound of formula (1): wherein R1, R2, R3 and Y are as defined herein, or a pharmaceutically-acceptable and -cleavable ester, or acid addition salt thereof, useful for promoting the release of parathyroid hormone, e.g. for preventing or treating bone conditions which are associated with increased calcium depletion or resorption... Agent: Novartis Institutes For Biomedical Research, Inc.

20100063076 - Endothelin receptor antagonists: This invention relates to novel endothelin receptor antagonists, derivatives, acceptable acid addition salts thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by compounds that block the endothelin signaling pathway... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20100063077 - Pyrimidine derivatives for the treatment of amyloid-related diseases: The present invention provides (I) These compounds are useful in prevention and treatment of neurodegenerative disorders, such as Alzheimer's, Parkinson's and Huntington's as well as type II diabetes.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20100063080 - Cxcr2 inhibitors: The present invention relates to compounds of formula (I) and the use of these compounds as pharmaceuticals, e.g. in preventing or treating a CXCR2 receptor mediated condition or disease.... Agent: Novartis Institutes For Biomedical Research, Inc.

20100063079 - Pyrimidyl sulphone amide derivatives as chemokine receptor modulators: A compound of formula (I), pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof for the treatment of asthma, allergic rhinitis, COPD, inflammatory bowel disease, irritable bowel syndrome, osteoarthritis, osteoporosis, rheumatoid arthritis, psoriasis or cancer.... Agent: Fish & Richardson P.C.

20100063078 - Spirocompounds useful as modulators for dopamine d3 receptors: wherein R5, R6, R7 and R8 are not simultaneously other than hydrogen; wherein only one R2 group ma be different from hydrogen and wherein when n is 0, X is a group —CR1R3—; processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20100063081 - Cpcr agonists: Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of obesity and diabetes.... Agent: Osi Pharmaceuticals, Inc.

20100063082 - Camptothecin derivatives with antitumor activity: Novel camptothecin derivatives having antitumor activity, the processes for the preparation thereof, the use thereof as antitumor drugs and pharmaceutical compositions containing them.... Agent: Mathews, Shepherd, Mckay, & Bruneau, P.A.

20100063083 - 5(s)-(2'-hydroxyethoxy)-20(s)-camptothecin and its preparation and use for the treatment of cancer: A 5(S)-(2′-hydroxyethoxy)-20(S)-camptothecin diasterisomer is described which is a better inhibitor of topoisomerase I than either the diastereoisomeric mixture 5(RS)-(2′-hydroxyethoxy)-20(S)-camptothecin, or the 5(R)-(2′-hydroxyethoxy)-20(S)-camptothecin diastereoisomer. Pharmaceutical compositions of the 5(S)-(2′-hydroxyethoxy)-20(S)-camptothecin diastereoisomer are also described as are methods of using the compound for the inhibition of topoisomerase I and for the treatment of... Agent: Nelson Mullins Riley & Scarborough LLPIPDepartment

20100063084 - Multi-phase release methscopolamine compositions: Formulations have been developed administering methscopolamine in multi-phases. In a preferred embodiment, the formulation contains methscopolamine in an immediate release. (“IR”) form and a sustained or delayed release (“DR”) form and/or poised release (“PR”) form. In another embodiment, the methscopolamine is released in a gradient, decreasing the side effects associated... Agent: Sheridan Ross PC

20100063085 - Method of treating learning impairment in down's syndrome subjects: The present invention provides compounds for use in the preparation of pharmaceutical formulations and medicaments, which alleviate learning and/or mental impairment in people suffering from Down's syndrome.... Agent: Myers Bigel Sibley & Sajovec

20100063086 - Pharmaceutical compounds: This application describes method of treating dementia and cognitive deficits associated with dementia that involve administration of dihydrotetrabenazine, and isomers and/or pharmaceutically acceptable salts thereof.... Agent: Schwegman, Lundberg & Woessner, P.A.

20100063087 - 5-amino-4-hydroxy-7-(imidazo [1,2-a] pyridin-6-ylmethyl)-8-methyl-nonamide derivatives and related compounds as renin inhibitors for the treatment of hypertension: Compounds of the general formula (I) or its salt or a compound in which one or more atoms are replaced by their stable, nonradio-active isotopes, in particular its pharmaceutically acceptable salt; in which X is —CH2—; R is a mono- to tetra-substituted, mono- or bicyclic, unsaturated heterocyclic radical having 1... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100063088 - Raf kinase inhibitors: Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.... Agent: Millen, White, Zelano & Branigan, P.C.

20100063089 - Succinate salt of 2-((4-(1-methyl-4-pyridin-4-yl)-1h-pyrazol-3-yl)phenoxy)methyl)quinoline: The present invention relates to a succinate salt of 2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinoline, and to a method for treating disorders of the Central Nervous System (CNS) and other disorders in a mammal, including a human, by administering to the mammal the succinate salt. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable... Agent: Pfizer Inc Mary J Hosley

20100063090 - Composition for repelling and deterring vermin: The invention describes essentially a non-therapeutical process for deterring vermin, which is based on the usage of the largely known beta amino-alcohol derivatives of formula (I), as defined herein before. Furthermore, it describes the corresponding vermin-deterring compositions which contain these substances as the active ingredient, compounds of the formula (I)... Agent: Womble Carlyle Sandridge & Rice, PLLC

20100063092 - 3-cyano-4-(4-phenyl-piperidin-1-yl)-pyridin-2-one derivatives: The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) including any stereochemically isomeric form thereof, or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein all radicals are defined in the application and claims. The compounds according to the invention are positive... Agent: Gardner Groff Greenwald & Villanueva. PC

20100063091 - Renin inhibitors: The present invention relates to disubstituted piperidinyl renin inhibitor compounds having the structure (Formula I) and their use in treating cardiovascular events and renal insufficiency.... Agent: Merck And Co., Inc

20100063093 - Methods for the administration of iloperidone: The present invention relates to methods for the identification of genetic polymorphisms that may be associated with a risk for QT prolongation after treatment with iloperidone and related methods of administering iloperidone to patients with such polymorphisms.... Agent: Hoffman Warnick LLC

20100063094 - Methods for treatment of colorectal cancer using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione: Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or... Agent: Jones Day

20100063095 - Hemiasterlin derivatives and uses thereof in the treatment of cancer: t

20100063096 - Biphenyl compounds useful as muscarinic receptor antagonists: wherein a, b, c, p, W, A, X1, R1, R2, R3, R6, R7, and R8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using... Agent: Theravance, Inc.

20100063097 - Azabicyclo [3.1.0] hexane derivatives as modulators of dopamine d3 receptors: e

20100063098 - Pyridone derivatives as p38a mapk inhibitors: A compound represented by the formula (I): wherein R1 is lower alkyl, cycloalkyl or aromatic hydrocarbon ring, each of which is optionally substituted with one or more substituents; R2 is hydrogen atom, halogen atom, lower alkyl, halo(lower)alkyl or lower alkoxy; and R3 is (1) a group represented by the formula:... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100063099 - Adenylyl cyclases as novel targets for the treatment of infection by eukaryotic pathogens: The present invention relates to a method of preventing or treating a disease caused by infection by a eukaryotic pathogen, wherein the method comprises administering an effective amount of a modulator of a eukaryotic pathogen's adenylyl cyclase. The invention also provides pharmaceutical compositions useful for preventing or treating a disease,... Agent: Kenyon & Kenyon LLP

20100063100 - Modulators of aldehyde dehydrogenase activity and methods of use thereof: The present invention provides compounds that function as modulators of aldehyde dehydrogenase activity; and pharmaceutical compositions comprising the compounds. The present invention provides therapeutic methods involving administering a subject compound, or a subject pharmaceutical composition.... Agent: Stanford University Office Of Technology Licensing Bozicevic, Field & Francis LLP

20100063101 - New benzimidazole derivatives: e

20100063103 - Compounds having crth2 antagonist activity:

20100063102 - Treatment of faecal incontinence: Use of a compound corresponding to formula (I) in which R represents hydrogen or a group chosen from alkyl, alkylene, alkylidyne, cycloalkyl, cycloalkylene, cycloalkylidyne and —CONH2 groups, and the —COR′ and —COOR′ groups, in which R′ is chosen from alkyl, alkylene, alkylidyne, cycloalkyl, cycloalkylene and cycloalkylidyne groups, it being possible... Agent: Oliff & Berridge, PLC

20100063104 - Nitrogen-containing heterocyclic compound and pharmaceutical application thereof: which has a p38 MAP kinase inhibitory activity, a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof. The compound of the invention is useful for preventing or treating a disease in which the abnormal production of a cytokine such as an inflammatory cytokine or a chemokine... Agent: Sughrue-265550

20100063106 - Aminopyrazole derivatives, process for the preparation thereof, and composition for preventing or treating ischemic diseases containing the same: Provided are aminopyrazole derivatives, a process for the preparation thereof, and a composition for preventing or treating an ischemic disease containing the same. Since the aminopyrazole derivatives of the present invention can reduce an ischemic cell death significantly, they can be effectively used for the prevention and treatment of ischemic... Agent: Sughrue Mion, PLLC

20100063107 - Hydroxy methyl phenyl pyrazolyl urea compounds usefull in the treatment of cancer: The compound 4-{4-[({3-tert-Butyl-1-[3-(hydroxymethyl)phenyl]-1H-pyrazol-5-yl}carbamoyl)amino]-3-fluorophenoxy}-N-methylpyridine-2-carboxamide and alternative forms thereof (e.g., salts, solvates, hydrates, prodrugs, polymorphs and metabolites); pharmaceutical compositions which contain them; and methods for treating cancer using them.... Agent: Millen, White, Zelano & Branigan, P.C.

20100063105 - Pharmaceutical uses and synthesis of nicotinanilide-n-oxides: Disclosed are nicotinanilide-N-oxide compounds, methods for their production, pharmaceutical compositions which include these compounds, and methods for their use in various therapies.... Agent: C. Rachal Winger C/o Ocip Group

20100063108 - Pyridin-4-yl derivatives as immunomodulating agents: The invention relates to pyridine derivatives of Formula (I) wherein A, R1, R2, R3, R4, R5, and R6 are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.... Agent: Hoxie & Associates LLC

20100063109 - Thiadiazolidinone derivatives: The present invention relates to compounds of the formulae herein, their acceptable salts, solvates, hydrates and polymorphs thereof. The compounds of this invention are useful in treatment of disease, particularly leukemia. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods... Agent: Ballard Spahr LLP

20100063111 - Formulation and use and manufacture thereof: This invention relates to a liquid pharmaceutical formulation for delivering nicotine to a subject. This invention also relates to a method and a system for delivering nicotine as well as manufacturing and use of said liquid pharmaceutical formulation.... Agent: Woodcock Washburn LLP

20100063110 - Orally administrable films: The invention relates to oral disintegrable films, which are mucoadhesive, which completely disintegrate in the mouth of a consumer within 1 to 10 minutes, and which include an alkaline substance and optionally a pharmaceutically active substance.... Agent: Frank A. Smith Novartis Consumer Health, Inc.

20100063112 - Polymorph iii of 4-[4-(amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide: The present invention relates to the polymorph III of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide, to processes for its preparation, to pharmaceutical compositions comprising it and to its use in the control of disorders.... Agent: Millen, White, Zelano & Branigan, P.C.

20100063113 - Novel pharmaceutical salts and polymorphs of a factor xa inhibitor: The present invention provides for salts comprising a compound of Formula I and an acid that has activity against mammalian factor Xa. The present invention is also directed to methods of making the compound of Formula I.... Agent: Portola Pharmaceuticals, Inc. C/o Swiss Tanner, P.C.

20100063114 - Inhibitors of protein prenyltransferases: The present invention is directed to novel compounds. These compounds can be useful in inhibiting the activity of GGTase I. The compounds can also be used as anti-cancer therapeutics including as part of methods for treating cancer, in assays, and in kits.... Agent: Venable LLP

20100063115 - 5-(1,3,4-oxadiazol-2-yl)-1h-indazole and 5-(1,3,4-thiadiazol-2-yl)-1h-indazole derivatives as sgk inhibitors for the treatment of diabetes: Novel aminoindazolylurea derivatives of the formula (I), in which L, X, Y, R3, R4 and R5 have the meanings indicated in Claim 1, are SGK inhibitors and can be used for the treatment of SGK-induced diseases and complaints, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular... Agent: Millen, White, Zelano & Branigan, P.C.

20100063116 - Use of pramipexole or a salt thereof for the treatment of parkinson's disease: The present invention refers to the use of pramipexole, pramipexole hydrochloride, pramipexole dihydrochloride or pramipexole dihydrochloride monohydrate for the manufacture of a medicament for the treatment of early Parkinson's disease by a maintenance, twice daily application.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100063117 - Novel oxazolidinone derivative with difluorophenyl moiety, pharmaceutically acceptable salt thereof, preparation method thereof and antibiotic composition containing the same as an active ingredient: e

20100063118 - Hydantoins having rnase modulatory activity: The present invention relates to hydantoin derivatives having RNase H, polymerase and/or HIV reverse transcriptase modulatory, and particularly, inhibitory activity. Included in the invention are the hydantoin derivatives, compositions containing the derivatives, methods of synthesis of the derivatives, screening methods to identify the derivatives, and methods of treatment using the... Agent: Fitzpatrick Cella (wyeth LLC)

20100063119 - Substituted carbinol compound: There is provided a novel LXRβ agonist useful as a preventative and/or therapeutic agent for arteriosclerosis; arteriosclerosis such as those resulting from diabetes; hyperlipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases caused by inflammatory cytokines, skin diseases such as allergic skin diseases, diabetes or Alzheimer's disease. The agonist is a carbinol derivative... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20100063120 - Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such: Compounds of formula (I): wherein X is O or S, R1 is acyl, aldehyde, cycloalkyl, an optionally substituted alkyl, alkenyl or alkynyl, R2 is H. alkyl, hydroxyalkyl, haloalkyl, alkenyl, or alkynyl; substituted alkyl; alkylcarbonyl; R3 and R4 are H, halogen, alkyl, alkenyl, alkynyl, alkoxyl, alkylthio, hydroxyalkyl, haloalkyl, haloalkenyl, or haloalkynyl;... Agent: Klauber & Jackson

20100063121 - Macrocyclic heterocyclic aspartyl protease inhibitors: Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m1 agonist or... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20100063122 - Novel 2-(2-hydroxyphenyl)benzimldazoles useful for treating obesity and diabetes: The present invention relates to novel compounds that act as chemical uncouplers. Compounds of the invention are useful, inter alia, in the treatment, including prevention, of obesity, diabetes and a number of diseases or conditions associated therewith.... Agent: High Point Pharmaceuticals, Inc.

20100063123 - Extended release formulation and method of treating adrenergic dysregulation: A composition and method of treating adrenergic dysregulation by administering the composition is disclosed, wherein the composition comprises a a2-adrenergic receptor agonist; a pharmaceutically acceptable hydrophilic matrix and a release-retardant of a metal alkyl sulfate. In embodiments, the composition provides a sustained release of the agonist, wherein after administration of... Agent: Myers Bigel Sibley & Sajovec

20100063124 - New pyrazole derivatives and diabetic medicine containing them: The present invention provides pyrazole-O-glycoside derivatives represented by the following formulae, used as a diabetic medicine.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100063125 - Melatonin derivatives and their use as antioxidants: The present subject matter relates generally to antioxidant compounds having the formula (I): wherein each of R1, R2, R3, and R4 are as defined below. These compounds are potentially useful as, for example, antioxidants.... Agent: Michael Best & Friedrich LLP

20100063126 - Carbazole-derived pharmaceutical compositions: The present invention relates to the use of specific carbazole derivatives in the preparation of medicaments for the treatment, prevention and/or amelioration of disorders relating to pathological processes in lipid rafts.... Agent: Fulbright & Jaworski L.L.P.

20100063127 - Antioxidant properties of tryptophan from human milk: As tryptophan is not available in sufficient amounts in infant formula or other replacement milks, we describe herein the supplementation of these milks to attain a Trp concentration similar to that of human milk. Such supplemented milks provide greater protection against free radicals.... Agent: Ade & Company Inc.

20100063128 - Indole compounds, a process for their preparation and pharmaceutical compositions containing them.:

20100063129 - Metabolites of wortmannin analogs and methods of using the same: Novel metabolites of wortmannin and wortmannin analogs and their use in inhibiting PI-3 kinase activity in mammals and the treatment and prevention of cancer or tumor formation in a subject are described herein.... Agent: Pepper Hamilton LLP 500 Grant Street

20100063136 - Insecticidal n-substituted sulfoximines: N-Substituted sulfoximines are effective at controlling insects.... Agent: Dow Agrosciences LLC

20100063137 - Cytotoxin compound and method of isolation: The present invention concerns compounds derived from tunicates of the species Synoicum adareanum, as well as to pharmaceutical compositions comprising these compounds and methods of use. Extracts from tunicates show selective toxicity against several different cancer cell lines in the NCI 60 cell line panel. These compounds are useful in... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100063138 - Novel substituted sulfamide derivatives: The present invention is directed to novel substituted sulfamide derivatives, pharmaceutical compositions containing said derivatives and the use of said derivatives form in the treatment of anxiety and related disorders; bipolar depression and mania; depression; epilepsy and related disorders; epileptogenesis; glucose related disorders; lipid related disorders; migraine; obesity; pain; substance... Agent: Philip S. Johnson Johnson & Johnson

20100063139 - Use in a cosmetic composition of lipochroman-6 to enhance the radiance of the complexion of the skin, especially the skin of the face: e

20100063140 - Water-soluble compositions of bioactive lipophilic compounds: are disclosed. The lipophilic compound is preferably selected from the group consisting of water-insoluble ubiquinones, ubiquinols, vitamins, provitamins, polyene macrolide antibiotics, and mixtures thereof. The hydrophobic moiety is preferably a sterol or a tocopherol and the hydrophilic moiety is preferably a polyalkylene glycol. In some embodiments, the sterol is cholesterol... Agent: Morgan, Lewis & Bockius LLP (sf)

20100063141 - Deuterated benzylbenzene derivatives and methods of use: Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions that are affected by SGLT inhibition.... Agent: Clark & Elbing LLP

20100063142 - O/w/o emulsion containing lignan compounds and composition containing the same: o

20100063143 - Pesticide composition comprising propamocarb-hydrochloride and a n insecticide active substance: The present invention relates to a pesticide composition intended for protecting plants, crops or seeds against phyto-pathogenic fungi or damaging insects, and the corresponding methods of treatment using the said composition. More precisely, the subject of the present invention is a pesticide composition based on propamocarb-HCl, an insecticide active substance... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20100063144 - Compounds and uses thereof: There is provided a compound of formula (I) wherein R1a, R2a, R3, X1 to X6, a, b and c have meanings given in the description, which compounds are useful as, or are useful as prodrugs of, inhibitors of HDAC enzyme activity, and thus, in particular, in the treatment of conditions... Agent: Nixon Peabody LLP - Patent Group

20100063145 - Acid containing oxaliplatin formulations: There is provided a pharmaceutical liquid formulation of oxaliplatin for parenteral administration, said formulation having (i) oxaliplatin; (ii) water; and (iii) an acid wherein the acid is stabilising and is not malonic acid, lactic acid or oxalic acid. Methods of preparing the formulation are also disclosed. There is further provided... Agent: Winston & Strawn LLP Patent Department

20100063146 - Method for treating disorders related to complement activation: A method for treating or preventing a complement activated T-cell mediated disorder in a subject includes administering a therapeutically effective amount of a pharmaceutical composition to the subject. The pharmaceutical composition includes at least one amidine compound or pharmaceutically acceptable salt.... Agent: Tarolli, Sundheim, Covell & Tummino, LLP

20100063147 - Anaplerotic therapy of huntington disease and other polyglutamine diseases: The present invention relates to a method for treating and/or preventing Huntington disease and other polyglutamine diseases, comprising the step of administering an effective amount of a precursor of propionyl-CoA to an individual in need thereof.... Agent: Mcandrews Held & Malloy, Ltd

20100063148 - Pharmaceutical combination: A composition of matter comprising in combination as component (a) at least one 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol compound, and as component (b) at least one antiepileptic, a pharmaceutical formulation and a dosage form comprising said composition of matter, and a method of treating pain, e.g. neuropathic pain, in which components (a) and (b)... Agent: Crowell & Moring LLP Intellectual Property Group

20100063149 - Food composition for binding acetaldehyde in mouth and in digestive track, and method for the preparation of the composition: The object of the invention comprises food compositions, to which one or more acetaldehyde-binding compounds are added. The purpose of the compositions is to reduce the amount of detrimental acetaldehyde in the area of the mouth, the pharynx, the oesophagus, the stomach, and the small and large intestines, and through... Agent: Sughrue Mion, PLLC

20100063151 - Acylamide compounds having secretagogue or inducer activity of adiponectin: The present invention provides acylamide compounds, prodrugs thereof, or pharmaceutically acceptable salts thereof; and an adiponectin inducer or secretagogue, and therapeutic methods by administering the same.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100063150 - Aflatoxin production inhibitor and method for controlling aflatoxin contamination using the same: The present invention also relates to a method for producing an aflatoxin production inhibitor in which dioctatin is prepared: by a method including culturing a dioctatin-producing microorganism, and at least one of separating and purifying dioctatin from a culture obtained, by centrifugal liquid liquid partition chromatography; or by chemical synthesis.... Agent: Edwards Angell Palmer & Dodge LLP

20100063152 - Method and topical formulation for treating localized edema: Methods and formulations are provided for the treatment of localized edema, particularly localized edema resulting from chronic venous insufficiency. A metal ion sequestrant is topically administered to a subject afflicted with localized edema in combination with a permeation enhancer selected from methylsulfonylmethane and a combination of methylsulfonylmethane and dimethylsulfoxide. Topically... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100063153 - Anti-cholesterolemic compounds and methods of use: The present invention provides novel compounds with hypocholesteremic activity from crude Embilica officinialis (EO) extracts and methods of use. The invention also provides nutraceuticals.... Agent: Edwards Angell Palmer & Dodge LLP

20100063154 - Polymorphs of acyl sulfonamides: e

20100063155 - N-(3-phenylpropyl)benzamide derivatives:

20100063156 - Anandamide: The present invention describes provides the use of anandamide for the manufacture of a nutraceutical for oral intake preferably a medicament for reducing appetite, giving a satiety effect, preventing or reducing inflammatory bowel disease or preventing or reducing irritable bowel syndrome... Agent: Nixon & Vanderhye, PC

20100063157 - Chemical process and new crystalline form: e

20100063158 - Crystalline form iii of agomelatine, a process for its preparation and pharmaceutical compositions containing it:

20100063159 - Use of dapsone as a neuroprotector in cerebral infarction: The use of dapsone is the first effective treatment against the disabling consequences associated with cerebral infarction in patients. Dapsone was evaluated as a neuroprotector in the cerebral infarction model produced by the occlusion of the middle cerebral artery in rats and in patients suffering from acute cerebral infarction caused... Agent: Egbert Law Offices

20100063160 - Polymorphs of o-desmethyl venlafaxine succinate: The present invention relates to crystalline forms of O-desmethyl venlafaxine (ODV) succinate monohydrate, namely Forms I and II, in pure form and to novel processes for their preparation. The present invention provides a process for the preparation of Form II free of Form I and a process for the preparation... Agent: Fulbright & Jaworski L.L.P. Attn: MnIPDocket

20100063161 - Treatment of pervasive developmental disorders with redox-active therapeutics: Methods of treating or suppressing pervasive developmental disorders (PDDs) including; autistic disorder, Asperger's syndrome, childhood disintegrative disorder (CDD), Rett's disorder, and PDD-not otherwise specified (PDD-NOS) or attention deficit/hyperactivity disorder (ADHD) comprising administering to a subject in need thereof a therapeutically effective amount of one or more compounds as disclosed herein.... Agent: Morrison & Foerster LLP

20100063162 - Method for predicting efficacy of rar-alpha agonist: A method for predicting preventive and/or therapeutic effect of an RAR-α agonist on a malignant tumor, which comprises the steps of measuring an expression level of a class of p160 family molecule and an expression level of a class of SP110 family molecule in a sample collected from the malignant... Agent: Greenblum & Bernstein, P.L.C

20100063163 - Extract solution comprising a b-cryptoxanthin component and food and drink soaps: There are provided an extract solution to be added to food and drink containing a β-cryptoxanthin component consisting of an extract containing a β-cryptoxanthin component dissolved or dispersed in fat or oil or in a solution comprising an emulsifier and an extract solution to be added to soaps or cosmetics... Agent: Hedman & Costigan P.C.

20100063164 - Transparent zinc sulphide having a high specific surface area: Zinc sulphide having a high specific surface area, a process for producing it and the use of this zinc sulphide.... Agent: Fulbright & Jaworski, LLP

20100063165 - Polyamide-polyether block copolymer: Copolymers having linked internal polyether blocks and internal polyamide blocks have advantageous physical properties and solvent-gelling abilities. The copolymer may be prepared from a reaction mixture that contains 1,4-cyclohexane dicarboxylic acid (CHDA) and poly(alkyleneoxy) diamine (PAODA). Optionally, the reaction mixture contains no monofunctional compound reactive with either amine or carboxylic... Agent: Arizona Chemical Company C/o Bo Segers

20100063166 - Thickners: Disclosed are thickeners comprising at least one polyfunctional alcohol ester of formula (I), where G is a moiety which is obtained by removing all alcoholic hydroxyl groups from a polyhydric alcohol; A is an alkylene group having 2 to 4 carbon atoms, where all identical or different alkylene groups may... Agent: Fox Rothschild LLP

20100063167 - Agrochemical formulations comprising co-polymers based on ethylenically unsaturated dicarboxylic mono and diesters: The present invention comprises the use of formulations comprising at least one pesticide and at least one co-polymer comprising (a) at least one comonomer (a) selected from the group consisting of olefins, vinylethers, vinyl pyrrolidone and styrene; and (b) at least one comonomer (b) selected from the group consisting of... Agent: Brinks, Hofer, Gilson & Lione

  
03/04/2010 > patent applications in patent subcategories. listing by industry category

20100056423 - Bacterial-derived blis for treatment of acne: This invention relates to a treatment of acne. Specifically, the invention is directed to the use of bacteriocin-like inhibitory substances (BLIS), isolated from S. salivarius as bactericide or bacteriostat for acne-causing bacteria, namely P. acnes.... Agent: Pearl Cohen Zedek Latzer, LLP

20100056424 - Cosmetic use of chitinase-type proteins: The present invention relates to the use, notably cosmetic and/or therapeutic, of the YKL-40 protein belonging to the family of chitinase-type proteins, of polypeptides derived from this protein or analogs thereof of a nucleic acid sequence encoding such a polypeptide or of an agent that modulates the activity or expression... Agent: Oliff & Berridge, PLC

20100056425 - Absorption enhancers such as e.g. bht, bha or propyl gallate: The invention provides a pharmaceutical composition comprising a mixture of (a) an active macromolecular principle, and (b) an aromatic alcohol absorption enhancer chosen from butylated hydroxy toluene, butylated hydroxy anisole and analogues and derivatives thereof, wherein the aromatic alcohol absorption enhancer is present in an amount by weight greater than... Agent: Nixon & Vanderhye, PC

20100056426 - Use of iron chelator for the treatment of myocardial infarction: The present invention relates to a method of treating and/or preventing myocardial infarction comprising administering an iron chelator to a warm-blooded animal. The iron chelator is preferably 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic.... Agent: Novartis Corporate Intellectual Property

20100056428 - Modified proteins: Method of conjugating glycoproteins by means of chemical modification is provided as well as new modified glycoproteins.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100056427 - N-terminal derivatisation of proteins with polysaccharides: The present invention relates to methods for producing N-terminal derivatives of proteins in which a polysaccharide, preferably having at least terminal sialic units and preferably consisting essentially only of sialic acid units, is reacted at the N-terminus of a protein or peptide under controlled conditions to produce an N-terminal derivative.... Agent: Morrison & Foerster LLP

20100056429 - Treatment of respiratory chain disorders using compounds having erythropoietin or thrombopoietin activity: Methods of treating mitochondrial respiratory chain disorders using compounds having erythropoietin activity or thrombopoietin activity are disclosed. Indicators for assessing the efficacy of treatment are discussed.... Agent: Morrison & Foerster LLP

20100056431 - Medical uses: The present invention provides the use of a polypeptide comprising an amino acid sequence according to SEQ ID NO: 1 (corresponding to the N-terminal 25 amino acid fragment of the human antimicrobial protein, LL-37) or a biologically active fragment, variant, fusion or derivative thereof, in the preparation of a medicament... Agent: Birch Stewart Kolasch & Birch

20100056433 - Novel peptides for use in the treatment of obesity: The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100056432 - Template-fixed peptidomimetics with antibacterial activity: Template-fixed β-hairpin peptidomimetics of the general formula (I) wherein Z is a template-fixed chain of 12 α-amino acid residues which, depend on their positions in the chain (counted starting from the N-terminal amino acid) are Gly, or Pro, or of certain types which, as the remaining symbols in the above... Agent: Hoffmann & Baron, LLP

20100056430 - Treatment and method for eliminating or reducing foot odor: The topical skin preparation may further include Topical Erythromycin, Topical Aluminum Chloride Hexahydrate, or Tea Tree Oil. Topical Erythromycin may be used as a gel or solution with a 2.0% concentration. Topical Aluminum Chloride Hexahydrate may be used in a concentration of about 5.0% to 20.0%. Tea Tree Oil may... Agent: John T. Wilson, Esq.

20100056434 - Depsipeptides and their therapeutic use: Compounds which are Spiruchostatin analogues of the general formula (I) or (I′), isosteres thereof and pharmaceutically acceptable salts thereof are found to inhibit HDAC wherein R1, R2, R3 and R4 are the same or different and represent an amino acid side chain moiety and each R6 is the same or... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100056435 - Depsipeptides and their therapeutic use: A compound of the general Structure (VII) or (VIII) including isoteres and pharmaceutically acceptable salts thereof, wherein R1, R2 (where X=—CONR6—), R3 and R7 are the same or different and each represents an amino-acid side chain moiety; R2 (where X=—CHZ—), R4 and R6 are the same or different and each... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100056436 - Pharmaceutical compositions including low dosages of desmopressin: The present invention is directed to a pharmaceutical composition comprising 0.5 ng to 20 μg desmopressin and a pharmaceutically acceptable carrier. The present invention is also directed to a pharmaceutical composition comprising desmopressin and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is effective to establish a steady plasma/serum desmopressin... Agent: Goodwin Procter LLP Patent Administrator

20100056445 - Adiponectin for the treatment and diagnosis of albuminuria: Disclosed are methods relating to the treatment and/or prevention of kidney disorders, especially kidney disorders characterized by or involving albuminuria. Methods described include the administration of an adiponectin polypeptide or a nucleic acid encoding such a polypeptide to treat or prevent the development of albuminuria. Also described are methods in... Agent: David S. Resnick

20100056452 - Angiogenesis-promoting substrate: To provide an angiogenesis-promoting substrate which can be easily and cost-effectively produced, it is proposed that the substrate comprise a non-porous shaped body formed from a gelatin-containing material which is insoluble and resorbable under physiological conditions.... Agent: Leydig Voit & Mayer, Ltd

20100056440 - Compositions and methods for administering gdnf ligand family proteins: Disclosed are methods of increasing serum exposure of an administered glial cell line-derived neurotrophic factor (GDNF) ligand family protein by administering to a subject via systemic delivery (i) a GDNF ligand family protein, and (ii) an amount of heparin or heparan sulphate that increases serum exposure of the administered GDNF... Agent: Fish & Richardson

20100056437 - Compositions for treating or preventing myocardial damage or heart failure: The present inventors compared myocardial damages after ischemia/reperfusion in wild-type mice and Midkine (MK)-deficient mice to confirm the effects and functions of MK. MK administration was found to significantly prevent cardiomyocyte apoptosis in both cultured cardiomyocytes (in vitro) and mouse models (in vivo).... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100056448 - Glut-1 as a receptor for htlv envelopes and its uses: The invention relates to the use of the ubiquitous vertebrate glucose transporter GLUT1, or of fragments or sequences derived thereof, for the in vitro diagnosis of cancers, when used as a tumor marker, or for the screening of compounds useful for the preparation of drugs for the prevention or the... Agent: Young & Thompson

20100056447 - Immunization against chlamydia pneumoniae: The published genomic sequence of Chlamydia pneumoniae reveals over 1000 putative encoded proteins but does not itself indicate which of these might be useful antigens for immunization and vaccination or for diagnosis. This difficulty is addressed by the invention, which provides a number of C. pneumoniae protein sequences suitable for... Agent: Novartis Vaccines And Diagnostics Inc.

20100056439 - Ligands that have binding specificity for egfr and/or vegf and methods of use therefor: Disclosed are ligands that have binding specificity for vascular endothelial growth factor (VEGF), for epidermal growth factor receptor (EGFR), or for VEGF and EGFR. Also disclosed are methods of using these ligands. In particular, the use of these ligands for cancer therapy is described.... Agent: Mcdermott Will & Emery LLP

20100056453 - Liquid, aqueous pharmaceutical compositions of factor vii polypeptides: The present invention is directed to liquid, aqueous pharmaceutical compositions stabilised against chemical and/or physical degradation containing Factor VII polypeptides, and methods for preparing and using such compositions, as well as vials containing such compositions, and the use of such compositions in the treatment of a Factor VII-responsive syndrome. The... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100056441 - Method for inhibiting angiogenesis: The invention provides methods for inhibiting angiogenesis in an animal in need thereof. The invention also pro-vides methods for preventing tumor growth and metastasis in an animal comprising inhibiting FoxM1B activity.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100056450 - Method for reducing postprandial blood glucose levels with a whey protein/fiber composition: A method is provided that is effective for reducing postprandial blood glucose levels. The method includes administering a blend of native whey protein and viscosifying fiber to a subject in an amount and at a time prior to a meal or concurrent with a meal that is effective for reducing... Agent: Fitch Even Tabin & Flannery

20100056454 - Method for screening modulators of apoptosis: The use and screening of modulators of apoptosis is disclosed. The modulators may be, for example, modulator of NF-κB activity. The modulators may be used, for example, in the treatment of NF-κB-mediated diseases, conditions, and injuries.... Agent: Polsinelli Shughart PC

20100056438 - Methods of producing nano-and microcapsules of spider silk proteins: The present invention is directed to a method of producing nano- and microcapsules from spider silk proteins The invention is further directed to nano- or microcapsules obtainable by this method as well as pharmaceutical, cosmetical and food compositions containing same.... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20100056446 - Na+k+-atpase-specific peptide inhibitors/activators of src and src family kinases: A method for regulating Src and its downstream signaling pathway which includes binding between Src and Na+/K+-ATPase is disclosed. The Na+/K+-ATPase/Src complex is a functional receptor for cardiotonic steroids such as ouabain. Also disclosed are Src inhibitors or activators which include either Na+/K+-ATPase or Src that interfere with the interaction... Agent: Macmillan Sobanski & Todd, LLC

20100056443 - Radiopharmaceutical to be used in distinction between inflammations and infections in orthopaedic implants: The present invention relates to a radio-pharmaceutical to be used in distinction between inflammations and infections in orthopaedic implants, containing one or more radiomarked human recombinant defensins of -α or -β type, in particular -β defensin of type 3.... Agent: Nixon & Vanderhye, PC

20100056451 - Stabilized pharmaceutical peptide compositions: Method for increasing the shelf-life of a pharmaceutical composition for parenteral administration comprising a glucagon-like peptide which is prepared from a peptide product that has been subjected to treatment at a pH above neutral pH.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100056444 - Treatment of alzheimer's disease using compounds that reduce the activity of non selective ca activated atp- sensitive cation channels regulated by sur1 receptors: NSC antagonists are disclosed as useful in the treatment of dementia, in delaying the onset of dementia, and in the prevention of dementia. Dementia so treated may be, for example, Alzheimer's Disease (AD). NSC antagonists for treating dementia such as AD may be administered alone, a) in combination with other... Agent: Goodwin Procter LLP Attn: Patent Administrator

20100056442 - Use of gpr101 receptor in methods to identify modulators of hypothalamic proopiomelanocortin (pomc)-derived biologically active peptide secretion useful in the treatment of pomc-derived biologically: The present invention relates to methods of using GPR101 G protein-coupled receptor (GPCR) to screen candidate compounds as modulators of hypothalamic proopiomelanocortin (POMC)-derived biologically active peptide secretion. Modulators of GPR101 receptor modulate hypothalamic POMC-derived biologically active peptide secretion and are useful in the treatment of POMC-derived biologically active peptide-related disorders.... Agent: Arena Pharmaceuticals, Inc. Bozicevic, Field & Francis LLP

20100056449 - Whey protein pre-load: A method is provided that is effective for reducing postprandial blood glucose levels and/or food intake levels. The method includes administering native whey protein to a subject in an amount and at a time prior to a meal that is effective for reducing postprandial blood glucose levels and/or reducing food... Agent: Fitch Even Tabin & Flannery

20100056456 - Omega conotoxins: The present invention relates to a method for increasing the binding reversibility of a ω-conotoxin to a N-type calcium channel, which comprises preparing a ω-conotoxin having a Ile and/or Ala residue at a position of amino acid (11 and/or 12), respectively in the second loop between cysteine residues (2 and... Agent: Clark & Elbing LLP

20100056455 - Therapies which act on neuropeptide s receptors: Compositions and methods that act on Neuropeptide S reseptors (NPSR) (also known as or “TGR23” or “vasopressin receptor-related receptor 1 (VRR1)”) to cause desired effects in the bodies of human or animal subjects. Neuropeptide S (NPS) and other agonists of the NPSR may be administered to cause arousal, awakening, alertness,... Agent: Stout, Uxa, Buyan & Mullins LLP

20100056459 - Cell-permeable peptide inhibitors of the jnk signal transduction pathway: The invention provides cell-permeable peptides that selectively block the branch of the JNK signaling pathway controlled by the islet-brain (IB) proteins. The provided cell-permeable peptides block the binding of intermediate kinases in the c-Jun amino terminal kinase (JNK) signaling pathway, thereby decreasing the downstream effects of c-Jun amino terminal kinase... Agent: Morgan Lewis & Bockius LLP

20100056458 - Peptides inhibiting angiotensin-converting enzyme: The invention provides novel peptides having ACE-inhibiting properties derived from milk proteins, as well as their mixtures and their use as hypotensive aids. The peptides have from 2 up to 14 amino acid residues, at least one of which is a branched-chain amino acid. Examples include IV, LV, VLGPV, VPYPQ,... Agent: Young & Thompson

20100056457 - Zinc finger binding domains for cnn: Polypeptides that contain zinc finger-nucleotide binding regions that bind to nucleotide sequences of the formula CNN are provided. Compositions containing a plurality of polypeptides, polynucleotides that encode such polypeptides and methods of regulating gene expression with such polypeptides, compositions and polynucleotides are also provided.... Agent: Schwegman, Lundberg & Woessner, P.A.

20100056460 - Combination of organic compounds: l

20100056461 - Cover layers to prevent weed growth: The invention relates to a soil cover, a method for preventing weed growth by using a soil cover, the use of potato steam peels and the use of a cork fraction of potato steam peels for preventing weed growth. A soil cover according to the invention comprises potato steam peels... Agent: Lucas & Mercanti, LLP

20100056462 - Medical composition for promotion of skin regeneration: The present invention provides a medical composition which, in autotransplantation which is the only method that can induce the epithelialization even in a widespread full-thickness skin defect, enables the fixation of an autotransplantation skin graft in a simple manner and can increase the efficiency of epithelialization to promote the regeneration... Agent: Pearne & Gordon LLP

20100056463 - Novel compositions: The present invention relates to novel compositions comprising hydroxytyrosol and/or oleuropein (I) and at least one additional component e.g. selected from the group of ligustilide, oleuropein aglycone, magnolol, honokiol, genistein, resveratrol, EGCG, magnolia bark extract, cashew fruit extract and Glycyrrhiza foetida as well as to the use of these compositions... Agent: Nixon & Vanderhye, PC

20100056606 - Combination therapy using budesonide and antisense oligonucleotide targeted to il4-receptor alpha: Provided herein is a method for reducing the amount of steroid required for the prevention, amelioration and/or treatment of pulmonary inflammation and/or airway hyperresponsiveness, comprising administration of the steroid and an oligonucleotide targeted to IL-4R alpha. Also described is a method for the prevention, amelioration and/or treatment of pulmonary inflammation... Agent: Swanson & Bratschun, L.L.C.

20100056607 - Compositions and their uses directed to hbxip: Disclosed herein are compounds, compositions and methods for modulating the expression of HBXIP in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.... Agent: Jones Day For Isis Pharmaceuticals, Inc.

20100056610 - Heptbeta as a target in treatment of angiogenisis mediated disorders: Disclosed herein is the use of HPTPbeta to screen agents useful in the treatment angiogenesis mediated disorders.... Agent: Ballard Spahr LLP

20100056609 - Methods and compositions for inhibition of axonal degeneration by modulation of the dlk/jnk pathway: Methods of reducing Wallerian degeneration are disclosed. These methods comprise inhibiting expression or activity of a mixed lineage kinas such as a dual leucine-zipper-bearing kinase (DLK), inhibiting expression or activity of a molecule acting downstream from DLK, such as a c-Jun N-terminal kinase (JNK), or a combination thereof. Further disclosed... Agent: Washington University-snr C/o Sonnenschein Nath & Rosenthal L.l.p

20100056608 - Methods for screening and treatment involving the genes gypc, agpat3, agl, pvrl2, hmgb 3, hsdl2 and/or ldb2: The present invention relates to a method for identifying a compound as a candidate drug, comprising the steps a. bringing said compound into contact with a cell expressing the genes CYPC, AGPAT3, AGL, PVRL2, HMGB 3, HSDL2; and b. analyzing if said compound modulates the expression of at least one... Agent: Brooks Kushman P.C.

20100056611 - Mn/ca9 splice variants: Herein disclosed is an alternatively-spliced [AS] variant of MN/CA9 mRNA and its related protein—AS MN/CA IX. Unlike the tumor-associated, full-length [FL] MN/CA9 mRNA and FL MN/CA IX, which in most tissues signify oncogenesis and/or hypoxia, the AS MN/CA9 mRNA is constitutively-expressed under normoxia and is not stimulated by hypoxia, and... Agent: Leona L. Lauder

20100056612 - Molecular entities for binding, stabilization and cellular delivery of charged molecules: In accordance with the present invention, it has been discovered that the uptake of charged molecules into cells can be enhanced by noncovalently associating such molecules with molecular entities comprising an amphiphilic core with oppositely charged arms. The molecular entities form well defined stoichiometric complexes with charged molecules. Various compositions... Agent: Foley & Lardner LLP

20100056464 - Compounds, compositions and methods of using same for modulating uric acid levels: Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of making and using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.... Agent: Wilson, Sonsini, Goodrich & Rosati

20100056465 - Compounds, compositions and methods of using same for modulating uric acid levels: Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of making and using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.... Agent: Wilson, Sonsini, Goodrich & Rosati

20100056466 - 2'-cyanopyrimidine nucleoside compound: [wherein one of X and Y is cyano and the other is hydrogen; and i) R1 is hydrogen, and R2 is alkyloxycarbonyl wherein the alkyl moiety is straight or branched C5-12 alkyl (the alkyl may be substituted), or alternatively, ii) R1 is alkyloxycarbonyl wherein the alkyl moiety is straight or... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100056467 - Combination of iap inhibitors and flt3 inhibitors: The present invention relates to methods of treating hematological malignancies, including acute myeloid leukemia (AML), comprising the combination of a compound that inhibits the binding of the Smac protein to IAPs (“IAP inhibitor”) and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; and a commercial package comprising... Agent: Novartis Corporate Intellectual Property

20100056468 - Pyrimidine derivatives as anticancer agents: The present invention includes methods of treating or preventing cancer by administering an effective amount of 6-substituted pyrimidine derivatives of the Formula I to a subject need thereof:... Agent: Pabst Patent Group LLP

20100056469 - Pesticidal active mixtures comprising aminothiazoline compounds: Pesticidal mixtures comprising aminothiazoline compounds The present invention relates to pesticidal mixtures comprising as active compounds 1) at least one aminothiazoline compound I of the Formula (I) wherein R1, R2, R3, R4, R5 and R6 are defined in the description; and 2) at least one active compound II selected from... Agent: Brinks, Hofer, Gilson & Lione

20100056472 - Grain compositions containing pre-biotic isomalto-oligosaccharides and methods of making and using same: Methods for the production of substrate, tuber, and grain compositions containing isomalto-oligosaccharides are described. The methods comprise (a) contacting a substrate, tuber or grain containing ungelatinized starch with a maltogenic enzyme and a starch liquefying enzyme to produce maltose; (b) contacting said maltose with a transglucosidic enzyme, wherein said steps... Agent: Danisco US Inc. Attention: Legal Department

20100056473 - Method of extracting fucoidan: A method of extracting fucoidan from a biological material is provided. The method comprises (a) combining a biological material containing fucoidan and a medium to form a mixture; (b) applying ultrasonic waves to the mixture while the mixture is at a temperature of less than about 60 C; (c) extracting... Agent: Wilson, Sonsini, Goodrich & Rosati

20100056470 - Plant compositions enriched in dehydrosoyasaponin i (d-i) and methods of producing such compositions: There is provided a method of producing a plant composition comprising dehydrosoyasaponin I (D-I), the method comprising the steps of extracting a plant flour with a solvent capable of extracting soyasaponins to produce an extract, and treating the extract with light. Also provided are compositions produced according to the method... Agent: Ronald I. Eisenstein Nixon Peabody LLP

20100056471 - Semi-fluid food product comprising beta-glucan fibres: The present invention relates to a semi-fluid thermised aqueous solution comprising β-glucan fibres and a sufficient amount of at least one viscosity depressant chosen from the group composed of maltodextrins having a maximum DE of 18, at least partially hydrolysed guar gum, inulin and fructooligosaccharides. Another subject of the invention... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100056474 - Methods and compositions for the prevention of and treatment of infections utilizing chitosan-derivative compounds: The present invention is directed to the treatment and prevention of nosocomial infections or MRSA infections utilizing soluble chitosan or chitosan derivative compounds. These chitosan-derivative compounds, e.g., chitosan-arginine and chitosan-acid amines, exhibit bactericidal activity against bacterial pathogens, e.g., drug resistant bacteria such as Methicillin-resistant Staphylococcus aureus (MRSA).... Agent: Lando & Anastasi, LLP

20100056475 - Cyclodextrin conjugates: It has been discovered that the uptake of anionic charged species into cells can be enhanced by noncovalently associating such species with specifically modified forms of cyclodextrin. The invention modified forms of cyclodextrin form well defined stoichiometric complexes with anionic charged molecules. This discovery enables one to produce various compositions... Agent: Foley & Lardner LLP

20100056476 - Pharmaceutical compositions comprising peranhydrocyclodextrin: The present invention relates to a pharmaceutical composition comprising a peranhydrocyclodextrin, a drug and a carrier, to the use of a peranhydrocyclodextrin as a drug transport enhancer (e.g. permeation enhancer), and to the use of a peranhydrocyclodextrin in the preparation of a pharmaceutical composition as a synergistic adjunctive system.... Agent: Novartis Corporate Intellectual Property

20100056477 - Fungicidal mixtures of amidinylphenyl compounds: This invention relates to fungicidal mixtures of certain phenylamidines, their N-oxides, and/or agriculturally suitable salts thereof, and to compositions comprising such mixtures and methods for using such mixtures as fungicides.... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20100056479 - The use of quaternary ammonium compounds in the remediation of mold, mildew, and funguses: The present invention relates to the use of quaternary ammonium compounds in the remediation of microbial growth such as mold, funguses, and mildew.... Agent: Albemarle Corporation Patent Department

20100056480 - Use of arginase inhibitors in the treatment of asthma and allergic rhinitis: The present invention relates to the use of an arginase inhibitor for the preparation of a medicament for the prophylactic maintenance therapy of an asthmatic or allergic patient by preventing obstruction of upper and lower airways, in particular allergen-induced bronchial obstruction and/or airway hyperresponsiveness. The patients are either asthmatic or... Agent: Organon Usa, Inc. C/o Schering-plough Corporation

20100056478 - Useful combinations of monobactam antibiotics with beta-lactamase inhibitors: A pharmaceutically composition, comprising a combination of an antibiotically active compound of the formula (I): with a β-lactamase inhibitor of one of the formulae (II) to (XIII) are active against Gram-negative bacteria, in particular such bacteria which have become resistant against antibiotics such as aztreonam, carumonam and tigemonam. Optionally the... Agent: Gibbons P.C.

20100056481 - Crystalline forms of zoledronic acid: The invention relates to new crystalline forms of low water soluble salts of zoledronic acid, the process for preparation of these crystalline forms, compositions containing these crystalline forms, and the use of these crystalline forms in diagnostic methods or therapeutic treatment of warm-blooded animals, especially humans. The invention relates to... Agent: Novartis Corporate Intellectual Property

20100056482 - Calixarene derivatives as anticancer agent: e

20100056483 - Methods and compositions for the treatment and prevention of bone loss: Disclosed herein are methods and compositions for the treatment and prevention of bone loss. The methods comprise providing a therapeutically effective amount of at least one chelating agent to a subject. The methods further comprise providing a therapeutically effective amount of estrogen or at least one estrogen analogue to a... Agent: Calfee Halter & Griswold, LLP

20100056484 - Dietary supplemental composition effective for enhancing cognitive performance, elevating mood and reducing oxidative stress: A dietary supplemental composition composed of Acetyl-L-Carnitine, Phosphatidylserine, L-Alpha-Glycerylphosphorylcholine, fish oils including Docosahexaenoic acid, Alpha Lipoic Acid, and optionally Eicosapentaenoic acid, and which in combination has been demonstrated to be effective in increasing cognitive performance, elevating mood and decreasing oxidative stress levels in mammals.... Agent: Mchale & Slavin, P.A.

20100056485 - Nanosoap containing silver nanoparticles: Disclosed herein is a silver nanoparticle based antimicrobial composition and methods for making the same. The antimicrobial composition comprises an amphiphilic molecule having at least one hydrophilic group and at least hydrophobic groups attached thereto; and an at least one silver nanoparticle in contact with the amphiphilic molecule. Also disclosed... Agent: Seung Bum Park

20100056486 - Combinations comprising antimuscarinic agents and corticosteroids: Combinations comprising (a) a corticosteroid and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for treatment of respiratory disease, e.g., asthma or chronic... Agent: Hoxie & Associates LLC

20100056487 - Modulators of amyloid-beta production: As described herein, the present invention provides compounds useful for treating or lessening the severity of a neurodegenerative disorder. The present invention also provides methods of treating or lessening the severity of such disorders wherein said method comprises administering to a patient a compound of the present invention, or composition... Agent: Choate, Hall & Stewart LLP

20100056488 - Corticosteroid conjugates and uses thereof: The invention features corticosteroids conjugated to either a charged group or a bulky group in a manner that resists in vivo cleavage, the resulting conjugate is a peripherally acting steroid with reduced activity in the central nervous system. The invention provides a method for treating a patient having an inflammatory... Agent: Clark & Elbing LLP

20100056490 - Cyclic sulfones with aminobenzyl substitution useful as bace inhibitors: e

20100056489 - Treatment of neuropathic pain: A method for treating a patient suffering from neuropathic pain, comprising administering to a patient in need of such treatment an effective amount of an agonist drug capable of binding to the neuronal nicotinic receptor (NNR) but which does not readily cross the blood-brain barrier.... Agent: Paul D. Yasger Abbott Laboratories

20100056491 - 4'-amino cyclic compounds having 5-ht6 receptor affinity: m

20100056492 - Compounds and uses thereof - 152: This invention relates to novel compounds having the structural Formula (I) below: and their pharmaceutically acceptable salts or tautomers, compositions and methods of use thereof. These novel compounds provide a treatment or prophylaxis of at least one symptom or condition associated with schizophrenia and other psychotic disorders, dementia and other... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20100056493 - Modified release pharmaceutical composition and a process of making the same: The present invention refers to a modified release pharmaceutical composition comprising an in-situ gelling agent (=0.5 % w/w) and a gellation facilitating agent (e.g. calcium sulfate) in an amount of 2-17.5 % w/w. Additionally, the composition contains a release rate controlling polymer such as an acrylate and optionally a pH... Agent: Ladas & Parry LLP

20100056494 - Purine compounds and compositions as kinase inhibitors for the treatment of plasmodium related diseases: The invention provides a class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with kinase activity, particularly malaria.... Agent: Genomics Institute Of The Novartis Research Foundation

20100056495 - Dimeric iap inhibitors: Compounds, compositions, and methods of using such compounds to modulate apoptosis including IAP antagonists are provided herein. Compositions including mimetics of the invention and, optionally, secondary agents, may be used to treat proliferative disorders such as, cancer and autoimmune diseases.... Agent: Banner & Witcoff, Ltd.

20100056496 - Muscarinic receptor antagonists: The present invention generally relates to muscarinic receptor antagonists, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The present invention also relates to processes for preparing compounds described herein, pharmaceutical compositions thereof, and methods for... Agent: Ranbaxy Inc.

20100056497 - Amide derivative: wherein R1a is a hydrogen atom, an optionally substituted C1-6 alkyl, etc.; R1b is an optionally substituted C1-6 alkoxy, etc.; R1c is a hydrogen atom, an optionally substituted C1-6 alkoxy, etc.; R2 is a hydrogen atom, an optionally substituted C1-6 alkyl, etc.; R3a, R3b, R3c and R3d are independently the... Agent: Sughrue Mion, PLLC

20100056498 - Substituted monocyclic cgrp receptor antagonists: (wherein variables A1, A2, A3, A4, m, n, J, Q, R4, Ea, Eb, Ec, R6, R7, Re, Rf, RPG and Y are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as... Agent: Merck And Co., Inc

20100056499 - 3-amino-1-arylpropyl azaindoles and uses thereof: h

20100056500 - Stable parenteral formulation: The present invention relates to pharmaceutical formulations of benzodiazepine compounds which are active against Respiratory Syncytial Virus (RSV) suitable for parenteral administration.... Agent: Novartis Institutes For Biomedical Research, Inc.

20100056501 - Substituted lactams as inhibitors of abeta protein production: having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the... Agent: Kelley Drye & Warren LLP

20100056502 - Compounds: Tricyclic nitrogen containing compounds and their use as antibacterials.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20100056503 - Compounds for modulating integrin cd11b/cd18: The application describes an assay for the identification of small molecule modulators of integrin CD11b/CD18 and small molecules capable of modulating activity of this receptor. Such compounds may be used in certain embodiments for treating a disease or condition selected from inflammation, immune-related disorders, cancer, ischemia-reperfusion injury, stroke, neointimal thickening... Agent: Ropes & Gray LLP

20100056504 - Novel 1,2-dihydroquinoline derivative having substituted phenylchalcogeno lower alkyl group and ester- introduced phenyl group as substituents: The R1 represents a hydrogen atom or a lower alkyl group; R2 represents a hydrogen atom or a lower alkyl group; R3 and R4 may be the same or different and represent a hydrogen atom or a lower alkyl group; R5 represents a hydrogen atom or a lower alkyl group;... Agent: Frishauf, Holtz, Goodman & Chick, PC

20100056506 - Substituted 2-amino-fused heterocyclic compounds: The present invention relates to compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein: R1, R2, Z1, t, and ring A are as defined in the specification. The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and methods of treating a condition... Agent: Pharmacia Corporation Global Patent Department

20100056505 - Substituted pyrazalones: The invention is related to compounds of formula (I) as antagonists of the TGFβ family type I receptors, Alk5 and/or AIk 4, compositions and methods of use. The compounds of formula (I) can be employed in the prevention and/or treatment of diseases such as fibrosis (e.g., renal fibrosis, pulmonary fibrosis,... Agent: Johnathan P. O'brien, Ph.d Honigman Miller Schwartz

20100056508 - Amine derivatives and their use in beta-2-adrenoreceptor mediated diseases: The present invention provides compounds of formula (I), wherein k, Ar, R2, R3, R4, R5, R4′, R5′, R6, R7, A, D, m and E are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20100056509 - Heteroaryl sulfonamides and ccr2: Compounds are provided that act as potent antagonists of the CCR2 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, and as... Agent: Brinks Hofer Gilson & Lione

20100056507 - Phenyl derivatives and their use as a medicament: The present invention relates to new phenylic derivatives exhibiting a good affinity for certain sub-types of cannabinoid receptors, in particular the CB2 receptors. These derivatives are of particular interest in a method for treating pathological conditions and diseases in which one or more cannabinoid receptors are involved. The invention also... Agent: Hunton & Williams LLP Intellectual Property Department

20100056510 - Macrocyclic compound: e

20100056511 - 2- [ (2-substituted) -ind0lizin-3-yl] -2-oxo-acetamide derivatives as antifungal agents: The invention provides compounds of formula (I), and pharmaceutically acceptable salts thereof wherein: R1, R2, R3, R4, R5, R6, R7, X and X1 are as defined herein. These compounds are useful in the manufacture of medicaments for use in the prevention or treatment of a fungal disease. Compounds of formula... Agent: Fulbright & Jaworski, LLP

20100056512 - Pyrimidine compounds: e

20100056513 - Stereospecifically substituted benzo[1,3]dioxolyl derivatives:

20100056514 - Thienopyrazoles: Thienopyrazoles, their preparation, pharmaceutical compositions comprising these compounds, and their pharmaceutical uses in the treatment of disease states capable of being modulated by the inhibition of the protein kinases, in particular interleukin-2 inducible tyrosine kinase (ITK).... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100056516 - 1-hydroxy naphthyridine compounds as anti-hiv agents: 1-Hydroxy naphthyridine compounds (e.g., 1-hydroxy naphthyridin-2(1H)-one compounds of Formula I are inhibitors of HIV integrase and/or HIV RNase H and inhibitors of HIV replication: (I) wherein X and R1-R6 are as defined herein. The compounds are useful in the prophylaxis and treatment of infection by HIV and in the prophylaxis,... Agent: Merck And Co., Inc

20100056517 - Arylsulfonamide compounds: wherein A1, A2, B1, B2, B3, X, Z, R1, R2, R3 and t are as described herein. The invention also relates to processes of preparing the benzenesulfonamide compounds that mimic portions of peptides and proteins, and to the use of such compounds in the regulation of cell death and the... Agent: Genentech, Inc.

20100056515 - Benzimidazole compounds: wherein R1 is an optionally substituted C1-10 alkyl; R2 is H, or a C1-6 alkyl which may be substituted with 1 to 3 substituents; R3 is a 5- or 6-membered aromatic group which may be substituted with 1 to 5 substituents, wherein the 5- or 6-membered aromatic group may be... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100056521 - (aza)indole derivative and use thereof for medical purposes: The present invention provides compounds useful as agents for the prevention or treatment of a disease associated with abnormal serum uric acid level which has a uricosuric activity or the like. The present invention relates to (aza)indole derivatives represented by the following general formula (I) having xanthine oxidase inhibitory activities... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20100056519 - Composition and method for reducing platelet activation and for the treatment of thrombotic events: A novel method of treating and preventing a vascular disease in an individual, comprising: selecting an individual having an elevated level of glycoprotein Ib, glycoprotein IIb/IIIa, PECAM-1, vitronectin receptor or thrombospondin receptor, or formation of platelet-neutrophil aggregates; and administering a therapeutically effective amount of a protease activated receptor-1 (PAR-1) antagonist,... Agent: Dickstein Shapiro LLP

20100056518 - Cycloalkylamine substituted isoquinolone derivatives: n

20100056520 - Formulations of phospholipase enzyme inhibitors: The present invention is directed to formulations of inhibitors of phospholipase enzymes, such as cytosolic PLA2, compositions containing the same and processes for manufacture thereof.... Agent: Wyeth LLC Patent Law Group

20100056522 - Intraocular pressure-lowering agent comprising compound having histone deacetylase inhibitor effect as active ingredient: An object of the present invention is to find a novel pharmacological effect of a compound having an HDAC inhibitory effect. The compound having an HDAC inhibitory effect of the invention has an excellent effect of cell morphological change on trabecular meshwork cells and/or effect of intraocular pressure reduction, and... Agent: Frishauf, Holtz, Goodman & Chick, PC

20100056525 - 5- and 6- substituted benzimidazole thiophene compounds: The present invention provides 5- and 6-substituted benzimidazole thiophene compounds pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20100056524 - Compound: e

20100056523 - Inhibitors of akt activity: Invented are novel 1H-imidazo[4,5-c]pyridin-2-yl compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20100056526 - Heteromonocyclic compound and use thereof: A compound represented by the formula (I): wherein R1 is an oxo group, ═N—R or the like; a group represented by the formula: is a group represented by the formula: R2 is a group represented by the formula: or a salt thereof. The compound of the present invention is useful... Agent: Foley And Lardner LLP Suite 500

20100056527 - Benzofuran compounds useful in the treatment of conditions mediated by the action of pge2 at the ep1 receptor: c

20100056528 - Sulfonamide derivatives with therapeutic indications: The invention provides sulfonamide compounds of formula (I) as defined herein, pharmaceutical compositions containing the same and methods of treatment using such compounds and pharmaceutical compositions. These compounds have a common wide range of beneficial therapeutic indications, in particular as analgesic and anti-inflammatory agents.... Agent: Winston & Strawn LLP Patent Department

20100056529 - Substituted triazolo-pyridazine derivatives: This invention relates to novel substituted triazolo-pyridazines, their derivatives, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an α1-GABA-A receptor antagonist and/or a... Agent: Edwards Angell Palmer & Dodge LLP

20100056533 - 18f-labelled folates: The present invention is directed towards new 18F-folate radio-pharmaceuticals, wherein the fluorine-18 is covalently linked to the aminobenzoyl moiety, which connects the condensed pyrimidine heterocycle to the amino acid portion within folate structures, as well as their precursors and their non-radioactive references, a method of their preparation, as well as... Agent: Millen, White, Zelano & Branigan, P.C.

20100056531 - Alkyl-substituted 3' compounds having 5-ht6 receptor affinity: e

20100056532 - Compounds that modulate intracellular calcium: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel... Agent: Wilson, Sonsini, Goodrich & Rosati

20100056530 - Glucokinase activators: Provided are compounds of Formula I wherein R1, R2, Y, Z and G are as defined herein, that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes mellitus. Also provided are methods of treating or preventing diseases and disorders characterized... Agent: Viksnins Harris & Padys Pllp

20100056535 - Inhibitors of hiv-1 reverse transcriptase: o

20100056534 - Pesticidal compositions: Pesticide compositions and their use in controlling pests are provided.... Agent: Dow Agrosciences LLC

20100056536 - Method of treating atrial fibrillation: The present invention relates to a method for the treatment of atrial fibrillation comprising the coadministration of a synergistic therapeutically effective amount of amiodarone and synergistic therapeutically effective amount ranolazine. This invention also relates to pharmaceutical formulations that are suitable for such combined administration.... Agent: Cv Therapeutics, Inc. Gilead Palo Alto, Inc.

20100056537 - Pharmaceutical composition having relatively low ionic strength: The present invention is directed to the provision of pharmaceutical compositions such as multi-dose, ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy preservative efficacy requirements in the United States and/or Europe. The compositions include sorbate or a non-polymeric diquaternary ammonium compound for enhancing preservation efficacy. Further, the compositions... Agent: Alcon

20100056538 - Pro-drugs of a2b adenosine receptor antagonists: Disclosed are prodrugs of A2B adenosine receptor antagonists, and their use in treating mammals for various disease states.... Agent: Cv Therapeutics, Inc. Gilead Palo Alto, Inc.

20100056540 - Stable pharmaceutical composition for optimized delivery of an hiv attachment inhibitor: A pharmaceutical composition contains the compound 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazine, and hydroxypropyl methyl cellulose (HPMC) having a viscosity of at least about 100 cP, wherein the composition does not contain any enzyme inhibitors.... Agent: Louis J. Wille Bristol-myers Squibb Company

20100056539 - Trazodone and trazodone hydrochloride in purified form: A process of production of trazodone or trazodone hydrochloride that comprises the steps of: (a) preparing an organic phase comprising trazodone in at least one organic solvent; (b) preparing an aqueous phase comprising at least one basic compound; (c) mixing said aqueous phase with said organic phase; (d) heating at... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100056541 - Biphenyl compounds useful as muscarinic receptor antagonists: wherein a, b, c, m, n, q, r, W, Z1, Ar1, Z2, R1, R2, and R3 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of... Agent: Theravance, Inc.

20100056542 - Compounds, compositions and methods of using same for modulating uric acid levels: Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of making and using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid... Agent: Wilson, Sonsini, Goodrich & Rosati

20100056543 - Posaconazole polymer conjugates and methods of treatment using posaconazole and polymer conjugates thereof: Improved posaconazole-based compositions and methods of treating and preventing fungal infections, cancer or metastatic diseases are disclosed. In preferred aspects, the conjugates are PEG-posaconazole conjugates in which the PEG has a molecular weight of about 20,000 daltons.... Agent: Lucas & Mercanti, LLP

20100056544 - Salts with crth2 antagonist activity: The potassium, sodium, ammonium, lysine, diethylamine, tromethamine (TRIS), piperazine, ethylenediamine and ethanolamine salt of a compound of general formula (I): wherein R1 is halo or cyano; R2 is C1-C4 alkyl; and R3 is quinolyl or phenyl substituted with methane sulfonyl; can be synthesised by a novel method and are substantially... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100056545 - Novel phenylacetate derivatives or pharmaceutically acceptable salts thereof, preparation method thereof and composition for prevention or treatment of diseases induced by activation of t-type calcium ion channel containing the same as an active ingredie: e

20100056546 - Sulfonylurea inhibitors of atp-sensitive potassium channels: The present invention relates to new sulfonylurea inhibitors of ATP-sensitive potassium channels, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx

20100056547 - Ophthalmic compositions comprising ddc: e

20100056548 - Thienopyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions: The present invention relates to novel pharmaceutical compositions comprising thienopyrimidine compounds. Moreover, the present invention relates to the use of the thienopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20100056551 - Anti-cancer cyclopenta [g] quinazoline compounds: Cyclopenta[g]quinazolines of the formula (I):—wherein: A is a group OR or NR0R1 wherein R0 and R1 are each independently hydrogen C1-4 alkyl, C3-4 alkenyl, C3-4 alkynyl, C2-4 hydroxyalkyl, C2-4 halogenoalkyl or C1-4 cyanoalkyl, or R0 and R1 together with the intermediate N form a five- or six-membered heterocyclic ring; p... Agent: Nixon & Vanderhye, PC

20100056549 - Highly soluble pyrimido-dione-quinoline compounds and their use in the treatment of cancer: The present invention features pyrimido-dione-quinoline compounds having improved solubility, pharmaceutical compositions of substituted pyrimido-dione-quinoline compounds and methods of treating a patient suffering from cancer, the method comprising administering to a patient one or more pyrimido-dione-quinoline compounds of the invention.... Agent: Edwards Angell Palmer & Dodge LLP

20100056550 - Tricyclic heteroaromatic compounds as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes: The present invention is directed to novel substituted tricyclic heteroaromatic compounds of structural formula (I) which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes.... Agent: Merck And Co., Inc

20100056552 - Combination for use in the treatment of inflammatory disorders: There is provided combination products comprising (a) suplatast, or a pharmaceutically-acceptable salt or solvate thereof; and (b) a statin, or a pharmaceutically-acceptable salt or solvate thereof. Such combination products find particular utility in the treatment of atherosclerosis and related conditions.... Agent: Ryan Kromholz & Manion, S.c.

20100056553 - Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives: e

20100056554 - Use of opioid formulations in needle-less drug delivery devices: The present invention concerns a needle-less drug delivery device being suitable for delivering drugs through a skin surface into a human or animal body comprising a pharmaceutical composition with at least one analgesic agent preferably being an opioid. The present invention also relates to the use of at least one... Agent: Duane Morris LLP - Ny Patent Department

20100056555 - Method of treating ras associated cancer: New methods of treating Ras associated cancer, and especially for treating cancer that is resistant or refractory to other treatment methods, including resistant or refractory to treatment with C225 and/or CPT-11, are provided. The new methods employ PEG-conjugated 7-ethyl-10-hydroxycampothecin, alone, or in combination with other art-known anticancer agents or modalities.... Agent: Lucas & Mercanti, LLP

20100056556 - Isoquinolinopyrrolopyridinones active as kinase inhibitors: Heteroarylpyridinone derivatives represented by formula (I) wherein R1, R2, R3, R4, R5, and X are as defined in the specification, compositions thereof, and methods of use thereof. Particularly, there are described isoquinolinoyrrolopyridinones, pharmaceutical compositions comprising them and their use as therapeutic agents in the treatment of cancer and cell proliferation... Agent: Scully Scott Murphy & Presser, PC

20100056558 - 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase inhibitors: processes for the preparation thereof, the application thereof in a process for the treatment of the human or animal body, the use thereof—alone or in combination with one or more other pharmaceutically active compounds—for the treatment of an inflammatory or obstructive airway disease, such as asthma, disorders commonly occurring in... Agent: Novartis Corporate Intellectual Property

20100056557 - Treatment for cutaneous metastases: The present invention provides methods for treating cutaneous metastases. In one aspect, the method can include identifying a treatment area that comprises one or more lesions containing metastatic cells; and administering an IRM compound to the treatment area in an amount effective for treating the lesion. In another aspect, the... Agent: 3m Innovative Properties Company

20100056562 - Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors: e

20100056561 - Hydrochloride salt of an azabicyclo[3.2.1]octane derivative: The invention relates to a hydrochloride salt of (1R,2R,3S,5S)-3-(3,4-dichlorophenyl)-2-[(methyloxy)methyl]-8-azabicyclo[3.2.1]octane, uses of the salt as a medicament in the treatment inter alia of disorders of the central nervous system and pharmaceutical compositions and dosage forms comprising the salt.... Agent: Birch Stewart Kolasch & Birch

20100056559 - Propellant-free aerosol formulation for inhalation: The present invention relates to propellant-free aerosol formulations for inhalation containing ipratropium bromide and salbutamol.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100056560 - Use for treating obesity and diabetes: Disclosed herein is the use of a composition, containing isoflavone-containing soybean extract, L-carnitine, caffeine and arginine as active ingredients, for the treatment of obesity and diabetes. The disclosed composition contains isoflavone-containing soybean extract, carnitine, caffeine and arginine in the form of a mixture, and thus shows not only the effect... Agent: Nixon & Vanderhye, PC

20100056563 - Novel 1.8-naphthyridine compounds: The present invention relates to naphthyridine compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.... Agent: Merck And Co., Inc

20100056564 - Association of an anti-atherothrombotic agent and an anti-platelet-aggregation agent: The present invention relates to a new association of an anti-atherothrombotic agent and an anti-platelet-aggregation agent.... Agent: The Firm Of Hueschen And Sage

20100056565 - Heterocyclic derivatives as m3 muscarinic receptors: This invention relates to M3 antagonists of formula (I) wherein R2, R4, R5, R6, W, V, A, D, X, t, u and v are as defined herein; pharmaceutical compositions containing them; methods for their preparation; and their use in the treatment of diseases where enhanced M3 receptor activation is implicated.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20100056566 - New substituted isoquinoline and isoquinolinone derivatives: i

20100056567 - Novel alkyl substituted piperidine derivatives as monoamine neurotransmitter re-uptake inhibitors: This invention relates to novel alkyl substituted piperidine derivatives useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.... Agent: Birch Stewart Kolasch & Birch

20100056568 - Cycloalkylamine substituted isoquinolone and isoquinolinone derivatives: i

20100056570 - Fungicides: Compounds of the general formula wherein the substituents are as defined in claim (1), are useful as fungicides.... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20100056569 - Heterocyclic non-nucleoside compounds, their preparation, pharmaceutical composition and their use as antiviral agents: The invention relates a kind of antiviral agents, more concretely, relates to a kind of heterocyclic non-nucleoside compounds with the following structures, their preparation and pharmaceutical compositions including the compounds. The said compounds can be used as antiviral agents and as medicaments for treating diseases such as hepatitis B, influenza,... Agent: Baker & Hostetler LLP

20100056571 - Novel pyrazole compounds as transforming growth factor (tgf) inhibitors: Novel pyrazole compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of transforming growth factor (“TGF”)- signaling pathway. They are useful in the treatment of various TGF-related disease states... Agent: Pharmacia & Upjohn

20100056572 - Compositions and methods relating to solenopsins and their uses in treating neurological disorders and enhancing physical performance: Provided herein are piperidine alkaloids and uses thereof in neurological disorders and physical enhancement applications.... Agent: Ballard Spahr LLP

20100056573 - 2-alkyl-indazole compounds for the treatment of certain cns-related disorders: 2-Alkyl-indazole compound and its pharmaceutically acceptable salts of acid addition, method and intermediates for preparing them, a pharmaceutical composition containing them and use of the latter. The 2-alkyl-indazole compound has the following general formula (I) in which R1, R2, R3, R4, R6, R7, X, Y, W, n, p, and m... Agent: Darby & Darby P.C.

20100056574 - Crystalline forms of sufentanil: The present invention provides crystalline forms of sufentanil citrate and methods for preparing crystalline forms of sufentanil citrate.... Agent: Mallinckrodt Inc.

20100056575 - Anesthetic compounds: In one embodiment the invention provides novel compounds of Formula (I) as well as prodrugs, salts, hydrates, solvates and N-oxides thereof. The invention also provides pharmaceutical compositions that include such compounds as well as methods for making and methods for using such compounds in medical therapy.... Agent: Pharmacofore, Inc. Bozicevic, Field & Francis LLP

20100056576 - Kinase inhibitors and methods of their use: New compounds, compositions and methods of inhibition of Provirus Integration of Maloney Kinase (PIM kinase) activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one PIM kinase. The new compounds and... Agent: Novartis Institutes For Biomedical Research, Inc.

20100056577 - Pyrrole compounds: wherein R1, R2 and R3 are each a hydrogen atom, a halogen atom, a C1-6 alkyl group optionally substituted by halogen or a C1-6 alkoxy group optionally substituted by halogen, R4 and R6 are each a hydrogen atom, a halogen atom or a C1-6 alkyl group optionally substituted by halogen,... Agent: Edwards Angell Palmer & Dodge LLP

20100056578 - Insecticidal n-substituted sulfoximines: N-Substituted sulfoximines are effective at controlling insects.... Agent: Dow Agrosciences LLC

20100056579 - Insecticidal n-substituted sulfoximines: N-Substituted sulfoximines are effective at controlling insects.... Agent: Dow Agrosciences LLC

20100056580 - Novel crystalline salt form of an antidiabetic compound: A novel crystalline anhydrous toluenesulfonic acid salt form of a selective PPAR gamma partial agonist which has a fused bicyclic aromatic group attached to an oxypropanoic acid moiety is stable and non-hygroscopic. The crystalline salt form is useful for making pharmaceutical formulations for the treatment of type 2 diabetes, hyperglycemia,... Agent: Merck And Co., Inc

20100056581 - Substituted piperidino phenyloxazolidinones: The present invention relates to certain substituted piperidino phenyloxazolidinones. Specifically, the invention relates to geminally disubstituted piperidino phenyloxazolidinones having antimicrobial activity with improved pharmacokinetic profile. The invention also relates to processes for the preparation of compounds of the present invention, pharmaceutical compositions containing the compounds of the present invention and... Agent: Bio Intellectual Property Services (bio Ips) LLC

20100056582 - Modulators of lxr: e

20100056583 - Polymorphic forms of rosiglitazone hydrobromide and processes for their preparation: The present invention provides crystalline forms of Rosiglitazone hydrobromide, methods of their preparation, as well as pharmaceutical compositions comprising these crystalline forms.... Agent: Kenyon & Kenyon LLP

20100056584 - Novel 2-aminio-pyridine derivatives and their use as potassium channel modulators: This invention relates to novel 2-amino-pyridine derivative useful as modulators of small-conductance calcium-activated potassium channels (SK channels). In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.... Agent: Birch Stewart Kolasch & Birch

20100056585 - N-(2-aminophenyl)-4-[n-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (ms-275) polymorph b: i

20100056586 - Inhibitors of udp-galactopyranose mutase thwart mycobacterial growth: Compounds which inhibit microbial growth or attenuate the virulence of pathogen microorganisms. Compounds of the invention inhibit UDP-galactopyranose mutase (UGM) and have activity as inhibitors of microbial growth of microorganisms which contain this enzyme and particularly those microorganisms in which this enzyme is responsible for the incorporation of galactofuranose residues,... Agent: Greenlee Winner And Sullivan P C

20100056587 - Substituted aminothiazole derivatives, pharmaceutical compositions, and methods of use: Substituted aminothiazole derivatives, methods of their preparation, pharmaceutical compositions comprising a substituted aminothiazole, and methods of use in treating human or animal disorders. The compounds may be useful as inhibitors of action of AgRP on a melanocortin receptor and thus may be useful for the management, treatment, control, or the... Agent: Kilpatrick Stockton LLP - 41305 Charles Calkins

20100056588 - Histone deacetylase inhibitors: In recognition of the need to develop novel therapeutic agents, the present invention provides novel histone deacetylase inhibitors. These compounds include an ester bond making them sensitive to deactivation by esterases. Therefore, these compounds are particularly useful in the treatment of skin disorders. When the compounds reaches the bloodstream, an... Agent: Harvard University & Medical School C/o Wolf, Greenfield & Sacks, P.C.

20100056589 - Plant disease damage control composition and plant disease damage prevention and control method: The invention provides a plant disease control composition including active ingredients of (RS)—N-[2-(1,3-dimethylbutyl)thiophene-3-yl]-1-methyl-3-trifluoromethyl-1H-pyrazole-4-carboxamide (common name: penthiopyrad) and at least one fungicidal compound other than penthiopyrad, and a plant disease prevention method wherein such a compound is applied to plant seeds or soil. According to the invention, a composition and a... Agent: Buchanan, Ingersoll & Rooney PC

20100056590 - Polymorphic forms of deferasirox (icl670a): The invention relates to crystalline forms of -[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid and to its amorphous form, to processes for the preparation thereof, to compositions containing the same and their uses for the manufacture of a medicament for the treatment of the human body.... Agent: Novartis Corporate Intellectual Property

20100056591 - Derivatives of n-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators: Compounds, compositions and methods are provided which are useful in the treatment of conditions such as central or peripheral nervous system disorders through the modulation of potassium ion flux through voltage-dependent potassium channels and/or depressing cortical and/or peripheral neuron activity are disclosed. Novel derivatives of N-phenylanthranilic acid are also disclosed.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20100056592 - Prodrugs of (3,5-bis(4-fluorophenyl)tetrahydro-1h-oxazolo[3,4-c]oxazol-7a-yl)methanol and derivatives thereof: A prodrug that has a prodrug moiety that degrades into a compound having the general Formula I with R3 being an alcoholic moiety can be useful in therapies for neurodegenerative diseases as well as cancer. Accordingly, the prodrug compounds can have a structure of Formula I, analogs thereof, derivatives thereof,... Agent: Workman Nydegger 1000 Eagle Gate Tower

20100056593 - Compounds, compositions and methods of using same for modulating uric acid levels: Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of making and using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.... Agent: Wilson, Sonsini, Goodrich & Rosati

20100056594 - Plant disease and insect damage control composition, and plant disease and insect damage prevention method: A composition including active ingredients of penthiopyrad and at least one neonicotinoid compound chosen from the group consisting of dinotefuran, clothianidin, nitenpyram, thiamethoxam, imidacloprid, thiacloprid, and acetamiprid, and a plant disease and insect damage prevention method of applying such a composition to a plant seed, are provided. According to the... Agent: Buchanan, Ingersoll & Rooney PC

20100056595 - Pyrazole derivatives as p2x7 modulators: The pyrazole compounds of formula (I) or salts thereof modulate P2X7 receptor function and are capable of antagonizing the effects of ATP at the P2X7 receptor (P2X7 receptor antagonists). The invention also relates to the use of such compounds or salts, or pharmaceutical compositions thereof, in the treatment or prevention... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20100056597 - Indoledione derivative: [wherein R1a and R2a each means hydrogen, lower cycloalkyl, lower alkyl, etc.; R3a means hydrogen, lower cycloalkyl, lower alkyl, etc.; R4a and R5a each means lower alkyl, lower cycloalkyl, etc. or R4a and R5a are bonded to each other to form lower cycloalkylidene; and R6a means lower alkyl, lower haloalkyl,... Agent: Merck And Co., Inc

20100056596 - Resistance-repellent retroviral protease inhibitors: Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.... Agent: Perkins Coie LLP

20100056598 - Cis-alkoxy-substituted spirocyclic 1h-pyrrolidine-2,4-dione derivatives serving as pesticides: s

20100056599 - Substituted indeno[1,2-b]indole derivatives as novel inhibitors of protein kinase ck2 and their use as tumor therapeutic agents, cytostatics and diagnostic aids: Synthesis of novel substituted indeno[1,2-b]indole derivatives of the type of 5,6,7,8-tetrahydroindeno[1,2-b]indole-9,10-diones and 5H-indeno[1,2-b]indole-6,9,10-triones, which show pronounced inhibition of the human protein kinase CK2, and the use thereof as active ingredients in medicaments and/or drug products in particular for the treatment of neoplastic diseases.... Agent: Millen, White, Zelano & Branigan, P.C.

20100056600 - 11beta-hsd1 active compounds: A novel class of compounds of the general formula (I), their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds modulate the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and are accordingly useful in the treatment... Agent: High Point Pharmaceuticals, Inc.

20100056601 - Control agent containing n-substituted indole derivative for acarian parasitic on animal: Conventional control agents against acarians parasitic on animals do not have sufficient selective toxicity and are hence not safe for the animals to which the control agents are applied. The control agents are not always satisfactory also in control effect and quick-acting properties. Intensive studies were made on the insecticidal... Agent: Nields, Lemack & Frame, LLC

20100056602 - Substituted pyrrole derivatives and their use as hmg-co inhibitors: The present invention relates to substituted pyrrole derivatives, which can be used as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors. Compounds disclosed herein can function as cholesterol lowering agents and can be used for the treatment of cholesterol-related diseases and related symptoms. Processes for the preparation of disclosed compounds are provided, as... Agent: Sheridan Ross PC

20100056603 - Ion channel modulating compounds and uses thereof: Ion channel modulating compounds are disclosed. The compounds of the present invention may be incorporated in compositions and kits. The present invention also discloses a variety of in vitro and in vivo uses for the compounds and compositions, including the treatment of arrhythmia and the production of analgesia and local... Agent: Seed Intellectual Property Law Group PLLC

20100056604 - Methods for stimulating nervous system regeneration and repair by inhibiting phosphodiesterase type iv: The invention relates to the novel identification of inhibitors of phosphodiesterase type 4 (“PDE4”) as agents which can reverse inhibition of neural regeneration in the mammalian central and peripheral nervous system. The invention provides compositions and methods using agents that can reverse the inhibitory effects on neural regeneration by regulating... Agent: Research Foundation Of The City University Of New C/o Darby & Darby P.C.

20100056605 - Oxidative degradation products of atorvastatin calcium: The present invention relates to oxidative degradation products of atorvastatin calcium and the process of the preparation thereof. The present invention also relates to atorvastatin calcium substantially free of oxidative degradation products and the pharmaceutical compositions containing such atorvastatin calcium.... Agent: Darby & Darby P.C.

20100056613 - Spiroquinone compound and pharmaceutical composition: wherein R1a, R1b, R1c and R1d each represents a hydrogen atom, a halogen atom, an alkyl group which may have a substituent, or an alkoxy group which may have a substituent, and R2a and R2b each represents a hydrogen atom, or an alkyl group which may have a substituent (e.g.,... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100056614 - C10 cyclopentyl ester substituted taxanes: A taxane having a cyclopentyl ester substituent at C10, a keto substituent at C9, a hydroxy substituent at C2, a 2-thienyl substituent at C3′ and an isopropoxycarbamate substituent at C3′.... Agent: Bryan Cave LLP

20100056616 - Iejimalid analoga and uses thereof: The invention relates to Iejimalides having the following formula (I) in which a, b, c, d, e, f, g, h, i, j, k, l, m, n, o, p are simple or double bonds, the continuous lines representing at least one simple bond, the dotted lines representing a possible bond. A... Agent: Briscoe, Kurt G. Norris Mclaughlin & Marcus, Pa

20100056615 - Use of tricyclic diterpenes and their derivatives for the treatment, co-treatment or prevention of inflammatory disorders and/or joint disorders: The present invention refers to the use of at least one tricyclic diterpenes for the manufacture of a nutraceutical or pharmaceutical for the treatment, co-treatment or prevention of inflammatory disorders and/or joint disorders.... Agent: Nixon & Vanderhye, PC

20100056617 - Role of limonoid compounds as neuroprotective agents: Disclosed herein are neuroprotective compounds. Methods for the preparation of such compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the compounds disclosed, alone or in combination with other therapeutic agents, for the treatment of neurodegenerative conditions are provided.... Agent: Edwards Angell Palmer & Dodge LLP

20100056619 - Chroman-derived anti-androgens for treatment of androgen-mediated disorders: Methods for the prevention and/or alleviation of androgen-mediated disorders by administering a chroman-derived anti-androgen compound are provided by the present invention. The invention further provides pharmaceutical and nutraceutical compositions containing chroman-derived anti-androgen compounds useful in the prevention and/or alleviation of androgen-mediated disorders, particularly prostate cancer.... Agent: Quarles & Brady LLP

20100056618 - Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives: Compounds of Formula (I) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors).... Agent: Pfizer Inc. Patent Department

20100056620 - Active compound combinations with insecticidal and acaricidal properties: The novel active compound combinations consisting, firstly, of cyclic ketoenols and, secondly, of beneficial species (natural enemies) have very good insecticidal and/or acaricidal properties.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100056621 - Agonists of a bitter taste receptor and uses thereof: The present invention relates to agonists of the hTAS2R14 bitter taste receptor and its role in bitter taste transduction. The invention also relates to assays for screening molecules that modulate, e.g. suppress or block hTAS2R14 bitter taste transduction or bitter taste response.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100056622 - Methods of using ramelteon to treat patients suffering from a variety of neurodegenerative diseases: Methods of using ramelteon to treat patients suffering from a variety of neurodegenerative diseases are disclosed.... Agent: Withers & Keys, LLC

20100056624 - Animal model for perimenopause and menopause and methods of inducing ovarian failure: The present invention relates to an animal model for human perimenopause and menopause. Also provided by the present invention are methods of making the animal model and methods of screening using the model. Also provided are methods of inducing ovarian failure in animals such as pets and wildlife.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100056623 - Fumagillol derivatives or method for preparation of fumagillol derivatives, and pharmaceutical compositions comprising the same: The present invention relates to a fumagillol derivative, pharmaceutically acceptable salts thereof and a method for preparing the same. The compounds of the present invention can be prepared through acylation, hydrolysis and alkylation. The compound of the present invention can be prepared in the form of a pharmaceutically acceptable salt... Agent: Heslin Rothenberg Farley & Mesiti PC

20100056625 - Non-toxic anti-cancer drug combining ascorbate, magnesium and a naphthoquinone: Compositions comprising combinations of magnesium ascorbate (magnesium Vitamin C of “MgVC2”) and Vitamin K3 or (VK3) or a quinone and semiquinone analogue of VK3, are used in methods for killing or inhibiting the growth of tumor or cancer cells or preneoplastic cells in a subject, or for treating cancer in... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20100056626 - Cosmetic product for the treatment of cicatricial tissues: A method for cosmetic treatment of cicatricial tissues comprising the step of applying to the cicatricial tissue a cosmetic product which contains one or more cyanoacrylates.... Agent: Modiano & Associati

20100056627 - Pharmaceutical compositions of alkyl gallates: A pharmaceutical composition of alkyl gallates of the present invention is characterized by containing (A) an alkyl gallate in which the carbon number of the alkyl group is in the range of 5 to 16 and (B) another alkyl gallate in which the carbon number of the alkyl group is... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100056628 - Preservative compositions: Green and naturally derived biocides such as Nα—(C1-C22) alkanoyl di basic amino acid alkyl (C1 to C22) ester salt cationic molecules can be combined with an anionic molecule not generally considered as having significant biocidal activity to provide antimicrobial, antibacterial, and/or antifungal properties with multifunctional benefits including preservative or self-preserving... Agent: Anthony J. Sawyer

20100056631 - Antiallergenic composition: An antiallergenic composition comprising 3-hydroxybutyric acid and/or a salt thereof. The antiallergenic composition is safe.... Agent: Birch Stewart Kolasch & Birch

20100056630 - Composition for the treatment and/or prevention of fire blight: The invention relates to an agent for treating and/or preventing fire blight, particularly present in wood and fruit trees, comprising formic acid and/or a salt of formic acid, particularly calcium formiate as an active component. Further disclosed is the use of formic acid and/or a salt of formic acid, particularly... Agent: Lanxess Corporation

20100056629 - Retrovirus-infection inhibitor: An infection inhibitor of retrovirus, particularly human immunodeficiency virus, comprising, as an active ingredient, at least one compound selected from the group consisting of a compound represented by the formula (I) (GGA) or a salt thereof, a compound represented by the formula (II) (NIK-333) or a salt thereof, and derivatives... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100056632 - Crystalline form of y-aminobutyric acid analog: A crystalline form of a γ-aminobutyric acid analog, and methods of preparing same, are provided.... Agent: Dorsey & Whitney, LLP Intellectual Property Department

20100056633 - Solid or aqueous alkaline preparation comprising a creatine component, process for the production thereof and the use thereof: A solid or aqueous alkaline preparation comprising a creatine component which comprises a buffer system which adjusts a pH of from 8.0 to 12.0 is described. The creatine is better protected with the aid of the buffer system from conversion into creatinine in the stomach. It has additionally emerged, surprisingly,... Agent: Fulbright & Jaworski, LLP

20100056634 - Novel compositions: The present invention relates to novel composition for the treatment, co-treatment or prevention of inflammatory disorders comprising an effective amount of carnosic acid 12-methylether.... Agent: Nixon & Vanderhye, PC

20100056635 - Novel protein kinase modulators and therapeutic uses thereof: The present invention provides new tyrphostin derivatives acting as substrate competitive protein tyrosine kinase (PTK) inhibitors and receptor tyrosine kinase (RTK) inhibitors, methods of their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as chemotherapeutic agents for preventions and treatments of PTK and... Agent: Fennemore Craig

20100056636 - N-substituted-p-menthane-3-carboxamide and uses thereof: e

20100056637 - Treatment methods using triaryl methane compounds: The present invention provides methods of treating or preventing asthma or an inflammatory disease. In one embodiment, the invention provides compounds and formulations for the treatment of asthma or an inflammatory disease.... Agent: Townsend And Townsend And Crew, LLP

20100056639 - Insecticidal compounds: A compound of formula (I): wherein A1, A2, A3, A4, R1, R2, G1, G2, Q1 and Q2 are as defined in claim 1; or a salt or N-oxide thereof. Furthermore, the present invention relates to processes and intermediates for preparing compounds of formula (I), to insecticidal, acaricidal, molluscicidal and nematicidal... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20100056638 - Oral and injectable formulations of tetracycline compounds: Injectable and oral formulations of a tetracycline compound are described. In one embodiment, the invention pertains to an oral formulation of a 9-aminomethyl tetracycline compound, or a salt thereof, in tablet form or capsule. The formulations may be used, for example, to treat infections.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100056640 - Amide compound and use thereof: Disclosed is an amide compound represented by the formula (1) below, which has excellent plant disease controlling activity. (1) (In the formula, substituents represented by A, Z, X1, X2 and X3 and the like are as defined in the description.)... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100056641 - Novel aminoguanidines as melanocortin receptor ligands: There are described compounds of general formula (I) and isomeric forms thereof wherein n is 0, 1, 2 or 3, saturated or unsaturated; most preferably at least one of R1 to R5 represents halogen; at least one of R1, R2, R3, R4 and R5 is selected from —S—R or —COOR,... Agent: Cantor Colburn, LLP

20100056642 - Hepatitis a viricide: The invention relates to agents which combat the hepatitis A virus, containing only minimal amounts of chlorine-containing and/or chlorine cleaving active ingredients, or none of said substances. The inventions also relates to the use of these agents and to a method for their production.... Agent: Ecolab Inc.

20100056643 - Chemically induced intracellular hyperthermia: An invention relating to therapeutic pharmacological agents and methods to chemically induce intracellular hyperthermia and/or free radicals for the diagnosis and treatment of infections, malignancy and other medical conditions. The invention relates to a process and composition for the diagnosis or killing of cancer cells and inactivation of susceptible bacterial,... Agent: Fulbright & Jaworski, LLP

20100056644 - Pharmaceutical compositions containing anhydrous calcipotriene: A stable pharmaceutical composition in a semisolid dosage form comprising a therapeutic effective amount of solubilized calcipotriene in an anhydrous form is disclosed.... Agent: Glenmark Pharmaceuticals Inc Usa

20100056645 - Chromatographic media and chromatographic equipment storage solutions and use thereof: Buffered antimicrobial solutions of benzyl alcohol and ethanol and their use for short or long term storage of chromatographic solids.... Agent: Mallinckrodt Inc.

20100056646 - Hydroswellable, segmented, aliphatic polyurethane ureas and intra-articular devices therefrom: Hydroswellable, non-absorbable, biostable, segmented, aliphatic polyether-urethane-ureas or polyether-siloxane-urethane-ureas form a single component, intra-articular device for restoring joints with artificial cartilage, as a cartilage substitute for degenerated cartilage and/or for enhancing the remaining cartilage of an arthritic joint. The intra-articular devices can be bicomponent in nature comprising a biostable, articulating, non-absorbable... Agent: Leigh P. Gregory

20100056647 - Copolymers useful as rheology modifiers and home and personal care compositions comprising said copolymers: The present invention relates to aqueous personal care, household care, and/or fabric care compositions comprising the instant copolymers. Also disclosed are methods for the rheological modification of aqueous personal care, household care, and/or fabric care compositions comprising the instant copolymers.... Agent: Ciba Corporation Patent Department

Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20140925: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 3.7149 seconds

PATENT INFO